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The first example of an intramolecular ester enolate-imine cyclisation reaction for the 
asymmetric synthesis of polycyclic -lactams and cyclic -amino acid derivatives has been 
developed. 
 
In Chapter 1, the synthesis of monocyclic -lactams using intermolecular ester enolate-
imine cyclisation reactions is reviewed. The use of chiral auxiliaries contained within the 
ester or imino functionality to control the diastereoselectivity of the reaction is discussed, as 
well as enantioselective approaches. The utilization of this methodology for the synthesis of 
natural products such as Taxol is described, as well as the use of polymer support 
protocols to improve the efficiency of this reaction. 
In Chapter 2, the synthesis of an appropriate cyclisation substrate containing an ester and 
imino functionality with a chiral auxiliary fragment is reported. Appropriate conditions were 
established that enabled an intramolecular enolate-imine cyclisation reaction to be used for 
the synthesis of the tricyclic -lactam benzocispentacin in good yield and excellent de. The 
formation of -amino ester side products was investigated and an explanation for the 
production of -lactams as major products over their corresponding -amino esters is 
proposed. This protocol was then applied to the asymmetric synthesis of six 
benzocispentacin derivatives all with good yields and excellent de, with the configuration of 
one of these derivatives being confirmed by X-ray crystallography. A deprotection 
methodology was then established to afford their corresponding tricyclic NH--lactams and 
cis and trans bicyclic -amino esters. 
In Chapter 3, the newly devised methodology was also applied to acyclic substrates for the 
synthesis of the antifungal cispentacin. The ability to access both cis- and transpentacin in 
both high yields and excellent de as monomers for foldamer synthesis is reported. A small 
series of bicyclic -lactam analogues was prepared in a short and efficient methodology, 
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1 The Ester Enolate-Imine Condensation Reaction for 
the Synthesis of -lactams 
1.1 Introduction 
In the past century, the design and development of -lactam antibiotics has been highly 
influential within drug discovery, due to their biological and pharmacological activity. 
The biological effects of the -lactam ring system were first identified due to the 
discovery of penicillin in 1928, this led to the discovery of the most widely used of all 
the antimicrobial agents.1 -lactam antibiotics are highly successful therapeutic agents 
which can inhibit both penicillin binding proteins and serine proteases,2 this is in 
addition to their bactericidal action on enzymes that cross-link the peptidoglycan of the 
bacterial cell wall. A variety of subgroups of -lactam antibiotics have been developed 
and some of the most commonly synthesised targets include penicillins 1, 
cephalosporins 2, carbapenems 3 and the monocyclic norcardicins 4 (Figure 1). These 
antibiotics successfully interfere with the peptidoglycan cell wall synthesis, due to their 
ability to inhibit bacterial enzymes, transpeptidases and carboxypeptidases.3  
 
Figure 1- Examples of -lactam antibiotic subgroups 
In addition, -lactam scaffolds have also been widely used as building blocks for 
synthesis of peptides, peptidomimetics, natural products and alkaloids, that have been 
subject to a series of detailed reviews.4-5  
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There are several main methods for the synthesis of-lactams which include the 
Staudinger reaction, the Gilman-Speeter reaction and the Kinugasa reaction. In order to 
prepare -lactams in their enantiopure form using these methodologies then either a 
chiral catalyst, chiral auxiliary or chiral starting materials need to be employed for 
stereocontrol. 
The Staudinger [2+2] cycloaddition was first reported in 1907, which involved the 
cycloaddition of stable ketenes such as diphenylketene 5 with an imine 6 to furnish the 
first example of the strained four membered lactam ring 7. 6 The nucleophilic addition of 
the nitrogen lone pair of the imine onto the carbon of the ketene results in the formation 
of a zwitterion which subsequently undergoes a cycloaddition forming a -lactam 
(Scheme 1).  
 
Scheme 1- Staudinger reaction producing first -lactam6 
The Staudinger reaction is the most common methodology for the synthesis of 
lactams with much recent research aimed at developing an enantioselective reaction 
using chiral catalysts (Scheme 2).7-8 
 
Reagents & Conditions: (i) Catalyst 11 (10 mol%), Cs2CO3 (10 mol%), THF, rt 
Scheme 2- Chiral N-heterocyclic carbene catalysed Staudinger reaction
7
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 In 1972, the synthesis of -lactams was shown to be possible by reacting copper(I) 
phenylacetylide 12 with nitrones in anhydrous pyridine (Scheme 3). The reaction times 
were typically short, with readily available starting materials forming exclusively cis--
lactams in good yield.9 
 
Reagents & Conditions: (i) Pyridine, rt, 1hr 
Scheme 3- First reported Kinugasa reaction
9
 
Since its initial discovery, the scope and limitations of the Kinugasa reaction has been 
explored, with more recent examples obtaining -lactams enantioselectively as well as 
the development of an intramolecular version of the reaction (Scheme 4).10 
 
Reagents & Conditions: (i) CuBr (5 %), ligand 17 (5 %), CyNMe2, MeCN, 0 °C 
Scheme 4- Catalytic enantioselective intramolecular Kinugasa reaction
11
 
Finally, the enolate-imine cyclisation reaction (Gilman-Speeter) is another highly utilized 
methodology employed for the synthesis of -lactams. This methodology forms the 
basis of the research programme described in this thesis, and as a consequence the 
highlights of this important reaction will now be reviewed in detail. 
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1.2 Enolate-Imine Condensation Reactions - Introduction 
The first enolate-imine condensation reaction was originally reported by Gilman and 
Speeter in 1943 who employed a Reformatsky type reaction of the zinc enolate of -
bromo-ester 18 with an imine for the production of an N-aryl--lactam such as 19 
(Scheme 5).12  
 
Reagents & Conditions: (i) Zn, toluene 
Scheme 5- First reported example of the Gilman-Speeter reaction for the synthesis of a -lactam12 
The ester enolate-imine condensation reaction can be considered analogous to the 
aldol condensation, whereby a metal enolate is generated that then effects nucleophilic 
attack at an imine to afford an intermediate -amino ester, which subsequently 
undergoes a ring closure reaction to form a -lactam structure (Scheme 6). This type of 
enolate-imine condensation reaction has attracted a large amount of interest, with 
much research concentrating on selectively accessing either cis- or trans--lactams. In 
this respect it represents an alternative to the established Staudinger methodology that 
involves [2+2] cycloaddition of a ketene and an imine.6 
 
 
Scheme 6- Basic mechanism of the ester enolate-imine condensation reaction 
Theoretical calculations support the proposed stepwise mechanism of the enolate-
imine condensation reaction which were carried out to include the electrostatic effects 
of the solvent.13 The reaction commences with C-C bond formation between the 
enolate and the imine which was calculated to be both irreversible and the rate 
determining step,13 this is then followed by a rapid ring closure reaction that results in 
elimination of methoxide to afford the -lactam ring.13 The cis/trans stereochemistry of 
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the resulting -lactam is dependent on the type of transition state formed in the initial 
nucleophilic addition step, which can proceed either via a chair or boat conformation 
depending on the conditions and type of metal counterion used for enolate formation 
(Figure 2).14-16  
 
Figure 2- Effect of metal counterion on -lactam formation 
In 1989, the then emerging area of using enolate-imine cyclisation reactions for the 
synthesis of -lactams was comprehensively reviewed, with a particular focus on the 
scope and limitation of different metal enolates on the yield and stereoselectivity of this 
reaction.17 This review will now describe on progress in this area for the asymmetric 
synthesis of -lactams, and demonstrate how this efficient methodology has been used 
for the synthesis of a number of medicinally useful -lactam targets. For consistency 
and clarity, the review will follow the format originally used by Hart in 1989, first 
describing progress in generating and using different types of enolate species, followed 
by asymmetric development and natural product syntheses.17 In this respect, it will 
briefly highlight the important factors known prior to 1989, and report important new 
developments that have contributed to this methodology now being widely used for the 
stereoselective synthesis of -lactams. 
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1.3 Selected Metal Enolates 
The greatest area of progress in demonstrating the potential of using enolate-imine 
cyclisation reactions for -lactam formation has been in the use of lithium and/or zinc 
enolates, whilst protocols employing titanium, aluminium and boron enolates have all 
been used to selectively generate -lactams with good levels of stereocontrol. 
1.3.1 Zinc Enolates 
The initial Reformatsky reaction carried out by Gilman et al. (Scheme 5) was further 
investigated, with a series of studies reporting that the reaction of zinc enolates of ethyl 
-bromoacetate 20 with numerous N-aryl aldimines gave good yields of N-aryl--
lactams (Scheme 7),18 in particular the yields of 3-unsubstituted-lactams were shown 
to be improved in the presence of ultrasound.19 Investigations into the stereoselectivity 
of -lactam formation revealed that the cis--lactam was normally formed as the major 
product when the -substituent of the ester enolate was an alkyl group, or THF was 
used as solvent for the reaction.20-21 Theoretical calculations revealed that reaction of 
the zinc enolate and imine occur via a twisted boat transition state in the case of tri- and 
tetra-coordinated zinc atoms in order to minimise steric interactions and electronic 
repulsion of electronegative atoms in the transition state.22 
 
Reagents & Conditions: (i) Zn, THF, reflux 




It was also shown that varying the temperature of the reaction enabled either -lactam 
24, or -amino ester 25 to be accessed from these types of reactions (Scheme 8). It 
was proven that isomerization was taking place as only the erythro-isomer of the -
amino ester 25 was observed at lower temperature, whereas when the reaction was 
warmed to 42°C the cis--lactam 24 was isolated in 80% de, which suggests that the 
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first step of the enolate-imine reaction might be a reversible reaction under these 
conditions.23,24  
 
Reagents & Conditions: (i) Methylal, 42°C; (ii) Methylal, -10°C 
Scheme 8- Effects of reaction conditions on Reformatsky enolate-imine cyclisation products 
Any suggestion that these cyclisation reactions were occurring via a ketene Staudinger-
type mechanism were quickly ruled out, when it was shown that reaction of imine 6 with 
isopropyl-ketene 27 gave exclusively the corresponding trans--lactam 28 (Scheme 
9).25 
 
Scheme 9- Staudinger reaction resulting in synthesis of trans--lactam 2825 
In 1991, the zinc enolate of N,N-disubstituted glycine ester 29 was generated via 
transmetallation of the lithium enolate, for the one-pot synthesis of trans-3-amino-2-
azetidinones 31 in high yields and de (Scheme 10).26 After an extensive study into the 
effects of the metal cation, solvent and substituents on the -amino zinc ester enolates, 
it was found that the best trans- selectivity was obtained using apolar solvents and a 
bulky/electron withdrawing protecting group on the -amino nitrogen of the enolate 
fragment.26 
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Reagents & Conditions: (i) a) LDA, Et2O, -78°C b) ZnCl2; (ii) -78°C to rt, H2O; (iii)H
+
/H2O 
Scheme 10- Synthesis of trans-2 azetinones using N,N-disubstituted glycine esters
26
 
In addition, zinc enolates have previously been shown to interact with both activated 
(N-substituted with an electron withdrawing group) and unactivated imines (N-
substituted with an electron donating group), which is advantageous when compared to 
lithium enolates which generally only react with activated imines. The catalytic use of 
ZnCl2 was shown to marginally increase the cis:trans diastereoselectivity from 58:42 to 
73:27 for -lactam 35 (Scheme 11).26  
 
Reagents & Conditions: (i) a) LDA b) 0.25 equiv. ZnCl2; (ii) THF, reflux, 1hr 
Scheme 11- Reformatsky reaction using N-alkyl-imines
26
 
Functionalisation of C4 on the 3-amino-2-azetidinone has further effects on the 
cis:trans selectivity of the cyclisation reaction used for its formation. The bis-imine 36 
had a much higher selectivity for the trans -lactam compared to oxygen or sulfur 
analogues as it is proposed that these types of imines cyclise via a more restricted 
transition state (Scheme 12).27 
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Reagents & Conditions: (i) a) LDA, Et2O -78°C; b) ZnCl2; (ii) -78°C to rt, H2O 
Scheme 12- C4 substituted trans--lactams27 
More recently in 2003, it was found that treatment of 4-bromo-crotonate with a mixture 
of Zn/Cp2TiCl2 afforded a zinc enolate that reacted with imine 38 to exclusively afford a 
trans--lactam 40 in 81% yield (Scheme 13).28  
 
Reagents & Conditions: (i) Zn/Cp2TiCl2, THF, rt 
Scheme 13- Zn/Cp2TiCl2 catalysed Reformatsky reaction
28
 
1.3.2 Lithium Enolates 
The first report of using lithium enolates for the enolate-imine condensation reaction 
was described in 1980, with lithium enolates of ,-disubstituted acetates reacting with 
N-arylaldimines to furnish either cis- or trans--lactams in good yields and excellent 
de.29 The conditions of the reaction, in particular the solvent, were shown to have a 
significant impact on the stereoselectivity of these reactions (Scheme 14). When THF 
was chosen as solvent then reaction of an (E)-enolate with an N-aryl-imine 38 resulted 
in formation of cis--lactam 42 as the major isomer in 83% yield, similar to the results 
observed using zinc enolates (Scheme 8). Conversely, when HMPA was added to the 
reaction, it resulted in a (Z)-enolate that selectively afforded a trans--lactam 43 in 80% 
yield as the major isomer.29,30 
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Reagents & Conditions: (i) a) LDA, THF; b) N-benzylidene-4-methoxyaniline 38, 25°C; (ii) a) LDA, THF; 
b) THF-HMPA, N-benzylidene-4-methoxyaniline 38, 25°C 
Scheme 14- Effect of solvent on the -lactam using lithium enolates29 
In 1985, Overman et al. demonstrated that N-substituted--amino nitriles 44 could be 
used as precursors to generate N-substituted formaldimines in situ, which then reacted 
with lithium enolates of N-protected glycine ester derivative 29 to afford the C4-
unsubstituted -lactam 45 in high yield (Scheme 15).31 
 
Reagents & Conditions: (i) LDA (2.0 equiv.), THF (ii) Amine 44; (iii) H2O 
Scheme 15- Reaction of a lithium enolate to afford a 3-amino--lactam31 
The development of a new methodology to generate N-(TIPS)- and N-(TBDMS)-imines 
enabled their effect on the selectivity of enolate-imine cyclisation reactions to be 
determined. The reaction of the lithium enolate of STABASE 29 and the N-
(TBDMS)imine 46 was shown to exclusively afford the trans--lactam 47 in 70% yield 
(Scheme 16).32 In comparison, N-(TMS)-imines are reported to selectively produce cis-
-lactams when used under the same conditions. 
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Reagents & Conditions: (i) THF, -78°C; (ii) Na2CO3, CbzCl, acetone 
Scheme 16- Use of N-(TBDMS)imines for -lactam synthesis32 
In addition, it has been demonstrated that the methodology for the synthesis of 
enolates can have significant implications on the stereochemistry of the resulting -
lactam 50. For example, the enolate could be formed by either the conjugate addition of 
LDA to methyl crotonate 48 (method A), or via treatment of the corresponding -amino 
ester 49 with LDA (method B). As such, the enolate was reacted with imine 52 to 
afford trans--lactam 50, that was subsequently de-aminated to afford -alkylidene--
lactam 51 as a mixture of E/Z isomers, that were then screened as potential -
lactamase inhibitors (Scheme 17).33  
 
Reagents & Conditions: (i) LDA, -78°C, (ii) (ethane-1,2-diylidene)bis(4-methoxyaniline) 52  
Scheme 17- Synthesis of -alkylidene--lactams33 
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Further work suggested that the stereoselectivity of the reaction is affected by the 
methodology used to generate the enolate for -lactam synthesis. Method A produced 
-lactam 50a as the major diastereomer, whereas method B produced -lactam 50b as 
the major diastereomer.34  
 
Figure 3- Major enantiomers formed during synthesis of -lactam 5034 
This methodology was then applied for the synthesis of -ethylidene -lactams using 
the enolate-imine reaction to allow access to polyoximic acids, these were 
subsequently used for the formation of a range of polyoxins.34 
The result of -hetero ester enolates with N-aryl imines has been well documented with 
the majority of substituents forming the trans--lactam.14 An investigation into the 
stereoselective synthesis of 3-fluoro-azetidinones revealed that the use of the ketene-
imine methodology to generate -fluoro--lactams was much more selective than the 
corresponding ester enolate-imine condensation reaction. A series of experimental 
conditions were investigated which revealed that the best conditions for the reaction of 
lithium fluoro-enolate 54 with N-aryl-imine 38 resulted in the predominant formation of 
the trans--lactam 55 in 56% de and 68% yield (Scheme 18).35  
 
Reagents & Conditions: (i) LDA, -78°C, THF 
Scheme 18- Synthesis of 3-fluoro-azetidinones
35
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More recently, alternative conditions for the synthesis of these types of 3-fluoro 
azetindinones have been devised using the (Z)-enolate of thioester 56 which afforded 
the cis--lactam 57 in 73% yield and 94% de (Scheme 19).36 
 
Reagents & Conditions: (i) LDA, -78°C, THF; (ii) rt, 4hrs 
Scheme 19- Synthesis of 3-fluoro azetidinones using thioesters
37
 
Previously, the highly selective synthesis of cis--amino acyl iron complexes has been 
reported using lithium enolates of chiral racemic iron acyl complexes and N-aryl 
imines.38 In 2001, the preparation of -lactams containing ferrocene units at the 3-
position via reaction of the lithium enolate of ethyl 3-ferrocenylpropanoate with imine 38 
was reported. This ester enolate-imine condensation produced lactam 59 as the 
major product and the hydroxy--lactam 60 as a minor side product (Scheme 20).39 
 
Reagents & Conditions: (i) LDA, -78°C, THF  
Scheme 20- Synthesis of C3-ferrocene substituted -lactams39 
1.3.3 Titanium Enolates 
Cinquini et al. originally reported on the synthesis of -lactams via the reaction of 
titanium enolates of 2-pyridylthioesters with imines,40 which revealed that an increase in 
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steric bulk on the -substituent resulted in an increase in trans selectivity. For example, 
it was shown that reaction of the lithium enolate of thioester 61 containing an -
isopropyl group with N-benzyl-imine 62 gave trans--lactam 63 in an 83% yield 
(Scheme 21). 
 
Reagents & Conditions: (i) TiCl4, Et3N, -78°C to 0 °C, 6hrs 




It was proposed that this trans--lactam 63 was formed via a transition state that 
involved an intramolecular chelate between the pyridine nitrogen atom and the titanium 
counterion of the enolate (Figure 4).40  
 
Figure 4- Transition state of titanium enolate of 2-pyridylthioester that affords -lactam 63 with 
good levels of (trans)--lactam selectivity40 
The reactivity of titanium (IV) and tin (IV) enolates of the thiopyridyl ester 64 with imines 
was investigated in order to determinine whether improved trans:cis ratios could be 
obtained.41 Tin enolates were found to afford better levels of stereocontrol with the use 
of SnCl4 affording the corresponding cis--lactam 66 in 80% de, whilst SnBr4 gave 
trans--lactam 65 in 74% de (Table 1).41  
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Entry MX4 Yield (%) trans:cis ratio 
1 TiCl4 74 39:61 
2 TiBr4 56 73:27 
3 SnCl4 18 10:90 
4 SnBr4 92 87:13 
 
The influence of the imine structure on the trans/cis ratio of these cyclisation reactions 
was further investigated by analysing the diastereoselectivity for reactions of enolates 
of achiral thioesters with achiral imines containing different substituents. It was found 
that trans--lactams were formed as a result of reaction of imines with bulky and non-
chelating heteroatoms, whereas cis-lactams were formed as major products from 
imines that contained small or chelating groups.42 




Entry R Yield (%) trans:cis ratio 
1 Ph 99 70:30 
2 HC=CHPh 99 60:40 
3 n-Pr 48 37:63 
4 CH2OTBDPS 40 46:54 
5 CH2OBn 40 23:77 
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Furthermore, in an attempt to determine how the enolate geometry of an achiral 
thioester affects the trans/cis ratio during -lactam formation, enolate 68 was trapped 
as a silylketene acetal. The trapped (E)-enolate (geometry determined by 1H NMR 
spectroscopy) was subsequently reacted with achiral imine 38  and a Lewis acid, 
titanium(IV)chloride, to afford the trans--lactam 69 in high de.43 In general, when the 
titanium (E)-enolate of the silyl ketene thioacetal was formed, the trans -lactam was 
observed in the corresponding (E)/(Z) ratio.43  
 
Reagents & Conditions: (i) TiCl4, DCM, 0°C to rt, 12hrs 
Scheme 22- Ketene-silyl acetals as nucleophiles for -lactam synthesis43 
1.3.4 Other Conditions 
The reaction of aluminium enolates of thioesters 71 with N-alkylimines 72 for the 
synthesis of a range of analogues of trans--lactams 73 in high yield and good de was 
first reported in 1987 (Scheme 23).44,45 Alternatively, if a more sterically demanding 
ester substituent is used, such as an isopropyl group, then the cis--lactam 
predominates.  
 
Reagents & Conditions: (i) a) LDA, THF; b) Et2AlCl; c) Imine 72 
Scheme 23- Aluminium enolate and enolisable N-alkylimines for -lactam formation45 
This use of aluminum enolates was further exploited via a transmetallation of the lithium 
enolate of N,N-disubsituted glycine thioester 29 with an excess of Me2AlCl which gave 
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a dialkylaluminium (Z)-enolate that reacts with N-methyl-imine 35 to furnish trans--
lactam 74 in 92% de and 87% yield (Scheme 24).46 
 
Reagents & Conditions: (i) LDA, Me2AlCl (1.2 equiv.), benzene, 0°C to rt, 0.5hrs; (ii) reflux 
Scheme 24- Synthesis of aluminium enolates and effect on stereoselectivity of -lactam46 
The ability to isolate a single diastereomer of a -lactam in good yield using an 
organocopper ester enolate-imine condensation reaction was first reported during the 
synthesis of the antibiotic thienamycin.47 Conjugate addition of a silyl anion generates 
an enolate from ester 75 that then reacts with imine 76 to afford trans--lactam 77 with 
good levels of stereocontrol.  
 
Reagents & Conditions: (i) (PhMe2Si)2CuCNLi2, THF, 0 °C, 20 mins; (ii) Imine 76, THF, 0 °C to rt, 3 hrs 
Scheme 25- Organocopper ester enolate-imine condensation reaction
47
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More recently, a novel strategy for the generation of iridium enolates was developed 
involving an in situ reduction of an ,-unsaturated ester 78 with a iridium hydride 
species, that generates an iridium enolate in situ which reacts with N-aryl-imine 6, to 
afford the trans--lactam 79 in 68% yield and 90% de (Scheme 26).48  
 
Reagents & Conditions: (i) 2.5mol% [(cod)IrCl]2, 10mol% P(OPh)3, Et2MeSiH, 60°C, 6hrs 




1.4 Chiral Esters 
The ability to prepare enantiopure -lactams is of great importance as they can be used 
as both versatile chiral building blocks for synthesis or as important biologically active 
agents. The first significant report of carrying out ester enolate-imine cyclisation 
reactions using a chiral ester fragment was reported in 1980, where it was 
demonstrated that reaction of the lithium enolate of menthyl ester 80 with imine 6 gave 
-lactam 81 in 60% ee (Scheme 27).29 The use of a chiral ester fragment to direct 
stereocontrol in this manner has the advantage that the final -lactam cyclisation step 
results in cleavage of the chiral alcohol fragment, and as such does not require an 
additional deprotection step. 
 
Reagents & Conditions: (i) LDA, THF 
Scheme 27- Asymmetric synthesis of-lactam synthesis using a menthyl ester for diastereocontrol29 
Furthermore, several alternative chiral auxiliaries were trialed, with the most successful 
the (E)-lithium enolate of -monosubstituted chiral ester 82, which was reacted with 
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cinnamaldimine 83 to produce the major -lactam 84 in 74% yield and an excellent 
91% ee.49 
 
Scheme 28- Synthesis of -lactams using camphor derived esters49 
 
Since these initial reports there have been several major developments in this area, 
with chiral esters being successfully employed for the synthesis of highly functionalized 
-lactams with high levels of stereocontrol.  
In 1990, Ojima et al. described the reaction of N,N-bis(silyl)glycinate chiral esters 85, 
that contain a (-)-menthyl ester group, with N-aryl-imine 38 to afford trans--lactams 
with good levels of stereocontrol.50 The stereochemistry of the initial cyclisation reaction 
was explained using a transition state, involving attack of a chiral (Z)-enolate at the Re-
face of the imine, to afford after subsequent cyclisation the trans-(3R,4R)-lactam 86 
in >99% ee (Scheme 29).50 In addition, lithium enolates of chiral esters containing both 
(+)- and (-)-trans-2-phenyl-1-cyclohexyl fragments were also shown to be successful in 
affording -lactam 86 in 58% yield and in >99% ee.  
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Reagents & Conditions: (i) LDA, THF, -78°C, 4hrs 
Scheme 29- Chiral enolate ester-imine condensation using a (-)-menthyl derived chiral auxiliary
50
 
When the cis-exo isomer of (+)-camphor was used as the chiral auxiliary, then the 
lithium enolate of ester 87 gave the substituted (S)--lactam 88a in 91% yield and very 
high ee (Scheme 30).51 
 
Reagents & Conditions: (i) LDA, Et2O, -78°C to -40°C 
Scheme 30- Ester enolate-imine condensation reaction controlled by a (+)-camphor auxiliary
51
 
Alternatively, when the cis-endo isomer of (+)-camphor was used as the chiral auxiliary, 
then the opposite configuration was observed yielding an (R)--lactam 88b in 92% ee, 
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with the addition of stoichiometric amounts of additives such as triethylborane or 
tetrabutyltin being shown to further improve selectivity levels.51  
 
Reagents & Conditions: (i) LDA, Et2O, -78°C to -40°C 
Scheme 31- Ester enolate-imine condensation reaction controlled by a (+)-camphor auxiliary
51
 
In 1995, it was reported that it was possible to exclusively access either cis- or trans--
lactams in high ee using different triphenylglycol derived esters as the nucleophilic 
component. The (R)-ester 90 was doubly deprotonated to afford a chiral propionate 
enolate, that was reacted with imine 91 to afford the trans--lactam 92 in >97% ee 
(Scheme 32).52  
 
Reagents & Conditions: (i) LDA (2.0equiv.), THF, -50°C to -35°C 
Scheme 32- Double lithiated chiral propionate for trans -lactam synthesis52 
Conversely, when the O-methyl derivative of a (R)-triphenylglycol ester 93 was 
monodeprotonated to afford enolate then reaction with imine 91 gave the alternative 
cis--lactam 94 in >97% ee (Scheme 33).52  
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Reagents & Conditions: (i) LDA (1.0equiv.), THF, -50°C to -35°C 
Scheme 33- Mono-lithiated chiral propionate for cis -lactam synthesis52 
This methodology was subsequently applied to the asymmetric synthesis of the 
cholesterol absorption inhibitor (-)-SCH 48461 96, which was successfully produced in 
>98% ee (Scheme 34).53 
 
Reagents & Conditions: (i) LiN(i-Pr)2 (2.0equiv.), THF, -78 °C to -65 °C, 1hr; (ii) Imine 52, THF, -78 °C 
to rt  
Scheme 34- Synthesis of (-)-SCH 48461 using triphenylglycol ester 95 
53
 
The highly enantioselective construction of chiral (3R)-3-alkyl-3-hydroxy--lactams was 
made possible by generating an (E)-enolate from Seebach’s auxiliary 97, which reacts 
with the imine 98 from its Re face- trans to the bulky tbutyl group chiral auxiliary 
fragment. The resultant intermediate then cyclises onto its carbonyl group, with 
elimination of the chiral auxiliary fragment affording -lactam 99 in 94% yield after 
recrystallisation (Scheme 35).54  
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Reagents & Conditions: (i) LHMDS, -78°C, THF/HMPA 
Scheme 35- Enantioselective synthesis of -lactams using 1,3-dioxolan-4-ones54 
Several years after the use of an organocopper ester enolate-imine condensation 
reaction using an achiral imine and an achiral ester (Scheme 25), the full potential of 
organocuprate catalysed conjugate addition reactions was established for the 
asymmetric conjugate addition of carbon nucleophiles to chiral ,-unsaturated esters 
100. The resultant enolate intermediate was reacted with a glyoxylate imine 76 to afford 
-lactam 101 in good de and ee (Scheme 36).55 This multi-component strategy was 
subsequently employed for the asymmetric synthesis of the antibiotic family 
Nikkomycins.56  
 
Reagents & Conditions: (i) Me2CuLi, 0°C, THF, 3hrs 
Scheme 36- Use of lithium dialkylcuprates for the asymmetric synthesis of -lactams55 
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More recently in 2004, an efficient and diastereoselective synthesis of trans--lactams 
was reported using enolates derived from a carboximide auxiliary prepared from 
salicylamide.57 This classic Reformatsky reaction occured via generation of a zinc (Z)-
enolate that was shown to afford either trans--lactam 103, or -amino amide 
derivatives, depending on the nature of the substrate substituents (Scheme 37).57 
 
Reagents & Conditions: (i) Zn, THF, reflux, 2hrs 
Scheme 37- Enantioselective Reformatsky reaction using a chiral auxiliary
58
 
It was possible to rationalize the stereochemistry of the reaction by reasoning that the 
(Z)-enolate formed attacks on the Re-face due to steric hindrance from the isopropyl 
group blocking the Si-face. This results in the formation of the (3R,4S) -lactam as the 
major isomer which was isolated in an 85% ee, whilst the chiral auxiliary could be 
recycled as required. 
1.5 Chiral Imines 
The first reported attempt at utilizing chiral imine components in ester-enolate imine 
cyclisation reactions were described using zinc enolates as nucleophiles which resulted 
in relatively poor diastereoselectivity.59 However, this methodology was more 
successfully utilized for the synthesis of monosubstituted -lactam 106 which was 
prepared with good stereocontrol due to formation of a chelated transition state 
between the (E)-enolate of 29 and -cyano amine 105.31  
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Scheme 38- -lactam synthesis using chiral -cyano amines31 
Early results also showed that -lactams could be formed in good ee using either tin60 
or boron61 enolates, however these reactions resulted in the formation of  -amino ester 
products that required subsequent cyclisation to afford the desired -lactam.  
In 1992, a bulky chiral imine containing an acetonide functionality was employed for the 
asymmetric synthesis of mono-substituted -lactams. Lithium enolate 107 was added to 
the chiral imine acetal 108 to give trans--lactam 109 in 66% yield with high 
diastereoselectivity.62 The absolute configuration was determined by subsequently 
converting 109 into the trans--lactam 110, that had been used previously as an 
intermediate for the synthesis of the antibiotic (+)-PS-5.62 
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Reagents & Conditions: (i) THF, -70°C 
Scheme 39- Synthesis of (+)-PS-5 intermediate using chiral imines
62
 
Further to this study, the ability to selectively access either enantiomer of a mono-
substituted -lactam 113 has been reported. In this study, the generation of lithium or 
zinc enolates with the (S,S)-tartrate derived imine 112 affords (4S)--lactam 113a, 
whilst a titanium enolate resulted in the (4R)--lactam 113b being observed.63  
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Reagents & Conditions: (i) LDA, DME, -78°C to rt, 12hrs; (ii) Ti(OiPr)3Cl, Et2O, -78°C to rt, 12hrs 
Scheme 40- Effect of metal enolates on stereochemistry of -lactam formation63 
This method was further extended to the synthesis of -lactams containing two 
contiguous stereocentres that incorporate a C3 amino substituent. The zinc enolate of 
N-protected tert-butyl glycinate 114 was reacted with chiral imine 112 affording 
(3R,4S)--lactam 115a, whilst its corresponding titanium enolate afforded (3S,4R)--
lactam 115b.64 
 
Reagents & Conditions: (i) Ti(O
i
Pr)3Cl, THF, chiral imine 112,  -78°C to -40°C, 12hrs; (ii) ZnCl, THF, 
chiral imine 112, -78°C to -40°C, 12hrs 
Scheme 41- Control of stereochemistry for C3-amino -lactams using different metal enolates64 
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The effect of different metal enolates on the outcome of the stereochemistry of -
lactams when using a chiral imine was subsequently employed to synthesise all four 
diastereomers of 3,4-dialkyl-substituted -lactams in good yield and high de.65 The 
(3S,4R)--lactam 116b was obtained by epimerization of the corresponding (3S,4R)--
lactam 116a.   
 
Reagents & Conditions: a) & b) (i) HMPA (12 equiv.), -78 °C to -60 °C; c) i) -78 °C to rt 
Scheme 42- Effect of different metals on the stereochemical outcome of -lactam synthesis 
In contrast, the products formed from reaction of ester enolates of -chloroacetates 
with chiral imines are dependent on the nature of the enolate counterion, with a titanium 
enolate affording (3R,4R)-3-chloroazetidine-2-one 118, whereas lithium or zinc 
enolates afford the alternative (2R,3S)- or (2S,3R)-aziridines 119 respectively.66  
 
Figure 5- Products of reaction of metal enolates of -haloacetates with a chiral imine66  
The synthesis of enantiopure 3-amino-4-(1’-O-silyl)-substituted monocyclic -lactams 
was first reported via reaction of achiral ester enolate 29 with a chiral silylimine 120.67 
The trans-selectivity observed in Scheme 43 has been rationalized by recent studies, 
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which suggests the trans-configuration is observed when the -imine substituent is 
bulky.67 
 
Reagents & Conditions: (i) LDA, -78°C, THF 
Scheme 43- Synthesis of 3-amino-4-(1’-hydroxy)-substituted -lactams67 
The ability to employ chiral substituents on the nitrogen atom was explored by 
incorporating chiral -amino acids into the imine starting material. It was reported that 
the double activation of both enolate of ester 29 and imine 122 was necessary for the 
zinc enolate to cyclise, which furnished the (3S,4S)--lactam 123 in good yield and high 
ee.68-69 
 
Reagents & Conditions: (i) LDA, ZnCl2 
Scheme 44-lactam formation from double zinc activation of enolate and imine components68 
 Page | 30  
 
It has been established that the use of zinc enolates for the ester enolate-imine 
cyclisation reaction normally favours the formation of trans--lactams. Consequently, 
an investigation was undertaken to examine the variables that could potentially 
encourage formation of the corresponding cis--lactam from reaction of enolates of 
ethyl 2,2,5,5-tetramethyl-1-aza-2,5-disilacyclopentane-1-acetate with N-alkyl imines. 
The factor that showed the most significant effect on changing the cis-trans- 
diasteromeric ratio was the addition of a highly polar cosolvent, with TMU, DMPU and 
HMPA markedly increasing the amount of cis--lactam 126 formed. For example, 
reaction of the zinc enolate of 29 with a chiral imine 124 derived from -
methylbenzylamine gave  trans-(3S,4S)--lactam 125 in 95% de with a 92% yield 
(Scheme 45),70 whilst addition of HMPA resulted in formation of the corresponding cis-
isomer 126 as the major product.15,70 
 
Reagents & Conditions: (i) a) LDA, Et2O; b) ZnCl2; (ii) -78°C to rt, H2O; (iii) HMPA, THF, -78°C 
Scheme 45- Effect of cosolvent HMPA on cis:trans selectivity
70,15
 
The ability to prepare -lactams containing two new contiguous stereocentres via 
enolate-imine condensation reactions has been widely investigated by Cainelli et al.16 It 
was demonstrated that changing the nature of the enolate counterion and the nature of 
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the O-protecting group on the imine affected the stereochemical outcome of the 
reaction. The presence of a bulky O-silyl substituent within the imine results in 
formation of the trans -lactam in high ee. As seen in Scheme 46, altering the imine 
substituent from a methyl 128 to a phenyl 129 fragment resulted in an increase in the 
ee of -lactam from 92% (130) to >98% (131).  
 
Scheme 46- Effect of imine substituents on stereoselectivity of -lactam formation16 
An investigation into the effects of reacting enolates of 2-pyridyl thioesters with different 
chiral imines has been undertaken by Annunziata et al. who demonstrated that the 
titanium enolate of thioester 64 reacted with imine 132 to afford the cis--lactam 133 in 
>98% de (Scheme 47).71 In light of this accomplishment, -lactam 133 was further 
developed as a potential precursor for the synthesis of a biologically active renin 
inhibitor.72  
 
Reagents & Conditions: (i) TiCl4, Et3N, DCM, -78°C to 0°C, 3hrs 
Scheme 47- Stereoselective synthesis of cis-lactams using a chiral imine71 
Imines derived from -substituted benzylamines react with titanium enolates of 2-
pyridyl thioesters to give trans -lactams in good yield and high selectivity as shown in 
Scheme 48.73 The selectivity of these reactions was rationalized using a transition state 
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involving coordination of titanium to both the enolate and the 2-pyridyl group,74 with 
improved stereocontrol occurring as the steric demand of either the imine or thioester 
substituent increases.73 
 
Reagents & Conditions: (i) TiCl4, Et3N, DCM, -78°C to 0°C, 5hrs 
Scheme 48- Use of -methylbenzylamine as a chiral auxiliary for imine formation 
In contrast, when the matched enolate-imine condensation reaction between the 
titanium enolate of chiral thioester 137 and chiral imine 138 was carried out, then a 
highly stereoselective reaction was observed, yielding the trans (3S,4S)--lactam 139 
in high de.75  
 
Reagents & Conditions: (i) TiCl4, Et3N, DCM, -78°C to 0°C, 5hrs 
Scheme 49- Matched stereocontrol using a titanium enolate of chiral thioester and a chiral imine
75
 
This excellent level of stereocontrol enabled a variety of different functional groups to 
be introduced, furnishing substrates that could be employed for the synthesis of 
carbapenem antibiotics, including thienamycin substrate derivatives.75   
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Figure 6- Structures of Thienamycin 140 and Meropenem 141 
More recently in 2007, Boyer et al76 demonstrated that zinc enolates could be used to 
prepare (rac)-gem-difluorinated -lactams 144 under standard Refomatsky conditions 
as potential metallocarboxy-peptidase inhibitors.77 The stereochemical outcome of this 
reaction could be controlled using (R)-phenylglycinol 142 as a chiral auxiliary, this 
enables chelation between the nitrogen and the zinc alkoxide to afford a five membered 
transition state, resulting in excellent diastereoselectivity.76  
 
Reagents & Conditions: (i) Zn, THF, reflux, 2hrs 
Scheme 50- Synthesis of gem-difluoro--lactams via a Reformatsky reaction76  
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1.6 Enantioselective Synthesis - External Ligands 
A number of protocols have been developed that enable stoichiometric amounts of 
external chiral ligands to be used as promoters to carry out the asymmetric synthesis of 
-lactams from achiral ester/imine starting materials. Boron enolates have been shown 
to afford cis--lactams with good levels of stereocontrol,78 which enabled an 
enantioselective ester enolate-imine cyclisation reaction to be developed using a 
stoichiometric amount of the chiral additive (1R,2S)-2-(dimethylamino)-1-phenylpropan-
1-ol.79 The chiral amino alcohol additive 146 acts both as a base to generate a boron 
enolate, as well as acting as a chiral ligand to coordinate to BCl3 to generate a chiral 
Lewis acid species that facilitated the enantioselective synthesis of trans--lactam 145 
in 74% ee (Scheme 51).79  
 
Reagents & Conditions: (i) [BCl3.Me2S + chiral amino alcohol 146], DCM, -78°C to rt 
Scheme 51- Effect of boron halide adduct as Lewis acids on absolute stereochemistry
79
 
In addition, (1R,2R)-1,2-dimethoxy-1,2-diphenylethane 149 has been used as a chiral 
ligand to coordinate the lithium counterion of ester enolate 146,80 to afford -lactam 148 
in 85% yield and 90% ee (Scheme 52).  
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Reagents & Conditions: (i) LICA, ligand 149, toluene, -50°C 
Scheme 52- The effect of an external chiral ligand on -lactam synthesis80 
These reaction conditions were further optimised using (1R,2R)-2-(2-methoxyethoxy)-
N,N-dimethyl-1,2-diphenylethanamine 150 as a ligand, in addition to altering the 
different aromatic substituents on the imine substrate, which enabled a range of chiral 
-lactams to be prepared in high yields and high enantioselectivites.81 
Table 3- “Matched” condensation of enolate 146 with imines catalysed by (1R,2R)-2-(2-
methoxyethoxy)-N,N-dimethyl-1,2-diphenylethanamine 150 forming -lactams 
 
Entry R Yield (%) ee (%) 
1 Ph 99 89 
2 PMP 99 90 
3 2-Naphthyl 99 88 
4 CMe=CHPh 99 82 
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The stereoselective synthesis of -lactam 152 was enhanced by addition of the chiral 
ether ligand 150 to the lithium enolate of menthyl isobutyrate. A catalytic amount of the 
chiral tridentate ligand significantly increased the enantiomeric excess from 50% to 
94% ee.82 Furthermore, changes made to the structure of the chiral ligand, or the chiral 
lithium enolate, enabled either -amino ester or -lactam products to be obtained.82 
 
Reagents & Conditions: (i) LDA, ligand 150, toluene, -35°C, 12hrs 
Scheme 53- Matched effect of chiral lithium enolates & chiral external ligands
82
 
In light of this success, investigations employing chiral bisoxazoline (BOX) ligands for 
use with achiral lithium ester enolates were reported,83 with the best conditions being 
obtained when 20 mol% of the BOX ligand containing an isopropyl substituent 154, was 
employed, giving -lactam 153 in 96% yield and 70% ee (Scheme 54).83 
 
Reagents & Conditions: (i) Ligand 154 (0.2 equiv.), toluene, -20°C, 4hrs 
Scheme 54- Controlling -lactam formation using chiral bisoxazoline (BOX) ligands83 
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1.7 Polymer Supported -Lactam Synthesis 
A number of approaches have been developed that enable the ester enolate-imine 
cyclisation reaction to be transferred to polymer support potentially allowing for the 
high-throughput synthesis of libraries of -lactams.84 The first polymer-supported 
synthesis of a -lactam was reported in 1998, whereby an imine 155 was immobilized 
via a soluble MeOPEG (poly(ethylene glycol)) bound linker which was reacted with a 
titanium enolate to afford the -lactam 157.85 The linker was removed by acid catalysed 
methanolysis of the polymer bound -lactam 158 to give the free -lactam in 54% 
yield.85  
 
Reagents & Conditions: (i) TiCl4, Et3N, DCM, 23°C, 15hrs 
Scheme 55- Synthesis of -lactams on polymer supported imines85 
A modified PEG support was subsequently employed to prepare an immobilized chiral 
imine 160 that was reacted with the titanium enolate of a chiral thioester 159 to 
generate the trans--lactam 161 in good ee.86 
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Reagents & Conditions: (i) TiCl4/(C8H17)3N (ii) DCM, -78°C to rt, 2hrs; (iii) CAN, MeCN:H2O, -30°C, 
2hrs 
Scheme 56- Enantiomerically pure immobilized imine and enolate in -lactam formation86 
An alternative strategy has been devised by Schunk et al. involving immobilisation of 
the ester functionality to polymer support using a T1-triazine linker that is stable under 
basic conditions.87 Subsequent generation of the lithium enolate of the polymer-
supported ester 163, followed by reaction with a range of imines and cleavage from 
polymer support gave a series of eight cis--lactams in excellent de and good yields.87 
The full potential of this immobilized ester enolate methodology was subsequently 
demonstrated for the synthesis of a variety of libraries of -lactams.88 
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Reagents & Conditions: (i) LiHMDS, THF, -78°C, 20 mins; (ii) -78°C to rt, 23hrs; (iii) a) 5% TFA, DCM; 
b) THF/DMF, 60 °C, 15 min 
Scheme 57- Synthesis of -lactams using an immobilised titanium ester enolate87  
However, the incorporation of a chiral auxiliary onto the polymer supported ester in 
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1.8 Natural Product & Antibiotic Synthesis 
The ability of the enolate-imine condensation reaction to produce -lactams in both high 
de and ee for a variety of highly substituted analogues has led to its use for the 
synthesis of a wide range of complex natural products. Many antibiotics contain the -
lactam moiety as their key feature and as such this methodology can be utilized to 
provide access to many of the biologically important targets. Initially, there was a large 
focus on employing -hydroxybutyrates as the chiral ester component within the 
enolate-imine condensation reaction, as these types of substrates could potentially 
provide an enantioselective route to carbapenem antibiotics, such as thienamycin 
140.14 
 
Figure 7- Structure of Thienamycin 140
89
 and  antibiotic PS-5 165 
One of the most significant developments involved reaction of the zinc enolate of -
hydroxybutyrate 166 with imine 167 which generated -lactam 168 in 78% yield as the 
only stereoisomer, this was proposed to proceed via a chelated transition state 
involving an (E)-enolate and the imine (Scheme 58).90  
 
Reagents & Conditions: (i) Et2Zn; (ii) LiHMDS, THF 
Scheme 58- Synthesis of -lactams using chiral -hydroxybutyrate 16690  
The condensation of -hydroxybutyrate enolates with N-aryl imines and N-trimethylsilyl 
imines is well documented, reporting good yields with the stereoselectivity highly 
dependent on the chosen reaction conditions.14  
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In addition, early work was also directed towards the synthesis of -lactam 171 as an 
intermediate for the synthesis of the structurally related antibiotic PS-5 165. The aim 
was to synthesise 4-acetoxy -lactams via an enantioselective enolate-imine 
condensation reaction91-92 involving the addition of lithium ester enolate 169 to a chiral 
imine 120 to give the trans--lactam 170 in good de, which was subsequently 
converted into the 4-acetoxy -lactam 171 in 61% yield.67 A synthesis employing 4-
acetoxy -lactam 171 had previously been reported and therefore enables a formal 
synthesis of (+)-P5-5 165 (Scheme 59).93  
 
Reagents & Conditions: (i) LDA, THF; (ii) a) TBAF, MeCN; (b) Pb(OAc)4, benzene, reflux; (iii) 1,2-DCE, 
Rh2(OAc)4; (iv) (ClP(O)(OC6H5)2, iPr2NEt, MeCN, N-acetylcysteamine; (v) H2, Pd/C, THF 
Scheme 59- Synthesis of 4-acetoxy -lactams for PS-5 synthesis92-93 
In 1991, the asymmetric synthesis of chiral -lactam building blocks that could be 
incorporated into the construction of the side chain of the anti-cancer agent taxol was 
successfully developed. Both high yield and high ee were obtained for formation of cis-
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-lactam 178  using a lithium chiral ester-enolate condensation reaction with N-TMS-
imine 177, that employed a (-)-trans-2-phenyl-1-cyclohexyl chiral ester fragment for 
diastereocontrol.94 This methodology was also employed for the generation of a series 
of taxol analogues with modified C-13 side chains.95  
 
Reagents & Conditions: (i) LDA, THF, -78°C 
Scheme 60- Asymmetric synthesis of -lactam 178 for use as taxol C-13 side chain94  
The use of this type of ester enolate-imine condensation reaction to incorporate 
heteroatom substituents into the parent -lactam enabled the synthesis and biological 
evaluation of a range of heteroaromatic taxanes, some of which were shown to be 
more cytotoxic against B16 melanoma cells than paclitaxel 179. 
 
Figure 8- Structure of Paclitaxel 179 
For example, the reaction of a chiral lithium enolate 180 with N-TMS-imine 181 gave 
the cis-2-furyl substituted -lactam 182 in high ee.96 
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In 1993, Bandini et al. demonstrated that it was possible to synthesise the -lactam 
antibiotic (+)-1-methyl PS-5 186, by employing the ester enolate-imine condensation 
reaction as the pivotal -lactam ring-forming step.97 The use of chiral imine 120 enabled 
the synthesis of an enantiomerically pure 3,4-disubstituted trans--lactam 185 that was 
subsequently converted into the carbapenem antibiotic (+)-1-methyl PS-5 186.97  
 
Scheme 62- Synthesis of (+)-1-methyl PS-5 via an ester enolate-imine condensation recation97 
The first asymmetric synthesis of SCH 48461 96, a proven cholesterol absorption 
inhibitor, could also be carried out using an ester-imine condensation that employed a 
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chiral ester fragment to introduce stereocontrol.98 Four different chiral auxiliaries were 
investigated including D/L-menthol and (+)/(-)Oppolzer’s chiral auxiliary with ee’s of up 
to 93% being obtained.98 This cis--lactam 188 was then epimerized under basic 
conditions to give the corresponding trans-(3S,4S)--lactam 96 in quantitative yield. 
HMPA was employed as an additive during the enolate-imine condensation reaction in 
an attempt to directly afford the trans--lactam, however these conditions led to a 
complete loss of stereocontrol.98 Furthermore, this methodology could be used to 
prepare a series of analogues of SCH 48461 96 in order to determine the structure-
activity relationships of the azetidinone fragment.99  
 
Reagents & Conditions: (i) LDA, THF, -78°C, (ii) KOtBu, THF 
Scheme 63- Asymmetric synthesis of cholesterol absorption inhibitor SCH 48461
98
 
This ester-imine condensation methodology allowed access to a series of N-alkyl and 
N-acyl-2--lactams, which led to the conclusion that the alkoxy group on the N-
substitued aromatic ring was not required for its pharmacological effect.99 
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1.9 Conclusion 
The ester enolate-imine condensation reaction has long been considered one of the 
main methods for the synthesis of -lactams. Control of the reaction conditions and 
appropriate selection of the metal enolate can be used to selectively alter the trans:cis 
ratio of the resultant -lactam.  In addition, the introduction of a chiral auxiliary into 
either the ester or imine functionality has the potential to afford asymmetric syntheses 
of a diverse range of substituted -lactams. The use of this methodology for the 
asymmetric synthesis of antibiotics and biologically active substrates has been 
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2 Results & Discussion – Development of an 
Intramolecular Enolate-Imine Cyclisation Reaction 
for the Synthesis of Benzocispentacin 
2.1 Introduction 
The ability to synthesise a range of enantiomerically pure -amino acids is essential to 
allow access to a variety of -peptide foldamer motifs.100 Recent developments in the 
field of foldamer synthesis have led to a renewed interest in diversifying the number 
of-amino acids available as building blocks for such scaffolds.101 There are a range of 
existing methodologies for the asymmetric synthesis of simple cyclic -amino acids 
containing a single stereocentre,102-103 but methodologies for constructing cyclic -
amino acids that contain more than one stereocentre are much less advanced.  An 
attractive approach is to generate -amino acids that contain multiple stereocentres, in 
particular -amino acid scaffolds containing aromatic substituents. They have the 
potential to encourage folding in oligoamides using secondary  stacking 
interactions104 to afford foldamers that have a wide range of potential applications.  
The original aim of the research project was to carry out a series of intramolecular 
enolate-imine cyclisation reactions, screening different chiral auxiliaries (R or R1) to 
afford enantiopure cyclic -amino acids such as cis-189 or trans-190 (Scheme 64). At 
the outset this involved the screening of a series of 5-exo-trig cyclisation reactions 
involving intramolecular nucleophilic attack of various enolates onto an imine with the 
stereochemistry controlled by an appropriate chiral auxiliary. 
 
Scheme 64- Development of -amino acid monomers for foldamer synthesis 
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2.2 Background - Foldamer Synthesis 
In the past decade, a vast array of research has been carried out into the synthesis of 
foldamers with significant contributions from the groups of Gellman105-106 and 
Seebach.107-109 The detailed discussion of this area is beyond the remit of this chapter, 
but an understanding of the fundamental properties of this research area are key to 
understanding why cyclic -amino acids are such desirable targets.  
Generally, a foldamer is considered to be an artificially adopted structure that assumes 
specific conformations that replicate biological macromolecules. In their original report, 
Gellman et al. investigated backbones that favour helical secondary structures and 
defined foldamers as ‘synthetic oligomers with unnatural backbones’(Figure 9).110 
 
Figure 9- Examples of helix bundle quaternary structures
111
  
Oligomers incorporating -amino acids producing foldamers continue to be widely 
investigated,112 due to the potential of  -peptides to modify biological activities.113-114 
The additional methylene unit allows extra conformational space that confers excellent 
folding properties within the -peptide,115 whilst they are also stable to proteolytic 
degradation.116 The use of -amino acids containing aromatic substituents can drive 
folding through stacking interactions and favourable side chain-solvent contact in 
secondary and tertiary stuctures.104,117 This enables reduction of destabilising 
backbone-solvent interactions while allowing relatively rigid conformations.117 Such 
repeating units are not found in natural biomolecules as short range interactions in -
peptides are mainly observed through hydrogen bonding. More recently work has 
begun into designing heterogeneous backbone foldamers, consisting of both  and - 
amino acid moieties which can afford additional different spatial orientations.111,118 
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In particular, Gellman et al.119 have highlighted the use of trans -amino acids such as 
trans-2-aminocyclohexanecarboxylic acid (ACHC) within -peptides to generate 14-
helical conformations. The helical numbering system is based upon the number of 
atoms in the hydrogen bonded rings, with different configurations resulting in a left or 
right handed helix. NMR techniques and crystallographic structures have been used to 
confirm the successful folding properties of conformationally restricted ACHC within a 
-peptide 14 helix (Figure 10).119 
 
Figure 10- Structure of α and β helices with carbon atoms in green, nitrogen atoms in blue and 
oxygen atoms in red, with hydrogens omitted for clarity
119
 
Such -peptides are being developed as foldamers with biomedical applications such 
as antimicrobial activity or protein surface mimicry, after having initially demonstrated 
promising biological activity.111 This has significant implications in the drug discovery 
process as these foldamers could have great potential as drugs that inhibit protein-
protein interactions (PPI’s) that are related to disease. For example, one recent 
success involves the synthesis of /-oligomers which can mimic both the structure and 
function of an -helical segment of the HIV membrane protein gp41, and as a result 
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these foldamers have been shown to exhibit potent antiviral activity in HIV anti-
infectivity assays.120  
The success of foldamer research relies on the wide availability of chiral monomers for 
the generation of specific conformations. As such, the development of methodology for 
the efficient asymmetric synthesis of cyclic -amino acid monomers is essential to allow 
further exploration of secondary and tertiary structures.  
2.3 Background - Previous Benzocispentacin Syntheses 
There are several reports of different synthetic methods for the asymmetric synthesis of 
the cyclic -amino acids shown in Scheme 64. These 1-aminoindane-2-carboxylic acid 
derived -amino acids are more commonly referred to as benzocispentacin, which have 
not only been used for the synthesis of receptor agonists121 but have also been used for 
-peptide synthesis.122 
Over a decade ago, the asymmetric synthesis of methyl (1S,2R)-1-amino-2,3-dihydro-
1H-indene-2-carboxylate 193 was achieved by the tandem conjugate addition of a 
chiral lithium amide 192 equivalent to ,-unsaturated ester 191, followed by a 
subsequent intramolecular electrophilic trap of the intermediate ester enolate.123 The 
protected trans -amino ester 193 was obtained in 80% yield and 87% de and was 
successfully deprotected to afford the parent -amino ester 194 (Scheme 65).123  
 
Reagents & Conditions: (i) THF, -78 
°
C; (ii) a) MeOH, HCl; b) Pd(OH)2, NH4HCO2, MeOH, HCl 
Scheme 65- Synthesis of bicyclic trans-amino ester 194123 
In 2000, both enantiomers of benzocispentacin were obtained by enzymatic resolution 
of the corresponding N-hydroxymethylated -lactams 195.124 The kinetic resolution 
methodology used a lipase catalysed esterification step to generate enantiopure 
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tricyclic -lactams 189a and 189b as shown in Scheme 66.125 The -lactams 195b and 
196a were obtained in 42% and 44% yields respectively and were easily hydrolysed 
and deprotected to afford the corresponding -amino acids.124  
 
Reagents & Conditions: (i) Lipase PS, vinyl butyrate in acetone, RT, 4hrs; (ii) HCl (aq) 
Scheme 66- Lipase PS catalysed β-lactam opening124 
Further to this, an improved enzymatic kinetic resolution method based on hydrolysis of 
NH--lactam 198 was reported,126 that offered a more direct route to benzocispentacin 
and its six and seven membered ring analogues. Lipolase catalysed enantioselective 
ring opening of 3,4-benzo-6-azabicyclo-[3.2.0]heptan-7-one provided access to both 
the (1R,2R)--amino acid 189a and the (1S,8S)--lactam 198b. The (R,R)--amino 
acid 189a was easily isolated with good yields of 40% and an ee of greater than 96%. 
Using aqueous HCl the remaining -lactam 198b was ring opened to afford 199b in a 
75% yield and an enantiomeric excess of 99%, resulting in a highly efficient enzymatic 
synthesis of benzocispentacin (Scheme 67).126 More recently this synthesis has been 
shown to be successful using a solvent-free method using 0.5 equivalents of water as 
the only reagent.127 
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Reagents & Conditions: (i) a) Chlorosulfonyl isocyanate; b) Na2SO3; (ii) H2O, Lipolase, 60 
°
C; (iii) 18% 
HCl 
Scheme 67- Synthesis of enantiopure benzocispentacin
126
 
Although both these methods allow access to both benzocispentacin enantiomers, 
there are several drawbacks with this enzymatic based methodology. For example, if a 
specific enantiomer is required then a maximum yield of only 50% can be obtained. 
Further to this, enzymes are very temperature, pH and substrate specific which can be 
problematic when preparing a series of structural analogues. More recently, a non-
enzymatic kinetic resolution protocol has been developed that involves the use of the 
amidine, (S)-Cl-PIQ 200, as a nucleophilic catalyst for the N-acylation of 4-aryl -
lactams.128 The -lactam 198a gave a moderate 42% conversion, with a relatively low 
selectivity factor compared to other polycyclic -lactams in the study (Scheme 68).128  
 
Reagents & Conditions: (i)10 mol% of 200, (iPrCO)2O, 
iPr2NEt, tert-amyl alcohol, 0 
°
C, 30 hrs 
Scheme 68- Kinetic resolution of -lactams via an organocatalytic N-acylation strategy  
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2.4 Background- Intramolecular Enolate-Imine Cyclisation 
Reactions Generating Multiple Stereocentres 
Andrews et al. have previously reported the significance of changing alkali metal 
counterions from lithium to sodium in (S)-N-(-methylbenzyl)allylamine complexes.129 
Unlike the stable lithium amide, the respective sodium complex was seen to undergo a 
1,3-sigmatropic rearrangement to generate the corresponding 1-aza allyl species 202 
(Scheme 69).  
 
Reagents & Conditions: (i) 
n
BuNa, TMEDA 
Scheme 69- Sodium amide 1,3-sigmatropic rearrangement
130
 
Such aza-allyl species were shown to undergo conjugate additions with -
unsaturated esters with high stereoselectivity,131 for the construction of a highly 
functionalised cyclohexylamine containing six contiguous stereocentres in a one-pot 
reaction. The reported conjugate addition involves addition of one equivalent of (E)-
aza-allyl amide 202 to two equivalents of (E)-tert-butyl cinnamate. The 
aminocyclohexane 205 was isolated in 44% yield as a single major product,132 with the 
absolute configuration of the stereocentres being determined using X-ray 
crystallography (Scheme 70). 
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Reagents & Conditions: (i) tert-butyl cinnamate (2.0 equiv.), THF, -78 
°
C, 12 hrs  
Scheme 70- One-pot cascade for the asymmetric synthesis of cyclohexylamine 205
132
 
The proposed mechanism suggests a cis-selective conjugate addition of the sodium 
aza-allyl species 202 to the first equivalent of the (E)-tert-butyl cinnamate generating a 
(Z)-tert butyl ester enolate 203 via an eight membered cyclic transition state. The 
enolate then undergoes a cis selective Michael addition onto the second equivalent of 
(E)-tert-butyl cinnamate to give an (Z)-tert-butyl ester enolate 204. In the final step of 
this reaction cascade a 6-exo-trig ring closure reaction of the enolate fragment of 204 
on to its imino functionality occurs with high diastereoselectivity,132 as shown in Scheme 
70. The ability to generate six new contiguous stereocentres, all with excellent 
stereocontrol, based on a single (S)-N-(-methylbenzyl)allylamine fragment is 
remarkable.132  
More recently there have been further reports of -amino acid derivatives with multiple 
contiguous stereocentres having been formed from one-pot reactions.133 For instance in 
2009, Davies et al. reported a tandem conjugate addition/cyclisation reaction that 
generates a cyclic -amino ester 207 with three contiguous stereocentres as shown in 
Scheme 71.134 The conjugate addition of lithium (R)-N-benzyl-N-(-methylbenzyl)amide 
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208 results in an enolate that undergoes a subsequent 6-endo-trig cyclisation reaction 
to produce a series of 2-aryl-4-aminotetrahydroquinoline-3-carboxylic acids 207 in 98% 
de.134  
 
Reagents & Conditions: (i) THF, -78 
°
C, 3 hrs  
Scheme 71- A tandem conjugate addition/cyclisation reaction
134
 
These examples demonstrate the potential for new intramolecular enolate-imine 
cyclisation protocols to be used for the asymmetric synthesis of cyclic -amino acids 
with multiple stereocentres. In light of this, the initial goal of this project was to further 
explore the final enolate-imine cyclisation step of the cascade reaction shown in 
Scheme 70, by using simple substrates in the presence of a chiral auxiliary to 
synthesise a range of chiral cyclic -amino acids.  
2.5 Retrosynthesis of Cyclisation Substrate 
In order to adapt the intramolecular enolate-imine methodology (Scheme 70) to 
produce cyclic -amino acids, the first aim was to devise a retrosynthetic route that 
would enable the desired cyclisation substrates to be prepared (Figure 11). 
Therefore, based on simplicity of synthesis, it was decided that the first pathway to be 
explored would involve using a chiral amine auxiliary for stereocontrol. The starting 
material of 2-bromobenzaldehyde 209 would have a C3-saturated ester side chain 
attached to the ortho position of the aryl ring and then the aldehyde functionality would 
be converted into an imine using the chiral amine. An enolate-imine cyclisation reaction 
could then be carried out in order to generate the desired cyclic -amino ester, which 
could be deprotected as required. 
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Figure 11 - Retrosynthetic analysis of a cyclic -amino acid 
With this in hand, the next step was to devise an appropriate methodology in order to 
synthesise the required chiral -imino ester. 
2.6 Synthesis of (S)-N-(-methyl-p-methoxybenzyl)-ω-imino-
esters 
 
The imino-ester in Figure 12 was chosen as an initial substrate to carry out 
investigations into using the enolate-imine cyclisation methodology for the synthesis of 
cyclic -amino esters. 
 
Figure 12- Target substrate for enolate-imine cyclisation 
This target structure had many benefits as a starting point for the development of a 
stereoselective enolate-imine cyclisation reaction. Firstly, the benzylic (E)-imine is 
configurationally stable, while there is no potential for competing enamine formation. 
Secondly, the aryl ring should predispose the conformation of the derived enolate 
towards 5-exo-trig cyclisation on to its imino functionality. Finally, (S)--methyl-p-
methoxybenzylamine was chosen as the chiral auxiliary over the cheaper (S)--
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methylbenzylamine, because it could be subsequently removed under either 
hydrogenolytic (Pd/C, H2), or oxidative (CAN, MeCN/H2O) conditions. 
To obtain the target substrate using the retrosynthesis shown in Figure 11, the first step 
of our synthesis required protection of the aldehyde functionality of 2-
bromobenzaldehyde 209 to afford its corresponding acetonide 210. This was achieved 
via treatment of 209 with propan-1,3-diol, in the presence of a catalytic amount of p-
toluenesulfonic acid at reflux for three hours (Scheme 72). A Dean-Stark trap was used 
to remove the water produced and drive the equilibrium of the reaction towards 
acetonide formation. The resultant 2-(2-bromophenyl)-1,3-dioxane 210 was obtained as 
a white crystalline solid in 80% yield.   
 
Reagents & Conditions: (i) Propan-1,3-diol, pTSA (cat.), Toluene, reflux, 3 hrs 
Scheme 72- Synthesis of 2-(2-bromophenyl)-1,3-dioxane 
The Mizoroki-Heck reaction is an efficient method that couples an aromatic halide and 
an electron deficient alkene using a palladium catalyst and a strong base.135-136 
Therefore, treatment of acetonide 210 and methyl acrylate with a catalytic amount of 
palladium(II)acetate and the ligand tri(o-tolyl)phosphine gave the ,-unsaturated ester 
211 in 84% yield (Scheme 73).137 
 
Reagents & Conditions: (i) Methyl acrylate, Pd(OAc)2, P(o-Tol)3, DIPEA, MeCN, 12 hrs  
Scheme 73- Synthesis of methyl 3-(2-(1,3-dioxan-2-yl)phenyl)acrylate 
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The next stage was removal of the alkene functionality of -unsaturated ester 211. 
Initially, a hydrogenation reaction using palladium on carbon was attempted on the 
methyl ,-unsaturated ester 211 at atmospheric pressure, which gave only recovered 
starting material. Subsequently the hydrogen pressure was increased to 4 atm and left 
for seven hours, which afforded the desired saturated ester 212 in 82% yield (Scheme 
74). 
 
Reagents & Conditions: (i) H2 (4 atm), Pd/C, MeOH, 7hrs  
Scheme 74- Synthesis of methyl 3-(2-(1,3-dioxan-2-yl)phenyl)propanoate acid by hydrogenation 
This hydrogenation reaction was successful on a small scale using 300 mg of 
acetonide 211 or less. However, when the reaction was scaled up it became apparent 
that the yield of ester 212 decreased dramatically, with most reactions affording 
significant amounts of starting material. To counteract this, both the pressure and 
length of time of the hydrogenation reaction were increased, including leaving the 
hydrogenation reaction for over 24 hours. Unfortunately, this did not increase the 
proportion of the desired ester 212 instead, affording competing products such as 213 
arising from hydrogenolytic cleavage of the acetal functionality (Scheme 75).  
 
Reagents & Conditions: (i) H2 (4 atm), Pd/C, MeOH, 24hrs  
Scheme 75- Palladium catalysed hydrogenolytic cleavage of acetonide 
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This resulted in an alternative and improved method for alkene reduction being 
investigated. In 2008, a chemoselective reaction was reported involving conjugate 
reduction of ,-unsaturated ester 214 using sodium borohydride and cobalt(II)chloride 
in ethanol. Jagdale et al.138 described chemoselective reduction of the alkene 
functionality of ester 214, which they used as part of their practical synthesis of (R)-
tolterodine (Scheme 76).  
 
Reagents & Conditions: (i) NaBH4, CoCl2 6H2O, EtOH, 10hrs 
Scheme 76- Chemoselective conjugate reduction of ethyl cinnamate
138
 
These conditions were successfully applied to the conjugate reduction of methyl ester 
211, which gave its corresponding ethyl ester 216, arising from alkene reduction as well 
as an unexpected Lewis acid catalysed transesterification reaction with the solvent 
ethanol (Scheme 77). 
 
Reagents & Conditions: (i) NaBH4, CoCl2 6H2O, EtOH 
Scheme 77- Chemoselective reduction of ester 211 using cobalt(II)chloride 
To confirm this, the reduction reaction was repeated using methanol as solvent with all 
other conditions remaining constant, which produced the desired saturated methyl ester 
212 in 70% yield after 72 hours (Scheme 78). 
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Reagents & Conditions: (i) NaBH4, CoCl2 6H2O, MeOH 
Scheme 78- Chemoselective reduction of ester 211 using cobalt(II)chloride in methanol 
In 1982, Heinzman et al. proposed that cobalt boride is formed in sodium borohydride 
cobaltous chloride reduction reactions, which subsequently coordinates to the alkene 
and as such catalyses a conjugate reduction reaction.139 This method is much milder 
than using H2 gas under pressure as the NaBH4 provides a source of H2 via 
decomposition over cobalt boride while possibly following a similar mechanism to the 
Luche reduction. 
Therefore, due to the occurrence of the trans-esterification process and the availability 
of ethyl acrylate, it was decided to carry out a chemoselective conjugate reduction on 
the ethyl ,-unsaturated ester 217, yielding the saturated ethyl ester in 81% yield 
(Scheme 79). 
 
Reagents & Conditions: (i) Ethyl acrylate, Pd(OAc)2, P(O-Tol)3, DIPEA, MeCN; (ii) NaBH4, CoCl2 
6H2O, MeOH 
Scheme 79- Synthesis of ethyl 3-(2-(1,3-dioxan-2-yl)phenyl)acrylate 217 
 Following the success in obtaining samples of both methyl 3-(2-
formylphenyl)propanoate 212 and ethyl 3-(2-formylphenyl)propanoate 216, it was now 
necessary to develop conditions that would allow deprotection of their acetal 
functionalities. After screening a range of deprotection conditions, it was found that 
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addition of acetic acid and water for 12 hours resulted in the acetal protecting group 
being smoothly removed to afford the desired aldehydes 218 and 219 (Scheme 80). 
 
Reagents & Conditions: (i) AcOH, H2O, 12 hrs 
Scheme 80- Hydrolysis of acetals 212 and 216 
The desired imines 220 and 221 were then prepared in essentially quantitative yield via 
addition of (S)--methyl-p-methoxybenzylamine to aldehydes 218 and 219 respectively. 
The equilibrium of imine formation was driven to completion by the use of magnesium 
sulphate to remove the water produced in the reaction (Scheme 81). 
 
Reagents & Conditions: (i) (S)-α-Methyl-p-methoxybenzylamine, MgSO4, DCM, 5hrs 
Scheme 81- Synthesis of chiral imino--esters 220 & 221 
The chiral imines 220 and 221 were generated in sufficient quantity to be used as 
substrates to investigate our proposed 5-exo-trig cyclisation methodology for the 
synthesis of -amino acids.   
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2.7 Initial Attempts at Developing an Intramolecular Enolate-
Imine Cyclisation Reaction 
 
With the desired chiral imino ester in hand (Figure 12), the next step was to generate its 
enolate in order to initiate a 5-exo-trig cyclisation reaction. At the outset, LiHMDS was 
chosen as a strong, bulky, non-nucleophilic base, which based on the precedent of 
Andrews et al.132 was predicted to afford an enolate that would cyclise to produce a cis-
-amino ester such as 222 (Scheme 82).
 
Scheme 82- Proposed cyclisation reaction 
Initially, the generation of the enolate of chiral--imino-esters, (S)-ethyl 3-(2-(((1-(4-
methoxyphenyl)ethyl)imino)methyl)phenyl)propanoate 221, was attempted using 1.1 
equivalents of LiHMDS as a base over an eight hour period at -78 °C, in keeping with 
the original conditions developed for the one-pot synthesis (Scheme 70).132 
Unfortunately, only starting material was recovered, so the reaction was repeated, but 
this time it was allowed to warm from -78 °C to room temperature. The crude reaction 
product still contained largely starting material, but small amounts (<10%) of major and 
minor diastereomeric products were present. 1H NMR analysis of the crude product 
reaction revealed that these diastereomers were not the cyclic -amino ester products 
as expected (Scheme 83). 
 
Reagents & Conditions: (i) LiHMDS (1.1 equiv.), THF, -78 
°
C to rt, 8 hrs 
Scheme 83- Initial cyclisation reaction using LiHMDS as a base 
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An appropriate solvent system was established for the separation of the two 
diastereomers by flash column chromatography, which enabled the major diastereomer 
to be isolated. Once isolated, the 1H NMR spectrum of the major diastereomer 
suggested that the cyclisation had occurred as envisaged, however an absence of 
peaks for an ethyl ester functionality suggested the potential formation of a cyclic -
lactam. Inspection of the IR data did not show the expected broad absorption between 
2500-3300 cm-1 for a carboxylic acid group. A carbonyl absorption at 1731 cm-1 
suggested either an ester (1735 cm-1) or possibly a -lactam (1745 cm-1).140 When 
examining the 13C spectrum of the major diastereomer a carbonyl peak was observed 
at 170 ppm, which was slightly lower than expected for a -amino acid (usually around 
180 ppm). However, such values correlate well with those previously reported for the 
carbonyl of a strained -lactam ring (between 167 ppm and 173 ppm).141 Finally, the 
high resolution mass spectrometry data revealed a clean and well defined m/z value of 
294.14, consistent with the formation of a -lactam 223. Therefore based on the data in 
hand it was proposed that the products formed were a set of diastereomers of the -
lactam as shown in Scheme 84. 
 
Reagents & Conditions: (i) LiHMDS (1.1 equiv.), THF, -78 
°
C to rt, 8 hrs 
Scheme 84- Identifcation of unexpected -lactam products 
The major diastereomer has a diagnostic doublet observed at 1.44 ppm and a quartet 
at 5.00 ppm whilset the minor diastereomer has a diagnostic doublet observed at 1.71 
ppm and a quartet at 4.48 ppm. Subsequently a COSY spectrum (Figure 13) of the 
major diastereomer was obtained, which helped confirm the structure of the major -
lactam diastereomer. 
  






Figure 13- COSY spectrum of -lactam 223 
 
The COSY spectrum reveals that proton B couples to protons A, A’ and C, with a 
coupling constant of J(BC)= 4.5 Hz, which is consistent with that expected for a -lactam 
ring system. The bridgehead protons B (3.87 ppm) and C (4.30 ppm) resonate at a 
lower field than would be expected for a -amino acid product. In conjunction with all 
ppm
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the other analytical data it was therefore concluded that the product formed was a 
tricyclic -lactam. 
2.8 Mechanism of -Lactam Formation 
There are two possible mechanisms by which -lactam formation could have occurred. 
The first proposed mechanism (in its simplistic form) is the formation of an (E)-enolate 
that subsequently attacks the imine fragment in a 5-exo-trig manner, resulting in the 
generation of a highly nucleophilic aza-anion. Consequently, the nucleophilic aza-anion 
substituent then undergoes a 4-exo-trig ring closing reaction to form the respective β-
lactams 223a and 223b (Scheme 85). 
 
Scheme 85- Enolate mechanism for β-lactam formation  
An alternative mechanism could be proposed based upon a Staudinger ketene 
cycloaddition pathway. This reaction manifold was first reported in 1907, when a [2+2] 
cycloaddition was employed to produce the first synthetic -lactam 7 (Scheme 86).6  
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Reagents & Conditions: (i) NEt3 (ii) N-benzylideneaniline 
Scheme 86- Staudinger ketene cycloaddition for the synthesis of -lactams 
Therefore, an alternative mechanism for -lactam 223 would require formation of a 
ketene intermediate 225. Subsequent nucleophilic attack of the imine lone pair onto the 
carbonyl of the ketene would then afford a zwitterionic intermediate, whose enolate 
fragment would then undergo ring closure onto the iminium species to afford the -
lactams 223a and 223b (Scheme 87). 
 
Scheme 87- Alternative ketene mechanism for β-lactam formation 
A review of the literature reveals that while there are numerous examples of Staudinger 
cycloaddition reaction using more reactive acid chlorides,142 there is no such precedent 
reported for less reactive ester groups. Bearing this lack of precedent in mind, it was 
concluded that -lactam formation was proceeding via a stepwise enolate-imine 
cyclisation mechanism. Furthermore, it should be noted that a -amino ester product 
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205 was isolated from Andrew et al.’s original cyclisation reaction (Figure 14), which is 
not consistent with a ketene based mechanism operating in these reactions. Therefore, 
in this case, we suggest that an enolate-imine cyclisation reaction occurs to afford a -
amino ester aza-anion, which is less likely to ring close to afford a lactam because of 
the presence of its bulky t-butyl ester. 
 
Figure 14- Cyclohexylamine 205 formed from original enolate-imine cyclisation reaction
132
  
Indeed, further reinvestigation of this cyclisation reaction has recently revealed the 
presence of a small amount of bicyclic -lactam 226 present in the crude reaction 
product of this cyclisation reaction (Figure 15). 
 
Figure 15- Minor bicyclic -lactam 226 product observed from original cyclisation reaction143 
The 4-exo-trig cyclisation of metalated -amino esters to afford -lactams is not entirely 
unexpected, with a review of the literature revealing good precedent for cyclisation. For 
example in 1974, it was reported that the treatment of (rac)--amino-ester 227 with 
MeMgI gave racemic -lactam 228, albeit in only 12% yield (Scheme 88).144 
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Reagents & Conditions: (i) MeMgI, Et2O,  0 
°
C, 2 hrs. 
Scheme 88- Synthesis of 7-ketobenzo[c]cis-6-azabicyclo[3.2.0]heptanes 228
144
 
In 2007, Davies et al. showed that magnesium amides cyclise to afford chiral -lactams 
in a similar manner.145 It has also been shown that it is possible to generate -lactams 
via the action of titanium halides146 and tin(II)amides147 on related precursors; in good 
yields (Scheme 89). 
 
Reagents & Conditions: (i) MeMgBr, Et2O, 0 
°
C 
Scheme 89- Synthesis of a β-lactam using MeMgBr to facilitate cyclisation145 
More directly related, Ha et al. have shown that treatment of -amino ester 231 with 
LiHMDS in THF at -78°C, resulted in cyclisation to afford -lactam 232 in 97% yield 
(Scheme 90).148 In conclusion, this evidence suggests that formation of -lactam 223 
occurs via an enolate-imine cyclisation mechanism.  
 
Reagents & Conditions: (i) LiHMDS, THF, -78 °C to 0 
°
C, 2hrs 
Scheme 90- Lactamisation reaction using LiHMDS as a base to induce cyclisation
148
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2.9 Determination of the Configuration of -Lactam 223 
In light of the discovery of this -lactam forming reaction and the ability to isolate the 
major diastereomer, the next step was to confirm the stereochemistry of the -lactam 
223.  
As the protected tricyclic -lactam 223 has been reported previously,126 it was decided 
to deprotect the major diastereomer 223 and use the sign of the specific rotation to 
assign its configuration. Davies et al. have previously shown that the treatment of -
lactam 233 with ceric ammonium nitrate (CAN) results in oxidative deprotection to 
afford the -lactam 234 (Scheme 91).149 
 
Reagents & Conditions: (i) CAN (3.0 equiv.), MeCN-H2O (5:1), rt, 16 hrs. 
Scheme 91- CAN deprotection reaction of -lactam 233149 
With an appropriate deprotection precedent in hand, the next step was to apply this 
oxidative cleavage methodology to the unknown major diasteromer obtained from the 
initial cyclisation reaction (Scheme 84). This deprotection strategy was successfully 
applied to N-aryl--lactam 223 yielding the free NH--lactam 198 in 76% yield.  
 
Reagents & Conditions: (i) CAN (3.0 equiv), MeCN-H2O (5:1), rt, 16 hrs 
Scheme 92- Deprotection of unknown -lactam diastereomer 223 using CAN 
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The free radical mechanism for the deprotection of tricyclic -lactam 223 is shown in 
Scheme 93. 
 
Scheme 93- Mechanism of CAN mediated deprotection reaction of -lactam 223 
Once purified, the -lactam 198 was characterized and the identification of the major 
diastereomer confirmed by comparing the negative sign of its specific optical rotation 
with the positive values previously reported for its (S,S)-enantiomer.126 Therefore, the 
specific rotation of the (S,S)--lactam diastereomer 198a was measured as +224 which 
compares with the previously reported value of -214 for the (R,R)--lactam 198b.126   
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Figure 16- Comparison of specific rotation values of 198 with literature values
126
 
This configurational assignment was further confirmed via hydrolysis of -lactam 198a 
with aqueous hydrochloric acid to give the known -amino ester salt hydrochloride salt 
199a (Scheme 94). This -amino acid salt 199a was isolated in an 83% yield giving a 
specific rotation of -2.5 which further correlates with the literature value of -5.7 reported 
previously for the same enantiomer of this amino acid.126 
 
Reagents & Conditions: (i) 18% HCl, reflux, 3hrs 
Scheme 94- -Amino acid synthesis from-lactam 198a 
A successful route had now been devised to prepare one of the model -amino acid 
targets; however the 5-exo-trig intramolecular enolate-imine cyclisation required 
optimization to enable the major diastereomer to be isolated in good yield and high de. 
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2.10  Optimisation of Enolate-Imine Cyclisation Conditions  
Initial attempts at developing the intramolecular enolate-imine reaction (Scheme 84) 
had shown that the cyclisation reaction proceeded to afford -lactam 223b. However, a 
yield of less than 10% and a diasteromeric excess of 50% were far from ideal and did 
not represent a useful synthesis of this type of tricylic -lactam. As such, an attempt to 
optimize these conditions was undertaken in order to not only improve the 
diastereoselectivity and yield, but also to provide a better insight into rationalising the 
stereoselectivity of the cyclisation reaction.    
The first variable to be selected was the base used to generate the enolate for 
cyclisation, with all reactions initially carried out at room temperature. A range of bases 
varying in pKa, steric bulk and reactivity were investigated in order to see how readily 
the enolate-imine cyclisation reaction would occur, and determine which base would 
provide the best yield and diastereoselectivity. 
As can be seen from Table 4 the trend suggested that the enolate-imine cyclisation 
reaction requires a strong sterically hindered base to proceed with good levels of 
stereocontrol. Initially, the use of LiHMDS gave a low 37% yield and also a moderate 
46% de (Table 4, Entry 1). Therefore, the reaction was attempted with the more 
reactive NaHMDS which showed a marked improvement in the 56% yield and 54% de 
(Table 4, Entry 2). As such, due to the positive correlation between reactivity and 
improved results, KHMDS was trialed as a base; however this was unsuccessful, with 
only a small amount of -lactam being formed in 0% de (Table 4, Entry 3). Potassium 
tert-butoxide, a weak base which has previously been reported to synthesise -lactams 
in intermolecular enolate-imine condensations,150 successfully generated -lactam 223a 
but in a low yield of 20% and a poor de of 30% (Table 4, Entry 4). Finally, sodium 
ethoxide, triethylamine and sodium hydride were all trialed but did not yield any -
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Table 4- Effects of choice of base on yield and diastereoselectivity of -lactam 223 
 
Entry Base Yield (%) de (%) 
1 LiHMDS 37 46 
2 NaHMDS 56 54 
3 KHMDS 18 0 
4 (CH3)3COK 20 30 
5 NaOEt 0 - 
6 Et3N 0 - 
7 NaH 0 - 
 
The non-metallic phosphazene base, also known as a “Schwesinger base”,151 has 
previously been shown to generate enolates from isopropyl acetate,152 with 
phosphazene base classed as ‘naked’ because their counterions are considered to be 
non-coordinating.153 Sadly, despite repeated attempts using phosphazene bases under 
various conditions no -lactam was ever observed with only starting material being 
recovered. In light of these results, the base chosen for further reaction optimization 
steps was NaHMDS (Scheme 95). 
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Reagents & Conditions: P4-t-Bu (1M in Hexanes), THF, -78°C to rt, 8 hrs 
Scheme 95- -lactam synthesis using phosphazene base 236 
The next variable that was examined was the reaction solvent. Toluene was chosen as 
a potential alternative as this non-coordinating, non-polar solvent has been successfully 
shown to improve the stereoselectivity in many enolate generating reactions.154 In 
comparison with THF, the cyclisation reaction in toluene gave the -lactam 223a in a 
slightly lower de of 48%, but the main effect was on the yield which was considerably 
reduced to only 14%. Therefore, THF was chosen as the solvent of choice for further 
reactions (Table 5, Entry 2). 
Table 5- Effects of solvent on yield and diastereoselectivity on -lactam 223 
 
Entry Solvent Yield (%) de (%) 
1 THF 56 54 
2 Toluene 14 48 
 
The next factor to be investigated was to include an additive in the reaction such as a 
crown ether. Crown ethers are cyclic compounds that contain ether groups which can 
bind strongly to specific cations depending on their size. In this case, as the base being 
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used was NaHMDS, the corresponding crown ether required was 15-crown-5. Due to 
the strong binding of the crown ether to the metal cation, the sodium counterion should 
not be involved in the transition state, thus generating a highly reactive “naked” enolate 
that might have a significant impact on the yield and diastereoselectivity.  
At the outset, the addition of 15-crown-5 to the reaction was investigated at room 
temperature. It was found that addition of 15-crown-5 had a significant impact on the de 
increasing it from 54% to 88% (Table 6, Entry 2). The effect of the quantity of base 
employed were also investigated, both with and without the crown ether. The aim was 
firstly to prove whether increasing the equivalents of the base (and the crown ether) 
had an impact on the yield and de of the cyclisation reaction, and to subsequently show 
whether the crown ether was as effective under these conditions. 
Table 6- Effects of crown ether additive on yield and diastereoselectivity of -lactam 223 
 
Entry R Group Crown Ether Yield (%) de (%) 
1 OEt No 56 54 
2 OEt Yes 85 88 
 
As Table 7 shows – the crown ether was as effective at increasing the yield and de 
using 2.0 equivalents of base as it was with 1.1 equivalents. However, the increase in 
the equivalents of base (and crown ether) showed a negligible difference in yield and 
the same de. Therefore, optimal conditions were established as the used of 1.1 
equivalents of base in THF in the presence of a stoichiometric amount of 15-crown-5 
that gave an 85% yield of the major diastereomer in 88% de. 
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Table 7 – Effects of equivalents of base on the yield and diastereoselectivity of -lactam 223 
 
Entry Equiv of Base Crown Ether Yield (%) de (%) 
1 1.1 No 56 54 
2 2.0 No 66 56 
3 1.1 Yes 85 88 
4 2.0 Yes 86 88 
 
The final and possibly most important factor to be investigated was temperature. All 
previous optimization reactions had been carried out at room temperature and so the 
effect of cooling the reaction was then examined. The temperature at which the enolate 
is formed could determine whether the thermodynamic or kinetic enolate was formed, 
as well as improving the facial selectivity of the cyclisation reaction. Therefore, a range 
of cryogenic temperatures were screened to see what trend between temperature and 
diastereoselectivity would be observed.  
The first step was to perform the cyclisation reaction at -78 °C for 2 hours and gradually 
allow it to warm to room temperature. Although this gave a poor 5% yield it did produce 
excellent diastereoselectivity (99% de; Table 8, Entry 2) which was not completely 
unexpected as stereoselectivity is normally improved at cryogenic temperatures. 
Therefore, in an attempt to improve the yield, but not to compromise the 
diastereoselectivity, the cyclisation reaction was carried out at -45 °C for 2 hours before 
warming to room temperature. This gave a very good and much improved yield of 73% 
while not affecting the diastereoselectivity which remained at 99% de (Table 8, Entry 3). 
The cyclisation was then attempted at 0 °C for 2 hours before warming to room 
temperature to see if the yield could be increased even further, this gave only a 67% 
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yield and a drop in de to 90% (Table 8, Entry 2). Finally the reaction was carried out at 
room temperature and these conditions saw a slight drop in the yield but the main 
drawback was the substantial decrease in the de from 99% to 88% de (Table 8, Entry 
1). These finding suggested that the optimal temperature profile for this enolate-imine 
cyclisation reaction is to start at -45 °C for 2 hours and allow the reaction to slowly 
warm to room temperature. 
Table 8- Effects of temperature on the yield and diastereoselectivity of -lactam synthesis 
 
Entry Temp (°C) Yield (%) de (%) 
1 rt 86 88 
2 -78 to rt 5 99 
3 -45 to rt 73 99 
4 0 to rt 67 90 
 
In conclusion, the optimization process had allowed a set of conditions to be identified 
that enabled the asymmetric synthesis of-lactam 223a to be carried out in good yield 
and with excellent levels of stereocontrol. The most significant modifications included 
the addition of a crown ether and reducing the temperature of the reaction to -45 °C, 
which allowed -lactam 223a to be formed in an excellent de of 99% and a good 73% 
isolated yield. 
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Reagents & Conditions: (i) NaHMDS (2.0 equiv.), 15-crown-5, THF, -45 °C to rt, 8 hrs 
Scheme 96- Optimised conditions for -lactam synthesis 
Not only did this generate a suitable methodology for the synthesis of -lactam 223a, 
but also the possibility of using it to generate a range of -lactam analogues.  
 
2.11 Occurrence of a Minor -Amino Ester Side Product 
Upon further inspection of the 1H NMR spectra of the crude reaction products of some 
of the enolate-imine cyclisation reactions described in the previous section, there were 
a few examples where a minor side product was present. This was significant as it 
could provide further understanding of the mechanism of the enolate-imine cyclisation 
reaction. 
Consequently, it was found that treatment of ester 221 with KHMDS in THF at room 
temperature resulted in a crude reaction product that was purified by chromatography 
to afford a small amount of a -amino ester side product. The 1H NMR spectrum of this 
side product contained a triplet at 1.24 ppm and a quartet at 4.19 ppm suggesting that 
the ethyl ester group was still present. Further to this, the presence of multiplets at 3.18 
ppm and 3.36 ppm of its bridgehead ring protons indicated that the initial 5-exo-trig 
cyclisation had also taken place. In addition, the high resolution mass spectrometry 
data reported a clean and well defined m/z value of 340.19, consistent with the 
presence of a -amino ester shown in Figure 17. 
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Figure 17--amino ester isolated from the enolate-imine cyclisation reaction 
Analysis of the 1H NMR spectra of the crude products revealed that using LiHMDS and 
KHMDS in THF at room temperature afforded the minor -amino ester in the best yield. 
In comparison, using NaHMDS as a base does not generate the -amino ester, with 
no-amino ester being present in the 1H NMR spectra for any of the optimization 
reactions carried out in Table 9. 
The appearance of a minor -amino ester is not completely unexpected when the work 
by Andrews et al. is considered,132 where their original conditions using LiHMDS 
resulted in -amino ester 205 being formed as the major product.  
Table 9- Ratio of -lactams and-amino esters products in enolate-imine cyclisation reactions 
 
Entry Base (1.1 equiv.) Temp (°C) Solvent 
Ratio of Products 
(223a:223b:237) 
1 LiHMDS rt THF 49:18:33 
2 KHMDS rt THF 30:31:39 
3 KOtBu rt THF 65:35:0 
4 NaHMDS rt THF 77:23:0 
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With the identification of a minor -amino ester side product established, the next step 
was to establish its stereochemistry. There are four possible diastereomers which could 
potentially be assigned to -amino ester 237 (Figure 18), so therefore the next step was 
to prepare authentic samples of all of these isomers for comparative purposes.   
 
Figure 18- Possible diastereomers of unknown-amino ester 237 
At the outset, the major diastereomer of (S,R,R)--lactam 223a was subjected to 
acidic conditions in ethanol, which resulted in a ring opening reaction to form the HCl 
salt of (S,R,R) -amino ester 242 shown in Scheme 97.  
 
Reagents & Conditions: HCl (1M in Et2O), EtOH, reflux, 3 hrs 
Scheme 97- Ring opening of (S,R,R)--lactam 223a 
In order to obtain the trans isomer (S,S,R) 241 an epimerization reaction was 
performed on the cis--amino ester 242 using the methodology reported by Fulop et al. 
that had been used previously to epimerise a similar benzocispentacin structure.126 
Therefore, the HCl salt of the trans diastereomer was synthesised by stirring with 
NaOEt in EtOH followed by acidification with 1M HCl for 30 minutes which gave the 
(S,S,R)-diastereomer 243 (Scheme 100). 
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Reagents & Conditions: (i) NaOEt, EtOH, reflux, 7 hrs; (ii) HCl (1M in Et2O), rt, 0.5 hrs  
Scheme 98- Synthesis of -amino ester 243 
Next, the alternative -amino ester cis diastereomer (S,S,S) 244 was synthesised 
from the (S,S,S) minor -lactam diastereomer 223b, that was isolated from an 
unselective cyclisation reaction. Previously established conditions using KHMDS as a 
base to carry out the enolate-imine cyclisation reaction on 221 had given an equal ratio 
of the two major and minor diastereomeric -lactams 223a and 223b (Table 4). 
Therefore, the cyclisation reaction was repeated on a larger scale and the crude 
product purified by chromatography to afford an authentic sample of (S,S,S)--
lactam 223b. With the (S,S,S)--lactam in hand the subsequent acid catalysed ring 
opening reaction was carried out to afford the corresponding (S,S,S)--amino ester 
244 (Scheme 99).126 
 
Scheme 99- Ring opening of minor diastereomer of -lactam 223b 
Lastly, to obtain the fourth and final diastereomer of the -amino ester, the cis 
(S,S,S)--lactam 244 was epimerized using NaOEt in EtOH, followed by stirring in 
1M HCl for 30 minutes to afford the trans-(S,R,S)--amino ester 245 (Scheme 
100).126 
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Reagents & Conditions: (i) NaOEt, EtOH, reflux, 48 hrs; (ii) HCl (1M in Et2O), rt, 0.5 hrs  
Scheme 100- Epimerisation of -amino ester 244 
With all four possible diastereomers in hand it was possible to compare their 1H NMR 
spectra, focusing on the three diagnostic protons of their 5-membered rings (Figure 19). 
 
A       (S,R,R)--amino ester salt 242
        
 
B       (S,S,R)--amino ester salt 243 
 
 


























































 Page | 82  
 
Comparison of the four 1H NMR spectra (Figure 19) showed that each diastereomer 
exhibited distinct resonances between 2.5 ppm and 5 ppm, with the 1H NMR spectrum 
of (S,S,R)--amino ester 245 being identical to the 1H NMR spectrum of the minor 
diastereomer isolated from the KHMDS enolate-imine cyclisation reaction. Therefore, 
based upon the 1H NMR data we can revise the scheme shown in Table 9 to include 
the stereochemistry of the minor -amino ester by-product (Scheme 101). 
 
Scheme 101- All possible cyclisation products with relevant stereochemistry 
To conclude, the structure of the -amino ester side product was determined as 
(1S,2R)-ethyl-1-(((S)-1-(4-methoxyphenyl)ethyl)amino)-2,3-dihydro-1H-indene-2-
carboxylate, which enabled a complete picture of the stereochemical outcome of this 
cyclisation reaction to be obtained.  
 
2.12 Rationale for the Stereochemistry of the Enolate-Imine 
Cyclisation Reaction 
 
The formation and geometry of the enolate generated in these cyclisation reactions is a 
crucial factor in explaining the stereochemical outcome of -lactam formation. There 
are two possible geometries when generating substituted enolates; either a (Z)-enolate 
or an (E)-enolate. Whereas the chiral auxiliary fragment determines the facial selectivity 
of the cyclisation reaction, the geometry of the enolate formed is highly significant since 
it determines the cis/trans diastereoselectivity of the initial stereodefining cyclisation 
reaction. 
Literature precedent suggests that deprotonation of an ester with NaHMDS in THF 
(Scheme 96) should result in the formation of an (E)-enolate. In 1976, Ireland et al.155 
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described how an appropriate base and solvent selection determines the geometry of 
the ester enolate formed, as part of their attempts to control the stereoselectivity of a 
subsequent [3,3] sigmatropic rearrangement. By trapping enolates of esters with tert-
butyldimethylsilyl (TBDMS) groups it was shown that an (E)-isomer 247 was formed 
using LDA in THF (~ 95%).156 However, when the solvent system was altered to include 
hexamethylphosphoramide (HMPA), the (Z)-enolate ester 248 was formed (~85%).156 
These findings were later confirmed by crystallographic data (Scheme 102).157 
 
Scheme 102- Formation of (Z)/(E)-lithium ester enolates
155
 
Further to this, research by Heathcock et al. showed that the percentage of (Z)-ester 
enolates generated by strong bulky bases like LDA is very low, with less than 5% of 
any (Z)-enolate being formed.158 Therefore it can be concluded that an (E)-ester 
enolate should be generated during our intramolecular enolate-imine cyclisation 
reactions. 
It has been demonstrated (Table 6) that the cyclisation of the sodium enolate onto the 
-imino ester produces the same -lactam regardless of the presence of 15-crown-5. 
Therefore, this suggests that the initial 5-exo-trig reaction proceeds via a non-chelated 
open transition state (Scheme 103). 
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Scheme 103- Mechanism of enolate-imine cyclisation via an (E)-ester enolate 
The next step was to consider the diastereomeric intermediates that could be formed in 
this cyclisation reaction and provide an explanation for the selective formation of the 
(S,R,R)--lactam 223a as the major product. There are four possible diastereomeric 
N-anions that could potentially be formed in this 5-exo-trig cyclisation reaction (Figure 
20). 
 
Figure 20- Possible N-anion intermediates after 5-exo-trig cyclisation 
These diastereomeric intermediates will have different transition state energies of 
formation; with the epimerisation studies carried out in Scheme 98 clearly 
demonstrating that trans cyclic -amino esters are more thermodynamically stable than 
their corresponding cis -amino esters. In order to further understand the relative 
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energies some computational modeling was carried out on all four possible 
diastereomeric intermediates whose structures are presented in Figure 21-Figure 24, in 
an orientation viewed down the forming bond. The computational modeling and 
theoretical calculations were carried out by Dr. Andrew Leach at AstraZeneca with the 
programme “Gaussian09” being applied to the methyl ester diastereomers to minimize 
the number of calculations required. 
In Figure 21, the lowest energy transition state conformation of the aza-anion 250 is 
shown which affords the observed (S,R,R) -lactam 223a. The key feature of this 
conformation is that the small benzylic hydrogen atom is presented towards the aza-
anion fragment. This enables this conformation to minimise steric hindrance with the 
ester fragment, which results in an orientation whereby the methyl group of the chiral 
auxiliary fragment pointed downwards, with the more sterically demanding phenyl 
group pointing upwards. In comparison, Figure 22 illustrates the relatively disfavoured 
conformation of aza-anion 251 that leads to the formation of the minor (S,S,S)  -
lactam 223b. This intermediate 251 is largely disfavoured on steric grounds due to the 
chiral auxiliary phenyl group clashing with the ester fragment. Figure 23 shows the 
lower energy transition state leading to the trans-(S,R,S)-N-anion 252 where a 
staggered conformation is observed, in which the phenyl group of the auxiliary fragment 
has rotated so that it is staggered along the bond with the methyl substituent in the 
same plane as the methoxy group. In contrast, the disfavoured transition state in Figure 
24 leading to trans-N-anion 253 results in its phenyl group being placed close to the 
methoxy group, and is therefore less likely to form.  
Therefore based on computational calculations, the transition state energies leading to 
the N-anions of the diastereomeric -amino esters 250-253 based upon their 
thermodynamic stability is as follows: 
trans-(S,S,R) 253 < trans-(S,R,S) 252 < cis-(S,R,R)  250 < cis-(S,S,S) 251 
Pleasingly, this result is consistent with the fact that (S,R,S)--amino ester 240 was 
isolated as a minor component of the KHMDS and LiHMDS mediated cyclisation 
reactions. However, these relative energies lead to the question as to why we see 
formation of the (S-R,R) -lactam 223a as the major product of these cyclisation 
reactions?


















Figure 22- Disfavoured cis-N-anion structure enabling -
lactam formation 251 
Figure 21- Favoured cis-N-anion structure enabling -
lactam formation 250 
Figure 23-Favoured trans-N-anion structure 253 Figure 24-Disfavoured trans-N-anion structure 252 
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It is proposed that the answer to this question lies in the fact that the reaction must 
generate a dynamic equilibrium whereby a reversible enolate-imine cyclisation reaction 
occurs to afford a rapidly interconverting mixture of trans/cis-N-anions under 
thermodynamic control (Scheme 104). 
 
Scheme 104- Molecular modelling of (S-R,R) -lactam formation 
Regardless of which of the thermodynamically stable trans-N-anions are formed there 
is no further ring closure pathway that the trans-N-anions (pKa NH ~ 35) can undergo, 
therefore these intermediates can revert back to the enolate (pKa enolate = 25) unless 
an adventitious proton source is present. Therefore, even though the cyclic cis-N-
anions have a higher energy barrier of formation to overcome, the fact that they can 
undergo a subsequent rapid 4-exo-trig pathway, to irreversibly afford their 
corresponding-lactams, leads to their selective formation. The formation of the 
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subsequent -lactam, means that the equilibrium of the cyclisation reaction is then 
driven to produce more of the cis-N-anions until the reaction is complete. Therefore, (S-
R,R) -lactam 223a is formed preferentially over the (S-S,S)--lactam 223b, as 
formation of the cis-N-anion 251 is calculated to be several kcals higher, therefore less 
than 1% of this diastereomer would be expected to be observed. All computational 
calculations are based upon the assumption that the rate determining step is the 
enolate formation/cyclisation and not the rapid 4-exo-trig cyclisation affording the -
lactam. This assumption agrees with previously reported modeling studies on related 
intermolecular ester enolate-imine cyclisation reactions to afford -lactams.13 There are 
also several examples in the literature where lithium ester enolates have been reported 
to undergo intermolecular cyclisation reactions on to imines resulting in the selective 
formation of cis--lactams as seen in Scheme 105.30,49-50,52 
 
Reagents & Conditions: (i) LDA, THF, -70°C to rt; (ii) N-benzylidene-4-methoxyaniline 
Scheme 105- Intermolecular lithium ester enolate reaction forming cis--lactams49 
To summarise, the intramolecular 5-exo-trig cyclisation reaction of (E)-enolate occurs 
under kinetic control to afford four possible N-anion intermediates under 
thermodynamic control. Despite the higher relative energies required for the formation 
of cis-N-anions, they are the only diastereomers that can undergo a subsequent 4-exo-
trig ring closure, which then drives the equilibria of the reaction to give -lactam 
products. 
 
2.13 Benzocispentacin Conclusion 
In conclusion, a chiral auxiliary strategy has been developed that enables an 
intramolecular ester enolate-imine cyclisation reaction to be used for the asymmetric 
synthesis of a tricyclic -lactam 223a with excellent levels of stereocontrol. The (E)-
 Page | 89  
 
enolate of an N-(-methyl-p-methoxybenzyl)--imino ester undergoes intramolecular 5-
exo-trig cyclisation to afford a cis-N-anion, which subsequently undergoes a 4-exo-tet 
ring closure to furnish a tricyclic (S,R,R)--lactam 223a in good yield and excellent 
de. An optimized protocol has been established using NaHMDS and a crown ether in 
THF, with potential side products in this reaction having been identified and their 
stereochemistry assigned. In the following section, application of this methodology for 
the asymmetric synthesis of a range of structurally related cyclic -lactams will be 
described. 
 
2.14 Development of Benzocispentacin Analogues 
2.14.1 Previous Synthesis of Indane Derived Amino Acids 
The availability of a versatile methodology to synthesise a range of highly functionalized 
cyclic -amino acids is highly desirable. In particular, there is a large amount of interest 
in the synthesis of indane amino acid derivatives due to their potential biological 
properties. For example, certain substituted indanes have been shown to be 
mechanism-based inhibitors of dopamine -hydroxylase.159 In addition -amino acids of 
substituted indanes, AIDA and APICA, have been shown to be antagonists of 
metabotropic glutamate receptors which are associated with neurological diseases 
(Figure 25).160 
 
Figure 25- Structures of AIDA 256 and APICA 257 
Due to their important biological activities there have been several attempts at 
preparing substituted indane amino acids, including an organocatalytic enantioselective 
synthesis using (R)-proline for the synthesis of both (S)-AIDA and (S)-APICA in 2005 
(Scheme 106) .161  
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Scheme 106- Synthesis of (S)-AIDA and (S)-APICA 
More recently in 2011, methodology for the synthesis of angularly fused indane amino 
acids was established,162 with addition of ethyl isocyanoacetate to dibromoarene 258 
resulting in construction of the new ring system of the tricyclic indane amino acid 
structure (Scheme 109).162 These types of -amino acids scaffolds have been widely 
used in recent years and the ability to access similar highly functionalized enantiopure 
analogues for benzocispentacin would be a welcome development.  
 
Reagents & Conditions: i) Ethyl isocyanoacetate, K2CO3, MeCN; (ii) a) EtOH, dil. HCl; b) Ac2O, DMAP, 
DCM 
Scheme 107- Synthesis of fused indane -amino acid derivatives162  
Previously, it had been reported that the addition of enolates onto chiral imines does 
not provide good methodology for accessing highly substituted -amino acids.163 
Despite this, there have been several other reported methods to generate substituted 
indane-amino acids (benzocispentacin). This includes the cyclisation of radical 
species onto oxime ethers with tributyltin hydride being used as a radical initiator to 
afford the cis-alkoxyamine 263 in 68% yield (Scheme 108).164 
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Reagents & Conditions: (i) MeONH2.HCl, pyridine, rt; (ii) Bu3SnH, AIBN, benzene, reflux 
Scheme 108- Synthesis of alkoxyamino-3-methylidene-chromanes
164
 
Furthermore in 2005, diastereoselective addition of an aryl anion to a chiral isoxazoline 
fragment generated benzocispentacin structures containing four contiguous 
stereocentres was reported.163 In particular, the generation of a quaternary centre in 
266 is highly valuable and therefore these types of highly functionalized structures have 
great potential as peptidomimetic scaffolds (Scheme 109).  
 
Reagents & Conditions: (i) a) 
t
BuLi, THF, -78°C; b) HCl/H2O, 0°C to rt 
Scheme 109- Synthesis of disubstituted -amino acids from chiral isoxazolines163 
As discussed earlier, one of the most useful methodologies for the synthesis of 
polycyclic -amino acids has been developed by Fulop et al., who have successfully 
managed to use the enzyme Lipolase to catalyse the kinetic resolution of racemic -
lactam 268 as shown in Scheme 110.126 Such work has provided a range of cyclic 
structures, but this methodology could not be used to prepare chiral -lactams 
containing aryl substituents due to the substrate specific nature of the enzymes active 
site. 
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Reagents & Conditions: (i) CSI, Na2SO3; (ii) H2O, Lipolase, 60°C 
Scheme 110- Synthesis of benzocishexacin using enzymatic resolution
126
 
Another highly researched area is the synthesis of fluorinated -amino acids that are 
important medicinal chemistry targets.165 There are many examples of the incorporation 
of fluorine into cyclic -amino acids which has recently been the subject of a large 
review.165 For example, the synthesis of a difluorinated analogue of cispentacin 271166 
and substituted -lactam 273167 has generated a large amount of research interest 
(Scheme 111).  
 
Reagents & Conditions: (i) a) H2, Pd/C; b) LDA, THF, -78 °C; (ii) BrCH2COEt, Zn, THF, reflux  
Scheme 111- Examples of fluorinated -amino acids/-lactams166-167 
Therefore, it was the aim of this work to develop our enolate-imine cyclisation reaction 
to prepare highly functionalized benzocispentacin analogues that incorporated methyl, 
methoxy and fluoro substituents as well as an angularly fused naphthyl indane -
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lactams which could mirror products previously shown to be valuable for -amino acid 
research.  
2.14.2 Synthesis of Benzocispentacin Analogues 
Six commercially available substituted 2-bromobenzaldehydes were subjected to the 
previously developed 5-step methodology to furnish their corresponding chiral -imino-
esters in moderate to good yields. These cyclisation substrates were derived from 2-
bromo-4-methylbenzaldehyde 274a, 2-bromo-5-(trifluoromethyl)benzaldehyde 274b, 2-
bromo-6-fluorobenzaldehyde 274c, 2-bromo-5-methoxybenzaldehyde 274d, 2-bromo-
4,5-dimethoxybenzaldehyde 274e and 1-bromo-2-naphthaldehyde 274f. The most 
significant alteration to the synthetic protocol was the conjugate reduction of the double 
bond of the naphthyl derivative 277f that required 72 hours instead of the 48 hours 
employed for the other analogues. Apart from this exception, all of the other reactions 
proceeded effectively to afford the desired cyclisation substrates (Scheme 112).  
 
Reagents & Conditions: (i) Propan-1,3-diol, pTSA, Toluene, (ii) Ethyl Acrylate, Pd(OAc)2, (o-Tol)3P, 
DIPEA, MeCN (iii) NaBH4, CoCl2 6H2O, Ethanol (iv) Acetic acid and water (v) (S)-(-)-4-methoxy-α-
methylbenzylamine, MgSO4, DCM 
Scheme 112- Synthesis of -imino esters (S)-279a-f 
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The yields obtained for each step of the synthetic protocol used to prepare six -imino 
esters 279a-f can be seen in Table 10, which ranged from good to excellent. 













85 71 70 73 82 
 
79 68 54 69 85 
 
50 81 49 79 82 
 
96 58 71 86 85 
 
84 76 87 77 93 
 
84 84 75 71 92 
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The intramolecular enolate-imine cyclisation conditions were then applied to the range 
of chiral -imino esters (279a-f) with the resulting de’s and yields obtained shown in 
Table 18. The de’s were determined from the integration of the diagnostic resonances 
for the major and minor -lactam diastereomers (280a-f) in the 1H NMR spectra of the 
crude reaction products. Cyclisation substrates containing a range of electron donating 
(Table 10, Entries 1, 4 and 6) and electron withdrawing (Table 10, Entries 2, 3 and 6) 
substituents in various ring positions, afforded a range of -lactams using this 
methodology. As can be seen from Table 11, the majority of the substrates gave 
cyclised -lactams with excellent de’s (>95%) and moderate to good yields. One 
exception is Entry 3 which had a notably lower de of 90% when the fluorine is ortho to 
the imine substituent, although this reaction does benefit from a much higher yield.  
Table 11- Asymmetric synthesis of (R,R)--lactams 280a-f 
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The X-ray crystallographic structure of one of the analogues, trifluoro-aryl--lactam 
280b, was obtained after successful recrystallisation from a mixed solvent of 
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dichloromethane and hexane. As shown in Figure 26, the X-ray crystal structure of the 
protected -lactam 280b shows that the major diastereomer of the enolate-imine 
cyclisation reaction is the (S,R,R)--lactam, where the methyl group on the auxiliary 
(C13) lies in the same plane as the -lactam ring (C3-N1 and C2-C1) with the three 
hydrogen atoms on C2, C3 and C12 all pointing out of the plane of the paper in the 
same direction (as drawn, Figure 26).  
 
Figure 26- X-ray crystal structure of (S,R,R)-trifluoro-aryl--lactam 280b with ellipsoids drawn 
at the 50% probability level 
Oxidative cleavage of the chiral auxiliary fragment of N-aryl--lactams 280a-f was then 
carried out using CAN in MeCN/H2O to afford the deprotected -lactams 281a-c in 
good yields under mild conditions (Figure 27).  
 
Figure 27- Synthesis of tricyclic -lactam analogues 
Attempts to remove the chiral auxiliary of the remaining three protected -lactams 
280d-f proved unsuccessful. Firstly, treatment of the protected -lactam 280d with CAN 
gave a 1H NMR spectrum that showed a number of products with the main component 
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from the deprotection reaction being identified as a keto--lactam. This product is 
formed from benzylic oxidation, instead of cleavage of the chiral auxiliary from the -
lactam ring. A similar benzylic oxidation was also observed for the structurally related 
N-aryl--lactam 280e (Scheme 113). 
 
Reagents & Conditions: (i) CAN (3.0 equiv.), MeCN-H2O (5:1), rt, 16 hrs. 
Scheme 113- Formation of keto--lactam 282 
A review of the literature revealed that the formation of such keto--lactams was not 
entirely unexpected, since CAN mediated benzylic oxidations of indane systems have 
been reported previously (Scheme 114).168 
 
Reagents & Conditions: (i) CAN, HNO3, 30°C, 1.5hrs 
Scheme 114- Partial oxidation with CAN
168
 
The naphthyl analogue 280f was also not deprotected successfully, yielding only small 
amounts of starting material and a range of other unidentifiable products. Therefore, the 
current methodology for the removal of the chiral auxiliary is not suitable for N-aryl 
protected -lactams 280d-f and further work will be required to investigate alternative 
deprotection conditions for these analogues. Alternatively, a different auxiliary might be 
used to control the stereoselectivity of the cyclisation reaction. 
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2.14.3 Synthesis and Optimization of the Asymmetric Synthesis of 
Benzocishexacin 
With a range of benzocispentacin derived analogues having been prepared the next 
step was to attempt to increase the acyclic ring size of the -imino ester that would 
cyclise to afford a six membered -lactam. In order to prepare the desired -imino ester 
the design of an alternative synthetic protocol was required, such as an extra 
methylene group which would need to be included in the ester side chain (Figure 28). 
 
Figure 28- Target starting material for benzocishexacin synthesis 
Whereas previously a Heck cross coupling reaction of 2-bromobenzaldehyde had been 
used to install the ester C3 side-chain, an alternative cross coupling methodology was 
required for addition of a longer C4 side-chain. To address this problem a review of the 
literature revealed there was precedent for such a transformation, whereby Sase et al. 
had reported a one pot Negishi cross coupling reaction of aryl halides with alkyl zinc 
reagents.169 In a two step reaction that involved the use of a PEPPSI ligand, a high 
yielding cross coupling procedure was used to furnish ethyl 4-(4-
formylphenyl)butanoate 288 in an 87% yield (Scheme 115).169 
 
Reagents & Conditions: (i) LiCl, Zn, dibromoethane, trimethylsilylchloride, iodine, THF, 50 °C, 12hrs; 
(ii) 4-bromobenzaldehyde, PEPPSI, DMI, rt, 1 hr                         
Scheme 115- One pot Negishi reaction using alkyl zinc intermediates
169
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PEPPSI 289 (Pyridine-Enhanced Precatalyst Preparation, Stabilisation and Initiation), 
is a particularly useful ligand for these types of cross-coupling reactions, as it is easily 
synthesized, air stable and highly active, and has shown an increase in the scope and 
reliability of the Negishi reaction (Figure 29).170  
 
Figure 29- Structure of PEPPSI ligand
170
 
It was proposed that this methodology could be utilized to obtain the desired ortho-
substituted ester. If possible, this technique would reduce the number of steps required 
for its synthesis when compared with benzocispentacin, since there would be no need 
to reduce a double bond or to protect the aldehyde functionality. As such, the one pot 
Negishi cross coupling was attempted using 2-bromobenzaldehyde 209 (Scheme 116), 
successfully affording ethyl 4-(2-formylphenyl)butanoate 291 in 51% yield. The only 
alteration to the original methodology was to extend the reaction time of the cross 
coupling reaction to 12 hours. 
 
Reagents & Conditions: (i) Lithium chloride, zinc, dibromoethane, trimethylsilylchloride, iodine, THF, 50 
°C, 12hrs; (ii) 2-bromobenzaldehyde 209, PEPPSI 289, DMI, rt, 12 hrs                      
Scheme 116- Synthesis of ethyl 4-(2-formylphenyl)butanoate from Negishi cross coupling 
This cross coupling reaction starts with the active Pd(0) complex which adds to the aryl 
halide 209 via an oxidative addition, with the resulting Pd(II) complex subsequently 
undergoing transmetalation with the zinc activated ethyl 4-bromobutanoate. This is then 
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followed by a reductive elimination reaction which gives the desired product 291, while 
regenerating the Pd(0) complex, as shown in Scheme 117. 
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The next step was the formation of the chiral imino--ester via reaction of the aldehyde 
functionality 291 with (S)-(-)-4-methoxy--methylbenzylamine under our standard 
conditions (Scheme 118). 
 
Reagents & Conditions: (i) (S)-(-)-4-methoxy--methylbenzylamine, MgSO4, DCM, rt, 5hrs 
Scheme 118- Synthesis of (S,E)-ethyl 4-(2-(((1-(4-methoxyphenyl)ethyl)imino)methyl)phenyl) 
butanoate 
 
With the chiral imino--ester in hand, it was decided that the optimized conditions 
previously established for the benzocispentacin derivatives (Scheme 96) would be 
applied to the first synthesis of the benzocishexacin -lactam 292. The cyclisation 
reaction of 285 proved successful, with the (E)-enolate undergoing a 6-exo-trig 
intramolecular cyclisation reaction by nucleophilic attack on to its chiral imine fragment. 
This gives a cis-aza-anion which subsequently performs a 4-exo-trig ring closing 
reaction resulting in the formation of -lactam 292. The-lactam was generated in a 
moderate yield of 57% and a good de of 85%. In an attempt to improve the yield and de 
further a brief optimization screen was then carried out (Table 12). 
 
Reagents & Conditions: (i) NaHMDS (2.0 equiv.), 15-crown-5, THF, -45 °C to rt, 8 hrs 
Scheme 119- Cyclisation reaction of chiral imino--ester 292 to afford -lactam 292 
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Initially, the cyclisation reaction was attempted with both LiHMDS and NaHMDS (Table 
12, Entry 1 and 2) without the crown ether to see if this made any improvement. The 
results show that both the de and conversion were much lower than when compared 
with the previously optimized conditions (Table 12, Entry 7). When the crown ether was 
added at room temperature (Table 12, Entry 3) there was a clear increase in the 
conversion rate and de. Furthermore, when the temperature was decreased (Table 12, 
Entries 4 and 5) there was a decrease in the conversion rate, but a significant increase 
in the de, apart from when the reaction was carried out at -78 °C which gave only 
recovered starting material. The increase of base from 1.1 equivalents (Table 12, Entry 
5) to 2.0 equivalents (Table 12, Entry 7) showed an impressive increase in the 
conversion, which may have been due to the presence of water in the reaction media 
which could have quenched the base when only 1.1 equivalents was used. Therefore, 
the best conditions established for this reaction are those of Entry 7, which were the 
initial conditions originally established in benzocispentacin synthesis. 
Table 12- Optimisation of a 6-exo-trig intramolecular enolate-imine cyclisation reaction 
 





1 LiHMDS rt 1.1 No 74 35 
2 NaHMDS rt 1.1 No 13 28 
3 NaHMDS rt 1.1 Yes 100 49 
4 NaHMDS 0 to rt 1.1 Yes 62 58 
5 NaHMDS -40 to rt 1.1 Yes 44 84 
6 NaHMDS -78 to rt 1.1 Yes 0 - 
7 NaHMDS -40 to rt 2.0 Yes 73 85 
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The explanation for the decrease in the yield and de for the formation of -lactam 292 
must be due to the presence of the extra methylene unit. Once the (E)-enolate has 
been formed there must be more conformational mobility between the enolate fragment 
and the imine substituent, resulting in less stereocontrol of the initial 6-exo-trig 
cyclisation reaction, which results in a poorer facial selectivity and a lower de.  
After purification by chromatography, the final step in the synthesis involved removal of 
the chiral auxiliary from N-aryl--lactam 292 by applying the CAN mediated oxidative 
deprotection shown in Scheme 92. The free -lactam 293 was obtained in a 72% yield 
(Scheme 120), which may then undergo subsequent acidic hydrolysis to generate the 
corresponding-amino acid as required.  
 
Reagents & Conditions: (i) CAN (3.0 equiv.), MeCN-H2O (5:1), rt, 16 hrs 
Scheme 120- Oxidative cleavage of chiral auxiliary 
To summarise, an alternative methodology has been devised for the synthesis of the 6-
membered-lactam 293. The synthetic route to the cyclisation precursor is much 
shorter than the one used for the synthesis of its 5-membered analogues due to the 
use of a Negishi cross coupling reaction. This approach directly incorporates the ester 
side chain onto the aryl ring without the need for any protecting groups and the removal 
of a double bond. Although the 6-exo-trig enolate-imine cyclisation reaction occurs in 
acceptable yield and a good de, it does not proceed with the same level of 
diastereocontrol previously demonstrated for the 5-membered benzocispentacin 
analogues. 
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2.14.4 Conclusion 
The application of the newly developed intramolecular enolate-imine cyclisation 
reaction for the synthesis of tricyclic -lactams has been achieved to furnish seven 
novel polycyclic -lactam analogues. The yields obtained range from moderate to high 
and the de’s range from good to excellent. There is a problem with the oxidative 
removal of the chiral auxiliary fragment for a few N-aryl--lactams but ultimately this 
novel enolate-imine cyclisation methodology was shown to be successful for the 
asymmetric synthesis of polycyclic -lactam ring systems. 
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3 Results & Discussion- Acyclic Substrates 
3.1 Introduction 
The original aim of developing stereoselective methodology for carrying out an 
intramolecular enolate-imine cyclisation reaction had been achieved for a series of 
benzocispentacin substrates. An exciting application of this research would be to apply 
this methodology for the asymmetric synthesis for a range of chiral monocyclic β-amino 
acids. The most commonly reported monocyclic -amino acids used for foldamer 
synthesis are cispentacin 294 and transpentacin 295, which are also known as 2-
aminocyclopentanecarboxylic acids (ACPCs) (Figure 30).  
 
Figure 30- Examples of cispentacin (ACPC) 294, transpentacin 295 & cishexacin (ACHC) 296 
Due to the high demand for short and efficient asymmetric syntheses of these type of 
chiral building blocks it was decided to apply our cyclisation methodology to simple 
aliphatic -imino ester starting materials, with the aim of using it for the asymmetric 
synthesis of cispentacin and related analogues.  
 
3.2 Synthetic Approaches to Cispentacin Derivatives 
 In the past decade interest in monocyclic -amino acids has increased significantly 
with the first and most widely researched target being cispentacin 294. Cispentacin 
(also referred to as cis-ACPC) exhibits potent antifungal activity and has found a broad 
range of applications including incorporation into -peptides. In all cyclic -amino acids, 
the carboxyl group is vicinal to the amine group, and consequently there are four 
possible stereoisomeric forms (Scheme 121).    
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Scheme 121- All four stereoisomers of ACPC 
The ability to access all four stereoisomers of ACPC is a challenge that has been 
targeted by a number of synthetic groups. Access to enantiopure cispentacins is 
particularly important when incorporating them into -peptides due to their ability to 
induce different folding properties. For example, transpentacin results in -peptides that 
exhibit a 12-helical conformation171 whereas cispentacin forms an extended strand type 
structure.172 
Initially, a range of methods for the synthesis of racemic cispentacin were reported. The 
first synthesis of rac-cispentacin 300 was reported in 1972 by Nativ et al. They 
demonstrated that rac-cispentacin could be synthesised using a [2+2] cycloaddition 
reaction of chlorosulfonyl isocyanate with cyclopentene 297 to afford -lactam 299, 
followed by subsequent hydrolytic ring opening (Scheme 122).173  
 
Reagents & Conditions: (i) ClSO2NCO; (ii) KI, NaHSO4; (iii) NaOH, pH 7; (iv) conc. HCl, 3hrs   
Scheme 122- Racemic synthesis of cispentacin via a [2+2] cycloaddition reaction
173
 
Several other methods for the synthesis of racemic acyclic -amino acids include 
protocols that rely on the selective reduction of enamines,174-175 Diels-Alder reactions,176 
Michael additions to cycloalkanecarboxylic acids177 and via 1,2-dicarboxylic acid 
rearrangements.178 There are now a number of routes for producing enantiopure 
pentacin derivatives using asymmetric synthetic protocols, including strategies that 
employ the chiral pool, chiral auxiliaries, chiral catalysts or kinetic resolution.  
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Cispentacin 294 was first prepared in enantiopure form by Davies et al.179 via conjugate 
addition of lithium (S)-(-methylbenzyl)benzylamide to an ,-unsaturated ester to 
afford (1R,2S)-cispentacin tert-butyl ester 302 in 98% de and 65% yield. Research by 
Davies et al. using chiral lithium salts to prepare both aliphatic and cyclic -amino acids 
has continued to be developed and was the subject of a large review in 2005 (Scheme 
123).180 
 
Reagents & Conditions: (i) 2,6-Di-tert-butylphenol, THF; (ii) a) H2, Pd/C, AcOH; b) HCl; c) Dowex 
50XB-200 
Scheme 123- Synthesis of (1R,2S)-Cispentacin using lithium (S)- α-methylbenzyl)benzylamide179 
The initial work by Davies et al. on the asymmetric synthesis of cispentacin using 
enantiomerically pure lithium amides has continued to be developed for the synthesis of 
substituted cispentacin derivatives via parallel kinetic resolution.181 In this case, 
treatment of (rac)-tert-butyl-cyclopentene-1-carboxylate with a mixture of (S)-N-benzyl-
N-(-methylbenzyl)amide and (R)-N-3,4-dimethoxybenzyl-N-(-methylbenzyl) amide 
results in enantiorecognition via a mutual kinetic resolution process, to give the 
enantiomeric addition products 306 and 308. This kinetic resolution enables the 
synthesis of a variety of C3-alkyl substituted cispentacin derivatives. In addition, 
epimerisation of the carboxylate centre enables access to alkyl substituted 
transpentacin derivatives182 which have since been successfully incorporated into -
peptides (Scheme 124).183  
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Reagents & Conditions: (i) Lithium (S)-N-benzyl-N(-methylbenzyl)amide, lithium (R)-N-3,4-
dimethoxybenzyl-N-(-methylbenzyl)amide (50:50), 2,6-di-tert-butylphenol THF, -78°C, 3hrs; (ii) DDQ, 
DCM:H2O (3:1);  (iii) Pd(OH)2/C, MeOH, H2, (5 atm), rt 
Scheme 124- Synthesis of -alkyl substituted cispentacin181 
Since the initial asymmetric synthesis of cispentacin in 1993, a number of new methods 
have been developed for the synthesis of chiral monocyclic -amino acids. One 
approach involves utilization of the chiral pool for the synthesis of a substituted 
cishexacin -lactam from (+)--pinene 309 (Scheme 125),184 whilst another example 
 Page | 110  
 
involves the use of a D-glucose derivative to access polyhydroxylated transpentacins 
(Scheme 126).185  
 
Reagents & Conditions: (i) CSI, 1hr, rt; (ii) KOH, Na2SO3 
Scheme 125- Synthesis of cishexacin -lactam using (+)--pinene 
The key steps in the formation of polyhydroxylated transpentacins involve the peptide 
coupling of lactone 313 with benzyloxycarbonylglycine, ethyl chloroformate and 
triethylamine to give the dipeptide 314 and the subsequent ring opening reaction using 
hydrazine to give the protected D-glucose derivative 315. 
 
Reagents & Conditions: (i) TBAF, THF; (ii) H2, Raney-Ni, MeOH; (iii) ClCO2Et, Z-Gly, Et3N, (iv) 
H2NNH2, MeOH; (v) t-BuNO2, HCl, DMF, dioxane; (vi) Gly-CO2Me, Et3N, DMF 
Scheme 126- Synthesis of substituted transpentacin from a derivative of D-glucose
185
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Although these examples show how the chiral pool can be used to provide access to 
some monocyclic -amino acids, this type of methodology has several drawbacks such 
as long synthetic routes, high expense and the configuration of the product being 
limited to the availability of naturally occurring chiral starting materials.  
The catalytic reduction of enamines to afford -amino acids has been well 
documented103 with the first asymmetric synthesis of monocyclic -amino ester via 
enantioselective reduction of an enamine using a chiral ruthenium catalyst being 
reported in 2003 (Scheme 127).186 Zhang et al. reported that N-acyl--amino ester 319 
could be produced in 99% ee and 100% conversion using (S)-BINAP as a chiral ligand, 
with a variety of other chiral ligands having also been investigated.186 The use of this 
chiral ruthenium catalyst provides an excellent way of converting a prochiral -amino 
ester into an enantiopure cis--amino ester, with the corresponding transpentacin being 
obtained by epimerization.186  
 
Reagents & Conditions: (i) Ru(COD)(Methallyl)2, (S)-BINAP, HBF4, H2, MeOH, rt 
Scheme 127-Enantioselective hydrogenation reaction to form a -amino ester186 
The stereoselective synthesis of -amino acid derivatives using enzymatic kinetic 
resolution is well documented and such methods have been investigated 
extensively.115,124,126,187-189 In 2003, Fulop et al. devised an efficient and simple 
methodology for the lipase-catalysed enantioselective ring opening of alicyclic fused -
lactams.190 This enantioselective ring opening reaction furnished enantiopure (1R,2S)-
cispentacin and the corresponding (1S,5R)--lactam in high yield and excellent ee that 
could be easily separated. The (1S,5R)--lactam was subsequently ring opened using 
acid hydrolysis to obtain the other cispentacin enantiomer. This enzymatic methodology 
has recently been employed for the synthesis of fluorinated alicyclic -amino esters191  
and key intermediates for the Taxol side chain.192 Therefore, while the significance of 
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this enzymatic process has been established, the main drawbacks of this approach are 
the substrate specific nature of the enzymes employed (Scheme 128). 
 
Reagents & Conditions: (i) H2O, Lipolase, i-Pr2O, 60 °C 
Scheme 128- Enantioselective ring opening of an alicyclic -lactam190 
In 2003, desymmeterisation of meso-anhydrides was achieved using either quinidine or 
quinine as nucleophilic catalysts to mediate the addition of benzyl alcohol to give mono 
benzyl esters 322 or 324. Subsequent Curtius degradation of these monobenzyl ester 
acids afforded the corresponding benzyl cispentacin esters in high ee.193 The (S)-
benzyl hemiester can be obtained using a quinidine mediated desymmetrisation, 
whereas the (R)-benzyl hemiester can be generated using a quinine additive. This 
allows access to either cispentacin enantiomer in up to 97% ee and 93% yield (Scheme 
129).193  
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Reagents & Conditions: (i) Quinidine (1.1 equiv.), benzyl alcohol (3.0 equiv.), toluene, -55°C; (ii) Quinine 
(1.1 equiv.), benzyl alcohol (3.0 equiv.), toluene, -55°C 
Scheme 129- Synthesis of cispentacin via desymmetrisation of a meso-anhydride 
More recently a quinine-mediated parallel kinetic resolution has been used to 
synthesise the antifungal Icofungipen. Icofungipen, also referred to as BAY 10-888, has 
a dual mode of action as a novel antifungal and is currently in phase II clinical studies 
as a treatment for yeast infections.194 For example, Mittendorf et al. have developed a 
synthesis that enables (1R,2S)-Icofungipen 239 to be prepared on a multi-kilogram 
scale.195  
As illustrated in Scheme 130 the substituted cyclopentanone diester 326 is synthesised 
from tetra-acid 325 using a Dieckmann cyclisation followed by acid catalysed 
decarboxylation and esterification with ethanol. The alkene functionality is installed 
using a methylene Wittig reaction and the dicarboxylic acid is converted into meso-
anhydride 327. A quinine mediated alcoholysis of the anhydride 327 was carried out 
using trans-cinnamyl alcohol, which generated the enantiomer 328 in >99% ee. Lastly, 
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a Curtius rearrangement furnished the protected -amino ester, which was 
subsequently deprotected to give (1R,2S)-Icofungipen 329 in an overall 23% yield 
(Scheme 130).195 
 





, t-BuOK, THF then KOH, THF; (vi) (EtCO)2O, 135°C; (vii) Quinine, (2E)-3-phenyl-2-
propane-1-ol, toluene, -15°C; (viii) (PhO)2PON3, NEt3, toluene, then (2E)-3-phenyl-2-propane-1-ol 
reflux; (xi) Pd(OAc)2, PPh3, morpholine, EtOH 
Scheme 130- Quinine mediated synthesis of (1R,2S)-Icofungipen 329
195
 
Research in this area continues and more recently in 2007 all four enantiomerically 
pure isomers of Icofungipen 329 have been synthesised using a quinine-mediated 
parallel kinetic resolution protocol.196 
Another asymmetric process for the synthesis of cispentacin involves an intramolecular 
nitrone cycloaddition onto a C2-symmetric ketene bis-sulfoxide.
197 The facial selectivity 
of the [3+2] cycloaddition reaction of the nitrone 330 onto the alkene functionality is 
controlled by diastereoselective steric interactions that occur within the transition state. 
This results in a defined tricyclic product that was subsequently reduced to form 
(1R,2S)-cispentacin 294a. More recently this methodology has been utilized to 
generate the cispentacin analogue cis-(3R,4R)-4-amino-pyrrolidine-3-carboxylic acid 
(Scheme 131).198 
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Scheme 131- Intramolecular nitrone cycloaddition for the asymmetric synthesis of cispentacin
197
 
In summary, there are a number of methodologies that have been devised in order to 
prepare enantiopure cispentacin analogues, including the use of chiral catalysts, kinetic 
resolutions, intramolecular nitrone cycloadditions as well as lithium amide conjugate 
additions. Despite attempts at functionalisation of the cispentacin ring, many of these 
methodologies are substrate specific and as such only give access to a limited range of 
derivatives. Therefore, it was the aim of the research described in this chapter to 
employ our intramolecular enolate-imine cyclisation methodology for the efficient 
asymmetric synthesis of cispentacin, as well as some of its analogues. 
 
3.3 Chiral Imino Ester Synthesis 
The aim of employing an intramolecular enolate-imine cyclisation reaction to generate 
cispentacin in high yields and diastereoselectivity required a simpler synthetic route 
compared with that used for the synthesis of the benzocispentacin substrates. The 
proposed retrosynthesis shown in Scheme 132 reveals that the asymmetric synthesis 
of cispentacin could potentially be prepared using a short and potentially high yielding 
methodology. 
 
Scheme 132- Retrosynthesis of cispentacin 
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In devising the cheapest and most efficient synthetic route, it was found that ethyl 6-
hydroxyhexanoate 332 was commercially available. Its alcohol fragment was easily 
oxidised to its corresponding aldehyde, using pyridinium chlorochromate (PCC) to 
afford ethyl 6-oxohexanoate 333 in 89% yield (Scheme 133). 
 
Reagents & Conditions: (i) PCC, DCM; (ii) (S)-α-methyl-p-methoxybenzylamine, MgSO4, DCM, 2hrs 
Scheme 133- Synthesis of (S,E)-ethyl 6-((1-(4-methoxyphenyl)ethyl)imino)hexanoate 
The chiral imine 334 was formed in a 90% yield via treatment of aldehyde 333 with (S)-
-methyl-p-methoxybenzylamine with its formation being established by the presence 
of an imine proton as a triplet at 7.71 ppm in the 1H NMR spectrum of the crude 
reaction product.  
The initial imine reaction was reanalyzed after a few hours, which revealed the 
emergence of an impurity over time. In fact after 48 hours there was none of the 
original imine 334 left in the reaction, with only a new imine product present, as well as 
residual amine in a 1:1 ratio. This observation required further investigation as it was 
important to understand what effect the formation of this new imine might have on the 
overall success of the enolate-imine cyclisation reaction. The unknown impurity was 
subjected to a series of 1D and 2D NMR experiments with the 1H, 13C, COSY, HSQC 
and HMBC spectra (Appendix 5.1 - 5.2) enabling the structure of the dimeric imine 335 
to be determined (Figure 31).  
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Figure 31- Proposed structure of impurity 335 
The key correlations in the HMBC spectrum which helped in the identification of 335 
showed that the imine proton (7.82 ppm) of this “imine dimer” was interacting with the 
carbon atoms of the adjacent double bond (139.9 ppm and 141.5 ppm), as well as to a 
methylene group at 25.2 ppm. The (E)-geometry of the double bond was confirmed 
using the NOESY spectrum which reported correlation between the protons at 2.48 
ppm and 2.29 ppm, and another correlation between the imine proton at 7.82 ppm and 
the alkene proton at 5.84 ppm. Furthermore, the high resolution mass spectrometry 
data reported a clean and well defined m/z value of 432.2744 consistent with the 
formation of a dimer 335 (Figure 32).  
 
Figure 32- Correlations observed in HMBC spectrum of 335 
A mechanism for the proposed formation of dimer 335 is shown in Scheme 134. 
Initially, (S,E)-ethyl 6-((1-(4-methoxyphenyl)ethyl)imino)hexanoate 334 is in equilibrium 
with its enamine tautomer, this enamine attacks a second equivalent of the imine 334 
resulting in the formation of a dimer. The amino group is then protonated and 
undergoes an E2-elimination reaction to form imine-diene, thus releasing -methyl p-
methoxybenzylamine.  
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Scheme 134- Proposed mechanism for formation of dimer 335 
In summary, the chiral imino ester (S,E)-ethyl 6-((1-(4-methoxyphenyl)ethyl)imino) 
hexanoate 334 which was required as a starting material for the enolate-imine 
cyclisation reaction could be prepared and isolated. However, this chiral imino ester 
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334 proved to be very unstable, with dimerisation occuring readily to form a conjugated 
imine substrate 335. This fact would need to be taken into account when attempting 
subsequent cyclisation reactions. 
 
3.4 Cispentacin Cyclisation and Optimisation 
The intramolecular enolate-imine cyclisation methodology was then tested on (S,E)-
ethyl 6-((1-(4-methoxyphenyl)ethyl)imino)hexanoate 334. Initial reactions were carried 
out using the optimized conditions developed for benzocispentacin, with the exception 
that the reactions were carried out at room temperature. As seen previously, carrying 
out the cyclisation reaction at room temperature should result in a lower de, but was 
predicted to maximise the yield of 336, thus enabling confirmation that the enolate-
imine cyclisation was viable for this substrate. Using these initial conditions the 
protected -lactam 336 was isolated in 44% yield and 92% de. The success of this 
reaction was determined by the presence of a diagnostic peak at 3.32 ppm in its 1H 
NMR spectrum (seen in Appendix 5.1). Further to this, the de could be determined by 
comparing the two sets of quartets from the chiral auxiliary in the major and minor 
diastereomers; observed at 4.81 ppm for the major diastereomer, and at 4.70 ppm for 
the minor diastereomer fragments (Scheme 135). 
 
Reagents & Conditions: (i) NaHMDS (2.0 equiv), 15-crown-5, THF, rt, 18 hrs. 
Scheme 135- Initial cyclisation reaction of (S,E)-ethyl 6-((1-(4-methoxyphenyl)ethyl)imino)- 
hexanoate 334 
The next step was to optimise the reaction in order to increase the yield for formation of 
the (S,1R,2S)--lactam 336. It was decided that due to its instability, it might be 
beneficial to form imine 334 in situ so that there would insufficient time for dimerisation 
to take place. In light of this, it was decided to carry out the imine formation in THF 
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rather than DCM, with molecular sieves added to remove any water produced during 
the imine formation. 
As can be seen in Table 13, the length of time employed for formation of the imine in 
situ has a marked affect on the isolated yield of the -lactam product 336. To 
summarise, if imine 334 is isolated and left for any length of time it distinctly reduces 
the yield of -lactam 336 (Table 13, Entries 1 and 2), which is to be expected as once 
the imine has dimerised it is no longer able to cyclise. Upon further inspection it 
became clear that imine formation was extremely rapid resulting in complete 
consumption of aldehyde 333 in less than 10 minutes. Therefore, as confirmed by Entry 
4, imine 334 can be generated in situ and the cyclisation reaction carried out after 10 
minutes via addition of NaHMDS and 15-crown-5 ether, which gave a much improved 
yield of -lactam 336 of 64% and a good 92% de. 
Table 13- Effect of imine 334 formation  
 




1 Stored- 96 hours 24 92 
2 Stored- 2 hours 44 92 
3 Insitu – 45 mins 63 92 
4 Insitu – 10 mins 64 92 
 
The second variable addressed was the temperature of the reaction, since previous 
results had shown that lower temperatures could improve the de of these types of 
cyclisation reactions. The cyclisation reaction was attempted at a range of lower 
temperatures in order to find the highest de, and in addition, the effect of refluxing the 
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reaction was also investigated. As predicted, lowering the temperature improved the de 
but at the same time resulted in a decrease in yield. In terms of stereoselectivity, 
carrying out the cyclisation reaction at -45 °C and allowing it to warm to room 
temperature gave N-aryl--lactam 336 in 50% yield and 98% de (Table 14, Entry 3). 
Interestingly, when the reaction was attempted at reflux (entry 5) the yield was lower 
than at room temperature, but there was also a significant decrease in the 
diastereoselectivity, potentially due to competing formation of a thermodynamic (Z)-
enolate (Table 14, Entry 5). 
Table 14- Effect of temperature on cyclisation reaction 
 




1 rt 64 92 
2 0 to rt 57 94 
3 -45 to rt 50 98 
4 -78 to rt 26 99 
5 Reflux 41 82 
 
A factor not previously investigated was the concentration of the cyclisation substrate, 
as prior experiments had previously been carried out at a standard concentration of 
0.05 M. Consequently, the effect of increasing and decreasing the concentration of the 
substrate was examined since this had the potential to reduce potential oligomerisation 
pathways and minimize the amount of imine 325 produced from the unwanted 
enamine-imine dimerisation pathway. Increasing the substrate concentration to 0.5 M 
resulted in a much lower yield with the de only affected slightly. By increasing the 
substrate concentration the chance of competing intermolecular enolate-imine 
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oligomerisation reactions and/or imine dimerisation reactions increases, resulting in 
unwanted products of polymerisation or dimerisation. In comparison, decreasing the 
substrate concentration to 0.005 M also gave an extremely poor yield and lowered the 
de to 81%. This reaction required a large amount of solvent and it was very difficult to 
uniformly maintain -45 °C throughout the reaction flask which may have resulted in the 
lower de. Therefore, our original concentration of 0.05 M for carrying out these 
cyclisation reactions was deemed optimal. 








1 0.05 50 98 
2 0.5 15 99 
3 0.005 4 81 
 
In order to obtain the highest yield the reaction had previously been left overnight for 18 
hours, but to improve the efficiency of the overall synthesis the optimum reaction time 
was explored. As can be seen from Entry 2 the cyclisation reaction gave identical 
results after 6 hours to those obtained after 18 hours - giving a slightly higher yield and 
a 99% de. However, if the reaction time was decreased further to only 1 hour the 
cyclisation reaction was found not to have proceeded to completion and therefore the 
yield was lower.  
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Table 16- Effect of reaction time on the cyclisation reaction 
 




1 18 50 98 
2 6 52 99 
3 1 38 99 
 
The highest yield of -lactam 336 observed in the optimization process was 64%, but 
this posed the question of where the rest of the starting material 334 was going? When 
the crude product was isolated after work up (using NH4Cl and water) only the -lactam 
336 was observed in the 1H NMR spectrum. Occasionally a small amount of starting 
material could be seen in the 1H NMR depending on the conditions. In contrast to the 
benzocispentacin substrates (Scheme 101), none of the corresponding-amino esters 
were ever observed. 
In order to determine what was happening to the rest of the starting material the 
reaction was monitored directly by LCMS. A sample from the reaction mixture was 
taken at 1 and 6 hours to identify what components were present in solution. The two 
main components in the LCMS traces had an m/z value of 246 and 135, corresponding 
to the -lactam 336 and a fragment of free amine 337 respectively (Figure 33). This 
suggests that either the imine 334 is unstable and adventitious water can convert back 
into its parent aldehyde and amine, or that excess base may be causing E2-elimination 
of the chiral auxiliary fragment of the -lactam product. Furthermore, the high resolution 
mass spectrometry data for the dimer 325, also revealed peaks at 135.08, supporting 
the theory that the imine 334 was dimerising during the reaction. 
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Figure 33- Fragments observed in LCMS analysis 
Therefore, based upon the data collected, the optimal reaction conditions required the 
imine to be generated in situ at room temperature for 10 minutes, the reaction then 
cooled to -45 °C, before NaHMDS and 15-crown-5 were added to initiate enolate 
cyclisation. This enabled ethyl-6-oxohexanoate 333 to be converted into the (S,R,S)-
-lactam of cispentacin in 52% isolated yield after purification by chromatography. 
 
Reagents & Conditions: (i) (S)-α-Methyl-p-methoxybenzylamine, MgSO4, THF, rt, 10 mins; (ii) NaHMDS 
(2.0 equiv.), 15-Crown-5, THF, -45°C to rt, 6 hrs. 
Scheme 136- Synthesis of (1R,5S)-6-((S)-1-(4-methoxyphenyl)ethyl)-6-azabicyclo[3.2.0]heptan-7-one 
 
3.5 Synthesis of Cispentacin and Transpentacin Ethyl Ester 
Having developed a successful synthesis of (1R,5S)-6-((S)-1-(4-methoxyphenyl)ethyl)-
6-azabicyclo[3.2.0]heptan-7-one 336, the next stage was to deprotect it to its 
corresponding -amino acid and -amino ester for use as foldamer monomers. The first 
step was removal of the chiral auxiliary using the previously described CAN mediated 
conditions.149 The deprotected -lactam (1R,5S)-6-azabicyclo[3.2.0]heptan-7-one 338 
was isolated as a white solid in 71% yield (Scheme 137). The configuration of the 
(S,R,S)--lactam 338 was confirmed by comparing its specific rotation value of 
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   -33.3 (c 0.87, CHCl3) to the reported literature value of     
  




Reagents & Conditions: (i) CAN (4.0 equiv), MeCN-H2O (1:1), rt, 4 hrs 
Scheme 137- Deprotection of (1R,5S)-6-((S)-1-(4-methoxyphenyl)ethyl)-6-azabicyclo[3.2.0]heptan-7-
one 338 
The hydrochloride salt of the corresponding -amino acid 300a (cispentacin) was then 
prepared by acidic hydrolysis of (1R,5S)-6-azabicyclo[3.2.0]heptan-7-one 338 in 97% 
yield (Scheme 138). A specific rotation of     
   -5.0 (c 0.5, H2O) was obtained for -
amino acid 300a, which compares favourably with the literature value of     




Reagents & Conditions: (i) 18% HCl, reflux, 3 hrs 
Scheme 138- Synthesis of (1R,2S)-2-aminocyclopentanecarboxylic acid hydrochloride 300a 
Alternatively, the hydrochloride salt of cis--amino ethyl ester 339 could also be 
synthesised by ring opening of the -lactam 338 in the presence of ethanol in 96% yield 
(Scheme 139). The (1R,2S)-2-aminocyclopentanecarboxylic acid ethyl ester 339 has 
been employed for the synthesis of a promising polymerase inhibitor.199 The literature 
method requires recrystallisation of the selected enantiomer resulting in a low overall 
yield of 29%,199 compared with the 35% overall yield using our methodology. 
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Reagents & Conditions: HCl (1M in Et2O), EtOH, reflux, 3 hrs 
Scheme 139- Synthesis of (1R,2S)-ethyl 2-aminocyclopentanecarboxylate hydrochloride 339 
Another target for our methodology was the synthesis of transpentacin. Gellman et al. 
have reported that transpentacin is one of the most competent subunits for the 
formation of helical foldamers.105 In 2001, they reported that reductive amination of a -
ketoester could be used to form the (S,S) -amino ester salt 341 using (S)--
methylbenzylamine in a 29% overall yield.200 Following this, the (S,S)--amino ester 
salt 341 was subjected to reductive removal of the auxiliary, saponification and 
protection with Fmoc.200 This produced the trans-Fmoc-ACPC residue 342 in an 85% 
yield which was a useful building block for the solid phase synthesis of -peptides 
(Scheme 140).200 
 
Reagents & Conditions: (i) (S)--Methylbenzylamine; (ii) NaBH3CN; (iii) HCl; (iv) Recrystallisation; (v) 
LiOH.H2O; (vi) H2, 10% Pd/C; (vii) Fmoc-OSu 
Scheme 140- Synthesis of trans-Fmoc-ACPC 342
200
 
Therefore, it was decided that our intramolecular enolate-imine cyclisation protocol 
would be expanded in an attempt to produce a more efficient synthesis of a precursor 
to the trans-Fmoc-ACPC residue 342. The synthesis was modified to use (S)--
methylbenzylamine as a chiral auxiliary to allow for its subsequent removal by 
hydrogenation as shown in Scheme 141.  
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The required imine was generated in situ, which was followed by the enolate cyclisation 
step to give the -lactam 343 in 53% yield and 99% de. This -lactam 343 was 
subsequently ring opened to form the cis--amino ester salt 344 in 95% yield. The final 
step involved epimerization of the ester group to give (S,S)--amino ester 345, giving 
diastereotopic protons that correlated to those reported by Gellman et al.,200 this 
produced the (1S,2S)-ethyl 2-(((S)-1-phenylethyl)amino)cyclopentanecarboxylate 345 
in an overall yield of 28%, with this derivative having previously been converted into the 
Fmoc-derivative 342.200 
 
Reagents & Conditions: (i) (S)--Methylbenzylamine, THF, rt, 10 mins; (ii) NaHMDS, 15-Crown-5, THF, 
-45 °C to rt, 6 hrs; (iii) HCl, EtOH, reflux, 3 hrs; (iv) KOtBu, EtOH, reflux, 4 hrs 
Scheme 141- Synthesis of (1S,2S)-ethyl 2-(((S)-1-phenylethyl)amino)cyclopentanecarboxylate  
These results provide evidence that (1R,5S)-6-((S)-1-(4-methoxyphenyl)ethyl)-6-
azabicyclo[3.2.0]heptan-7-one 345 can be rapidly prepared using our intramolecular 
enolate-imine cyclisation methodology, thus enabling access to a range of useful 
scaffolds for -peptide foldamer formation.   
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3.6 Attempted Synthesis of Methyl-Substituted Cispentacin 
Synthesis 
Another desirable building block for -peptide formation would be (1R,2S)-2-amino-1-
methylcyclopentanecarboxylic acid 349 which contains a quaternary -stereocentre. A 
search of the literature showed that the synthesis of the racemate of 2-amino-1-
methylcyclopentanecarboxylic acid was reported in 1983, based on the selective 
reduction of an oxime (Scheme 142).201 Therefore our methodology could potentially 
afford the first asymmetric synthesis of this -disubstituted -amino acid 349.  
 
Reagents & Conditions: (i) a) KOH, ethanol; b) methyl iodide, toluene, 6 hrs, reflux; (ii) HONH2.HCl, 
KOH, ethanol; (iii) NaOH, ethanol, 1hr, reflux 
Scheme 142- Racemic synthesis of -amino acid target containing a quaternary -centre201 
The cheap and readily available ethyl 6-hydroxyhexanoate 332 was chosen as the 
starting material and in its alcohol functionality would need to be protected as a silyl 
group. Consequently, treatment of 332 with TES-triflate and 2,6-lutidine in DCM was 
used to form the TES-protected alcohol 350 in 77% yield. In order to introduce the 
methyl substituent, the ester enolate was generated using NaHMDS in THF at -78 °C, 
followed by alkylation with methyl iodide to afford (rac)-ethyl ester 351 in 65% yield 
(Scheme 143). 
 
Reagents & Conditions: (i) TES-triflate, 2,6-lutidine, DCM; (ii) NaHMDS, methyl iodide, THF, -78°C 
Scheme 143- -Alkylation of ethyl 6-hydroxyhexanoate 
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The triethylsilyl group of 351 was then removed using TBAF to give ethyl 6-hydroxy-2-
methylhexanoate 352 in 67% yield, whose alcohol group was then oxidized via 
treatment with PCC in DCM to give ethyl 2-methyl-6-oxohexanoate 353 in 60% yield 
(Scheme 144). 
 
Reagents & Conditions: (i) TBAF, THF; (ii) PCC, DCM 
Scheme 144- Synthesis of ethyl 2-methyl-6-oxohexanoate 353 
Due to the previously reported problem with the dimerisation of imine 334 it was 
decided to generate ethyl 6-(((S)-1-(4-methoxyphenyl)ethyl)imino)-2-methylhexanoate 
354 in situ, with the progress of the reaction being monitored by TLC to ensure 
complete imine formation. Imine formation was complete after 1 hour and the 
cyclisation reaction was attempted via addition of NaHMDS and 15-crown-5 at room 
temperature. Unfortunately after 18 hours analysis revealed no presence of any -
lactam 355 in the 1H NMR spectrum of the crude products. The reaction was repeated 
numerous times to no avail; therefore it was proposed that the introduction of the 
methyl substituent must affect the orientaton of the enolate so that it is unable to cyclise 
effectively onto its imino functionality (Scheme 145). 
 
Reagents & Conditions: (i) (S)-α-Methyl-p-methoxybenzylamine, MgSO4, THF 1 hr; (iv) NaHMDS, 15-
crown-5, THF, rt, 18 hrs 
Scheme 145- Attempted cyclisation of 354 to form (1R,2S)-2-amino-1-methylcyclopentanecarboxylic 
acid 355 
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3.7 Synthesis of Cishexacin 
It was decided that the next step in the project was to attempt to increase the size of 
the aliphatic chain in order to produce cishexacin 360 using our enolate-imine 
cyclisation reaction. Trans-2-aminocyclohexanecarboxylic acid (ACHC) has been 
widely reported as a monomer for incorporation into -peptides that display 14 helical 
conformations.202 Therefore, an efficient route for the asymmetric synthesis of the 
analogous cishexacin 360 (Figure 30) would prove invaluable. Once an improved route 
to cishexacin 360 had been established then the corresponding -amino ester could be 
epimerized to give trans-ACHC. As can be seen in Scheme 146, the first step was the 
Baeyer-Villiger oxidation of cycloheptanone 356 with potassium persulphate and 
subsequent ring opening using ethanol to afford ethyl 7-hydroxyheptanoate 357 in a 
74% yield.203 This was followed by a successful PCC oxidation to furnish the 
corresponding aldehyde 358 in 98% yield (Scheme 146). During the formation of imine 
359, it was found that after two hours (S,E)-ethyl 7-((1-(4-methoxyphenyl)ethyl)imino)-
heptanoate 359 had started to dimerise due to emergence of a triplet at 5.79 ppm and a 
singlet at 7.78 ppm in the 1H NMR spectrum. In light of this, it was decided that the 
imine would be prepared in situ, before cyclisation of its enolate was attempted, as 
previously carried out for cispentacin.  
Once the imine 359 had been formed in situ the initial cyclisation conditions of 
NaHMDS and 15-crown-5 at room temperature were applied, however no -lactam 360 
was observed in the 1H NMR spectrum of the crude reaction. Despite several attempts 
the enolate-imine cyclisation of this substrate was unsuccessful, only affording 
fragments of recovered starting material fragments. Therefore, it appears that the extra 
methylene group in the aliphatic chain prevents 6-endo-trig cyclisation of the enolate 
from occurring. In comparison, the synthesis of benzocishexacin 292 was successful, 
but this might be due to the aryl ring predisposing the derived enolate to cyclise onto its 
imino functionality.  
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Reagents & Conditions: (i) K2S2O8, H2SO4, ethanol, rt, 12 hrs; (ii) PCC, DCM; (iii) (S)-α-methyl-p-
methoxybenzylamine, MgSO4, DCM, 2 hrs; (iv) NaHMDS (2.0 equiv.), 15-crown-5, THF, rt, 6 hrs 
Scheme 146- Attempted synthesis of (1R,6S)-7-((S)-1-(4-methoxyphenyl)ethyl)-7-
azabicyclo[4.2.0]octan-8-one 360 
 
3.8 Gem-Dimethyl Substituted Cispentacin Synthesis 
One of the first type of cispentacin analogues prepared was (1R,2S)-2-amino-4,4-
dimethylcyclopentanecarboxylic acid, more commonly referred to as dm-ACPC.204 To 
date, a review of the literature suggests there are only a few examples of trans-4,4-
disubstitued ACPC residues having been reported (Figure 34). 
 
Figure 34- Previously synthesised 4,4-disubstituted-ACPC monomers
205
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The trans-dm-ACPC residue has recently been incorporated into -peptides resulting in 
a 12-helical scaffold,204 that contains hydrogen bond orientations comparable to those 
seen in -peptide helicies.204 At present there is currently only one reported 
stereoselective methodology for the synthesis of dm-ACPC 368, which is shown in 
Scheme 147. 
 
Reagents & Conditions: (i) KMnO4, NaOH, H2O, rt, 40 hrs; (ii) MeOH, benzene, H2SO4; (iii) KO
t
Bu, 
THF; (iv) (R)--methylbenzylamine, AcOH, MeOH; (v) NaBH3CN 
Scheme 147- Asymmetric synthesis of dm-ACPC 368
205
 
This current method for the synthesis of dm-ACPC 368  requires 5 steps, is lengthy 
(~105 hours) and very low yielding (~9% overall).205 Therefore, in an effort to improve 
the existing route, our intramolecular enolate-imine methodology was employed in 
order to provide an alternative synthesis of dm-ACPC. 
It was first necessary to synthesise the starting cyclisation substrate from 4,4-
dimethylcyclohexanone 364. A Baeyer Villiger reaction had previously been employed 
to generate ethyl 7-hydroxyheptanoate 356 from cycloheptanone 357 and was applied 
to the 4,4-dimethylcyclohexanone 364 generating alcohol 369 (Scheme 148).203 
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Reagents & Conditions: (i) K2S2O8, H2SO4, Ethanol, rt, 12 hrs 
Scheme 148- Synthesis of ethyl 6-hydroxy-4,4-dimethylhexanoate 369 
The corresponding aldehyde 370 was prepared via oxidation with PCC in 87% yield, 
followed by formation of the imine 371 in 87% yield. Imine 371 was left for 72 hours, 
with 1H NMR analysis revealing it was remarkably stable, with no signs of any new 
imine products from the enamine-imine dimerisation pathway being formed (Scheme 
149).    
 
Reagents & Conditions:(i) PCC, DCM; (ii) (S)-α-Methyl-p-methoxybenzylamine, MgSO4, DCM, 2 hrs 
Scheme 149- Synthesis of (S,E)-Ethyl 6-((1-(4-methoxyphenyl)ethyl)imino)-4,4-dimethylhexanoate 
Therefore, with the chiral imino ester 371 in hand, the intramolecular enolate-imine 
cyclisation reaction was attempted in order to generate the protected lactam 372. As 
with all previous reactions, the cyclisation reaction of 371 was first undertaken at room 
temperature to maximize the chances of the reaction being successful. It was found 
that (1R,5S)-6-((S)-1-(4-methoxyphenyl)ethyl)-3,3-dimethyl-6-azabicyclo[3.2.0]heptan-
7-one 372 was produced in high 78% yield, but also in 99% de. This was dissimilar to 
the optimum methodology for previous substrates which required the reaction to be 
cooled to -45 °C and warmed to room temperature to obtain a very high de (Scheme 
150).  

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Reagents & Conditions: (i) NaHMDS (2.0 equiv), 15-Crown-5, THF, rt, 6 hrs 
Scheme 150- Cyclisation of imine 371 to afford N-aryl--lactam 372 
The yield observed for the gem-dimethyl -lactam 372 was much higher than the yield 
obtained for cispentacin 336, which was attributed to the Thorpe-Ingold effect helping 
cyclisation to occur. In 1915, it was proposed that the introduction of a gem-dimethyl 
group resulted in compression of the internal angle of the nucleophile which favours 
intramolecular cyclisation reactions.206 The literature contains many examples where 
the Thorpe-Ingold effect has had a significant effect on the success of cyclisation 
reactions. Therefore, it is proposed that the yield of the intramolecular enolate-imine 
cyclisation is improved due to geminal methyl substituents stabilizing the reactive 
conformer that leads to enolate cyclisation, and/or due to the fact that the parent imine 
does not undergo dimerisation.  
The removal of the chiral auxiliary fragment from 372 was then carried out using the 
previously devised CAN methodology (Scheme 151). 
 
Reagents & Conditions: (i) CAN (4.0 equiv.), MeCN-H2O (1:1), rt, 4 hrs 
Scheme 151- Deprotection of -lactam 372 
The -lactam (1R,5S)-3,3-dimethyl-6-azabicyclo[3.2.0]heptan-7-one 373 was purified 
by recrystallisation from dichloromethane and hexane to afford a white solid in 87% 
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yield, which gave the X-ray crystallographic structure shown in Figure 35, clearly 
revealing the bicylic -lactam ring structure. 
 
Figure 35- X-ray crystal structure of (1R,5S)-3,3-dimethyl-6-azabicyclo[3.2.0]heptan-7-one 373 with 
ellipsoids drawn at the 50% probability level 
In addition, the substituted -lactam 373 could be ring opened using acidic conditions in 
the presence of ethanol to synthesise (1R,2S)-ethyl 2-amino-4,4-dimethylcyclopentane 
carboxylate hydrochloride 374 in 90% yield with a specific rotation value of D
-2 (c 
1.01, CHCl3) (Scheme 152).  
 
Reagents & Conditions: (i) HCl (1M in Et2O), EtOH, reflux, 3 hrs 
Scheme 152- Synthesis of -amino ester 374 
Therefore, our enolate-imine cyclisation methodology can be used to rapidly prepare -
amino ester 374 in an overall yield of 37% in around 25 hours. Also, unlike previous 
methodologies chromatographic purification was not required to separate any mixtures 
of diastereomers.   
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3.9 Cyclisation of Acetal Substituted Cispentacin 
In light of the success of the cyclisation reaction to form -lactam 373 that contains a 
gem-dimethyl substituent it was decided to introduce an acetonide group into the same 
position. Firstly, it was hoped that the acetonide functionality would function in a similar 
manner to the gem-dimethyl substituent 373, giving high yields and an excellent de for 
its cyclisation reaction due to the Thorpe-Ingold effect. Also, once enolate cyclisation 
had taken place, the acetonide group could be removed under mild conditions allowing 
access to the corresponding ketone (Scheme 153). The ability to generate a -lactam 
with a ketone functional group would be highly advantageous as this could potentially 
allow introduction of a plethora of highly valuable functional groups.  
 
Scheme 153- Retrosynthesis for acetal substituted -lactam  
An alternative set of conditions for the Baeyer-Villiger and ring opening reactions 
needed to be established that were more basic and compatible with the presence of the 
acid sensitive acetal protecting group.207 The use of mCPBA as an oxidant proved 
successful and the seven-membered lactone 376 was obtained in an 80% yield. The 
ring opening reaction of the lactone 376 was carried out under basic conditions using 
K2CO3 and ethanol to furnish ethyl 3-(2-(2-hydroxyethyl)-1,3-dioxolan-2-yl)propanoate 
377 in an 87% yield (Scheme 154). 
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Reagents & Conditions: (i) mCPBA, DCM; (ii) K2CO3, EtOH 
Scheme 154- Synthesis of ethyl 3-(2-(2-hydroxyethyl)-1,3-dioxolan-2-yl)propanoate 377 
From this point, our established methodology was applied involving oxidation of the 
alcohol 377 using PCC, followed by subsequent imine formation to form 379 in 98% 
yield. Once again, stability studies revealed that this imine was stable over a period of 
48 hours (Scheme 155). 
 
Reagents & Conditions: (i) PCC, DCM; (ii) (S)-α-Methyl-p-methoxybenzylamine, MgSO4, THF, 2 hrs 
Scheme 155- Synthesis of (S,E)-Ethyl 3-(2-(2-((1-(4-methoxyphenyl)ethyl)imino)ethyl)-1,3-dioxolan-
2-yl)propanoate 379 
With the imine in hand, the intramolecular enolate-imine cyclisation was attempted both 
at room temperature, and -45 °C to room temperature, to afford the desired acetal-
protected -lactam 380. A good 77% yield of the -lactam 380 was obtained at room 
temperature in 86% de. The optimum conditions of -45 °C to room temperature were 
then applied and the yield again decreases slightly to 59% but this generated an 
excellent diastereoselectivity of 98% de (Table 17, Entry 2). In comparison with the 
gem-dimethyl cyclisation, it can be seen that the de obtained was not as high as 
observed for the gem-dimethyl -lactam 380 at room temperature. However, when the 
temperature was reduced to -45 °C the de was significantly improved, which was more 
in line with the results that were observed for cispentacin 336.   
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Table 17- Attempted intramolecular enolate-imine cyclisation on imine 379 
 
Entry Temp (°C) Yield (%) de (%) 
1 rt 77 86 
2 -45 °C to rt 59 98 
 
The removal of the chiral auxiliary proved unsuccessful, with only fragments of the 
starting material being observed in 1H NMR spectra of the crude products. 
 
Reagents & Conditions: (i) CAN (4.0 equiv.), MeCN-H2O (1:1), rt, 4 hrs 
Scheme 156- Removal of chiral auxiliary on -lactam 380 
There is literature precedent for the use of CAN as a mild deprotection reagent for the 
removal of acetonide groups, which suggested that two competing reactions might be 
taking place.208 As such, it was decided to selectively remove the acetal first, to give the 
ketone functionality, before removal of the chiral auxiliary using an alternative 
methodology. The use of iodine as a mild deprotection reagent enabled the acetal 
protecting group to be selectively removed while retaining the -lactam ring, yielding-
lactam 382 in 79 % yield (Scheme 157).209 
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Reagents & Conditions: (i) Iodine, acetone, rt, 30 mins 
Scheme 157- Synthesis of (1R,5S)-6-((S)-1-(4-methoxyphenyl)ethyl)-6-azabicyclo[3.2.0]heptane-3,7-
dione 382 
The removal of the auxiliary using CAN was attempted on -lactam 382, again this 
proved unsuccessful with the 1H NMR spectrum of the crude product showing cleaved 
1-(4-methoxyphenyl)ethanone but the isolation of any -lactam was unsuccessful. The 
problematic removal of the auxiliary suggests that for the synthesis of both -lactam 
381 and -lactam 382 that an alternative auxiliary would be preferred such as (S)--
methylbenzylamine that could be removed using a hydrogenolytic strategy. Previously, 
(S)--methylbenzylamine was avoided due to the symmetry within the tricyclic -lactam 
structures, in these bicyclic -lactams there is no such symmetry (Scheme 158).  
 
Reagents & Conditions: (i) H2, Pd/C, rt, 24 hrs 
Scheme 158- Proposed deprotection of -lactam 383 containing an (S)--methylbenzylamine 
auxiliary 
In conclusion, it has been demonstrated that our enolate-imine cyclisation methodology 
can also be used to rapidly prepare -lactams 381 and 382 in high yield and excellent 
de. The removal of the current chiral auxiliary has proved unsuccessful; therefore 
further work is required in order to successfully generate the free -lactams of 381 and 
382. 
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3.10    Future Work - Enantioselective Cyclisation 
The final work into the intramolecular enolate-imine cyclisation for the synthesis of 
cispenatcin involved an attempt to control the facial selectivity of the enolate-imine 
cyclisation reaction in an enantioselective manner. This involved employing an 
asymmetric Lewis acid catalyst, with the aim of generating cis -lactams in high ee. It 
was decided to employ Tomioka’s methodology that had utilised chiral bisoxazoline 
(BOX) ligands 154 (Figure 36) for the asymmetric synthesis of -lactams using an 
intermolecular enolate-imine condensation.81 
                             
              Figure 36- Isopropyl chiral bisoxazoline ligand 
Both high yields and good ee’s for -lactams have been reported using both catalytic 
and stoichiometric amounts of the copper BOX ligands.83 In particular, a chiral BOX 
ligand was shown to mediate an intermolecular cyclisation reaction between lithium 
ester enolates and a benzylic imine, to afford the corresponding -lactam in 70% ee 
(Scheme 159). 
 
Reagents & Conditions: (i) i-Pr-BOX ligand 154(0.2 equiv.), LDA, DCM, -20  
0
C 
Scheme 159- Asymmetric Mannich reaction using (R)-iPr-BOX
83
 
In order to apply this enantioselective methodology for the asymmetric synthesis of a 
cispentacin derivative, an achiral imino-ester substrate without a chiral auxiliary group 
was synthesised. Due to the instability of such imine substrates, the imine 387 was 
generated in situ and an enolate-imine cyclisation reaction carried out, to afford the 
racemic -lactam 388 in an unoptimised 30% yield (Scheme 160). 
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Reagents & Conditions: (i) Benzylamine, mol. sieves, THF, 15 mins; (ii) NaHMDS, rt, 18 hrs. 
Scheme 160- Synthesis of racemic cispentacin -lactam 388 
This allowed appropriate chiral HPLC conditions (AS-3, 90% iso-hexane, 10% ethanol) 
to be developed that gave well resolved peaks for its enantiomers.  
Tomioka’s conditions were then applied to the cyclisation of imino ester 387 whose 
enolate was generated in the presence of 0.2 equivalents of the isopropyl-BOX ligand 
154. This reaction was analysed by 1H NMR and showed only the presence of starting 
material, with no -lactam having been formed. Therefore, the original cyclisation 
conditions using NaHMDS in THF at -45 °C to room temperature were applied with the 
addition of a stoichiometric amount of the chiral BOX ligand 154, which produced the -
lactam 388, albeit in a poor 6% yield, which was shown to be racemic by chiral HPLC 
analysis. The main problems with using this methodology is that when the reaction is 
carried out in an intermolecular fashion the lithium enolate is first generated, and then 
the chiral BOX ligand is added, which allows for its complexation to the enolate before 
the addition of the imine. Unfortunately, for the intramolecular reaction the enolate is 
always generated in the presence of the imine, so cyclisation can potentially occur 
before the BOX ligand can have any control over the cyclisation reaction. 
Enantioselective control of both direct and indirect Mannich reactions has been the 
subject of several major reviews210-211 and therefore there are many more approaches 
that could be taken in this area of work. For example, the enantioselective reaction 
could be potentially attempted using a silyl ketene acetal as shown in Scheme 161. 
 
Reagents & Conditions: (i) TMS-Cl, LDA, THF, -78 °C 
Scheme 161- Potential synthesis of silyl ketene acetal for an indirect Mannich reaction 
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3.11    Conclusion 
In conclusion, our previously developed intramolecular enolate-imine cyclisation 
reaction has been applied to the asymmetric synthesis of four acyclic -lactam 
analogues. An asymmetric synthesis of cispentacin has been developed that also 
enables the rapid access to the highly desirable transpentacin. An improved 
methodology for the synthesis of (1R,5S)-6-((S)-1-(4-methoxyphenyl)ethyl)-3,3-
dimethyl-6-azabicyclo[3.2.0]heptan-7-one 372 has been developed,g which is not only 
quicker but also higher yielding than previous syntheses. Furthermore, the limitations of 
this methodology have been established by unsuccessfully attempting the cyclisations 
of acyclic enolates of 6-membered and -methyl substituted -imino-esters. Finally, 
unsuccessful approaches towards an enantioselective intramolecular enolate-imine 
cyclisation reaction were attempted in order to synthesise a range of -amino acids 
enantiomers without the need for a chiral auxiliary. 
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4 Experimental 
General Experimental Details 
All reactions were performed under a nitrogen atmosphere in oven-dried apparatus, 
unless otherwise stated. Anhydrous acetonitrile, dichloromethane and tetrahydrofuran 
were obtained from an Innovative Technology Inc. PS-400-7 solvent purification 
system. Petrol refers to the fraction of petroleum ether boiling at 40-60 °C. All other 
commercially available compounds were used as obtained from the chemical suppliers. 
Analytical thin layer chromatography was performed using commercially available 
aluminium backed plates coated with Merck G/UV254 neutral silica. Plates were 
visualised under UV light (at 254 nm) or by staining with phosphomolybdic acid 
followed by heating. Flash chromatography was performed using chromatography 
grade silica, 60 Å particle size 35-70 microns from Fisher Scientific. 1H NMR spectra 
were recorded at 500 MHz, 400 MHz or 300 MHz and 13C{1H} spectra were recorded at 
125 MHz or 75 MHz on a Brüker Avance 500, 400 or 300 spectrometer respectively. 
Chemical shifts, δ, are quoted in parts per million and are referenced to the residual 
solvent peak. The following abbreviations are used: s, singlet; d, doublet; t, triplet; q, 
quartet; dd, doublet of doublets; dt, doublet of triplets; hep., heptet; m, multiplet; pent., 
pentet; td, triplet of doublets; app., apparent and br., broad. Coupling constants, J, are 
quoted to the nearest 0.5 Hz. High resolution mass spectra were recorded on a Brüker 
Daltonics microTOF spectrometer with an electrospray source and external calibration. 
Masses were recorded in positive electrospray ionisation mode and were introduced by 
flow injection. Masses are accurate to 5 ppm and data was processed using 
DataAnalysis software from Brüker Daltonics. Infrared spectra were recorded on a 
Perkin Elmer Spectrum 100 FT-IR spectrometer, using a Universal ATR accessory for 
sampling, with only selected absorbances quoted as ν in cm-1. Optical rotations were 
recorded on an Optical Activity Ltd AA-10 automatic polarimeter with a path length of 1 
dm; concentrations (c) are quoted in g/100 mL. All capillary melting points were 
measured using Stuart digital SMP10 melting point apparatus with 1 degree resolution. 
X-ray data was collected at 150K on a Nonius KappaCCD area detector diffractometer 
using Mo-Kradiation ( = 0.71073 Å). All structures were solved by direct methods 
and refined on all F2 data using SHELXL-97 suite of programs, with hydrogen atoms 
included in idealised positions and refined using the riding model.  
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4.1 General Procedures 
4.1.1 General Procedure 1: Acetal Formation212 
To a stirred substituted 2-bromobenzadehyde (1.0 equiv.) in toluene (50 mL), 1,3-
propanediol (1.5 equiv.) and p-toluene sulphonic acid (PTSA) (0.1 equiv.) were added 
and the resulting solution was heated at reflux under Dean-Stark conditions for 3 hours. 
After cooling to room temperature, the reaction mixture was washed with water, the 
organic extract dried using MgSO4 and the solvent evaporated under reduced pressure. 
The crude compounds were purified by recrystallisation using a suitable solvent 
system. 
4.1.2 General Procedure 2: Heck Reaction of Protected 2-Bromo-
benzaldehydes137 
To a solution of substituted 2-(2-bromophenyl)-1,3-dioxolan (1.0 equiv.) in acetonitrile, 
palladium(II) acetate (0.05 equiv.) and tri(o-tolyl)phosphine (0.10 equiv.) were added. 
Diisopropylethylamine (3.0 equiv.) and the appropriate acrylate (1.0 equiv.) were added 
and the mixture was heated at reflux for 24 hours. After cooling to room temperature, 
the reaction was diluted with water (50 mL) and the aqueous layer extracted with 
toluene (2 x 50 mL). The combined organic extracts were washed with water (2 x 50 
mL) and brine (30 mL) and then dried over MgSO4. The mixture was filtered through a 
plug of Celite® and then the solvent was removed under reduced pressure. Crude 
compounds were purified by flash column chromatography. 
4.1.3 General Procedure 3: Chemoselective Conjugate Reduction of Esters138 
Substituted ethyl 3-(2-(1,3-dioxan-2-yl)phenyl)propanoates (2.0 equiv.) were stirred in 
ethanol (10 mL) for 30 minutes prior to the addition of cobalt(II) chloride hexahydrate 
(0.02 equiv.). The solution was then cooled to 0 oC and sodium borohydride (4.0 equiv.) 
was added. The solution was allowed to warm to room temperature and stirred for up to 
48 hours. The reaction was quenched with water (50 mL) and diluted with ethyl acetate 
(30 mL). The organic layer was separated, washed with brine (50 mL), dried with 
MgSO4 and the solvent evaporated under reduced pressure. Crude compounds were 
purified by flash column chromatography. 
4.1.4 General Procedure 4: Acetal Deprotection 
Substituted ethyl-3-(2-formylphenyl)propanoates were added to a solution of acetic 
acid: water (7 mL : 3 mL) and left to stir open to the air overnight. The residue was 
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partitioned between water (50 mL) and diethyl ether (50 mL). The aqueous layer was 
extracted with diethyl ether (2 x 30 mL) and the organic layers were combined and 
washed with a saturated solution of NaHCO3 (2 x 30 mL) and then brine (30 mL). The 
organics were dried using MgSO4 and filtered before being evaporated under reduced 
pressure to yield analytically pure products. 
4.1.5 General Procedure 5: Imine-Enolate Cyclisation Reaction 
Substituted (S,E)-ethyl-3-(2-((1-(4-methoxyphenyl)ethylimino)methyl)phenyl)propane-
ates (1.0 equiv.) were dissolved in THF. 15-Crown-5 (1.1 equiv.) and NaHMDS (1.1 
equiv.) were added and the mixture was stirred for 8 hours at -40 oC. The reaction was 
quenched with a saturated solution of NH4Cl (10 mL). The aqueous layer was extracted 
with Et2O (3 x 30 mL) and the organic layers were combined and washed with water 
(50 mL). The organics were dried using MgSO4 and filtered before being evaporated 
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The title compound was prepared according to General Procedure 1 from 2-
bromobenzadehyde 209 (10.0 g, 54 mmol), 1,3-propanediol (6.16 g, 81 mmol) and 
PTSA (0.86 g, 5.0 mmol). The crude product was purified by recrystallisation from 
diethyl ether, yielding a white solid (10.47 g, 80 %).  
1H NMR (300 MHz, CDCl3): H = 7.59 (1H, dd, J = 8.0 and 1.5 Hz, CBrCH), 7.40 (1H, d, 
J = 8.0 Hz, Ar), 7.20 (1H, t, J = 7.5 Hz, Ar), 7.04 (1H, td, J = 8.0 and 1.5 Hz, Ar), 5.63 
(1H, s, ArCH), 4.10 (2H, dd, J = 11.0 and 5.0 Hz, OCH2), 3.85 (2H, td, J = 12.5 and 2.0 
Hz, OCH2), 2.16-1.98 (1H, m, OCH2CH2), 1.24 (1H, br. d, J = 13.5 Hz, OCH2CH2); 
13C{1H} NMR (75 MHz, CDCl3): C =137.6, 132.6, 130.4, 128.2, 127.6, 122.4, 100.9, 
67.6, 25.7; IR (film / cm-1) ѵ = 2846 (O-CH-O); HRMS: m/z (ES) 243.0018, C10H11O2Br 
[M+H]+ requires 243.0021; mp 53-55 oC. 
Methyl-3-(2-(1,3-dioxan-2-yl)phenyl)acrylate 211 
 
The title compound was prepared according to General Procedure 2 from 2-(2-
bromophenyl)-1,3-dioxolan 210 (2.67 g, 11.0 mmol), methyl acrylate (0.99 mL, 11 
mmol), palladium (II) acetate (0.12 g, 0.55 mmol), tri(o-tolyl)phosphine (0.33 g, 1.1 
mmol) and diisopropylethyl amine (5.7 mL, 33.0 mmol). The crude product was purified 
using flash column chromatography [Petrol : EtOAc (85:15), Rf 0.28] yielding a yellow 
oil (2.29 g, 84 %). 
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1H NMR (300 MHz, CDCl3): H = 8.16 (1H, d, J = 16.0 Hz, ArCHCH), 7.57-7.48 (2H, m, 
Ar), 7.35-7.23 (2H, m, Ar), 6.28 (1H, d, J = 16.0 Hz, ArCHCH), 5.63 (1H, s, ArCHO), 
4.21 (2H, ddd, J = 12.0, 5.0 and 1.5 Hz, OCH2CH2), 3.94 (2H, td, J = 12.5 and 2.5 Hz, 
OCH2CH2), 3.74 (3H, s, OMe), 2.30-2.12 (1H, m, OCH2CH2), 1.44-1.34 (1H, m, 
OCH2CH2); 
13C{1H} NMR (75 MHz, CDCl3): C = 167.8, 142.9, 137.6, 133.2, 129.5, 
128.5, 127.4, 127.2, 119.9, 100.6, 67.9, 52.1, 26.1; IR (film / cm-1) ѵ = 1712 (C=O), 
1635 (C=C); HRMS: m/z (ES) 249.1116, C14H16O4 [M+H]
+ requires 249.1127 
Methyl-3-(2-(1,3-dioxan-2-yl)phenyl)propanoate 212 
 
The title compound was prepared according to General Procedure 3 from methyl 3-(2-
(1,3-dioxan-2-yl)phenyl)acrylate 211 (1.46 g, 5.9 mmol) and cobalt(II) chloride 
hexahydrate (0.01 g, 0.06 mmol) in methanol (30 mL) with the addition of sodium 
borohydride (0.44 g, 11.8 mmol) and was stirred at room temperature for 48 hours. The 
crude product was purified using flash column chromatography [Petrol: EtOAc (80:20), 
Rf 0.79] yielding a brown oil (1.01 g, 70 %). 
1H NMR (300 MHz, CDCl3): H = 7.33-7.16 (4H, m, Ar), 5.68 (1H, s, CHO2), 4.33-4.24 
(2H, m, OCH2CH2), 4.02 (2H, td, J = 2.5 and 12.0 Hz, OCH2CH2), 3.71 (3H, s, OCH3), 
3.14- 3.05 (2H, m, ArCH2CH2), 2.71-2.62 (2H, m, ArCH2CH2), 2.37-2.17 (1H, m, 
OCH2CH2), 1.47 (1H, app d of hep., J = 13.5 and 1.0 Hz, OCH2CH2). 
(E)-Ethyl 3-(2-(1,3-dioxan-2-yl)phenyl)acrylate 217 
 
The title compound was prepared according to General Procedure 2 from 2-(2-
bromophenyl)-1,3-dioxane 210 (10.8 g, 44.4 mmol), ethyl acrylate (4.82 mL, 44.4 
mmol), palladium (II) acetate (0.49 g, 2.2 mmol), tri(o-tolyl)phosphine (1.35 g, 4.5 
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mmol) and diisopropylethyl amine (23.2 mL, 133.4 mmol) in acetonitrile (120 mL). The 
crude product was purified by flash column chromatography [Petrol : EtOAc (80:20), Rf 
0.39] yielding a yellow oil (11.2 g, 96 %). 
1H NMR (300 MHz, CDCl3): H = 8.16 (1H, d, J = 16.0 Hz, ArCHCH), 7.53 (2H, app. td, 
J = 2.0 Hz, Ar), 7.35-7.24 (2H, m, Ar), 6.28 (1H, d, J = 16.0 Hz, ArCHCH), 5.63 (1H, s, 
CHO), 4.25-4.16 (4H, m, OCH2CH2 and OCH2CH3), 4.00-3.89 (2H, m, OCH2CH2), 2.30-
2.13 (1H, diastereotopic m., OCH2CH2), 1.40 (1H, app. d of hep., J = 13.5 and 1.5 Hz, 
OCH2CH2), 1.27 (3H, t, J = 7.0 Hz, CH2CH3); 
13C{1H}  NMR (75 MHz, CDCl3): C = 
167.0, 142.2, 137.1, 132.9, 129.8, 129.1, 127.0, 126.7, 119.9, 100.3, 67.6, 60.5, 25.7, 
14.3; IR (film / cm-1) ѵ = 2851 (O-CH-O), 1728 (C=O), 1608 (C=C); HRMS: m/z (ES) 
287.1259, C15H20O4 [M+Na]
+ requires 287.1259.  
Ethyl 3-(2-(1,3-dioxan-2-yl)phenyl)propanoate 216 
 
The title compound was prepared according to General Procedure 3 from ethyl 3-(2-
(1,3-dioxan-2-yl)phenyl)acrylate 217 (1.91 g, 7.7 mmol), cobalt(II) chloride hexahydrate 
(0.02 g, 0.08 mmol) in ethanol (30 mL) with the addition of sodium borohydride (0.58 g, 
15.4 mmol). The crude product was purified using flash column chromatography [Petrol 
: EtOAc (80:20), Rf 0.74] yielding a yellow oil (1.65 g, 81 %). 
1H NMR (300 MHz, CDCl3): H = 7.62-7.57 (1H, m, Ar), 7.31-7.16 (3H, m, Ar), 5.67 (1H, 
s, ArCHO), 4.27 (2H, ddd, J = 10.5, 5.0 and 1.0 Hz, OCH2CH2), 4.16 (2H, q, J = 7.0 Hz,  
OCH2CH3), 4.01 (2H, td, J = 2.5 and 12.5 Hz, OCH2CH2), 3.12-3.03 (2H, m, 
ArCH2CH2), 2.69-2.59 (2H, m, ArCH2CH2), 2.35-2.17 (1H, m, OCH2CH2), 1.50-1.41 (1H, 
m, OCH2CH2), 1.27 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 
173.6, 138.9, 136.8, 129.9, 129.3, 127.0, 126.8, 100.6, 67.7, 60.7, 36.5, 28.3, 26.1, 








The title compound was prepared according to General Procedure 4 from methyl 3-(2-
(1,3-dioxan-2-yl)phenyl)propanoate 212 (1.01 g, 4.1 mmol), which was added to a 
solution of acetic acid : water (7 mL : 3 mL) and stirred open to the air overnight. The 
crude product was purified using flash column chromatography [Petrol : EtOAc (75:25), 
Rf 0.70] yielding a yellow oil (0.57 g, 73 %). 
1H NMR (300 MHz, CDCl3): H = 10.14 (1H, s, CHO), 7.80-7.77 (1H, m, Ar), 7.48-7.27 
(3H, m, Ar), 3.59 (3H, s, OCH3), 3.29 (2H, t, J = 7.5 Hz, ArCH2CH2), 2.58 (2H, t, J = 7.5 
Hz, ArCH2CH2); 
13C{1H} NMR (75 MHz, CDCl3): C = 193.1, 173.5, 143.2, 134.2, 134.0, 
132.3, 127.5, 52.0, 35.7, 28.5; IR (film / cm-1) ѵ = 1733 (C=O), 1693 (C=O); HRMS: m/z 
(ES) 193.0854, C11H12O3 [M+H]
+ requires 193.0864. 
Ethyl 3-(2-formylphenyl)propanoate 219 
 
The title compound was prepared according to General Procedure 4 from ethyl 3-(2-
(1,3-dioxan-2-yl)phenyl)propanoate 216 (0.55 g, 2.2 mmol), which was added to a 
solution of acetic acid : water (7 mL : 3 mL) and stirred open to the air overnight. The 
crude was purified using flash column chromatography [Petrol : EtOAc (75:25), Rf 0.63] 
yielding a colourless oil (0.32 g, 75 %). 
1H NMR (250 MHz, CDCl3): H = 10.25 (1H, s, ArCHO), 7.89-.7.80 (1H, m, Ar), 7.60-
7.27 (3H, m, Ar), 4.14 (2H, q, J =7.0 Hz, OCH2CH3), 3.89 (2H, t, J = 7.5 Hz, ArCH2CH2), 
2.67 (2H, t, J = 7.5 Hz, ArCH2CH2), 1.25 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR 
(75 MHz, CDCl3): C = 192.7, 172.6, 142.9, 133.8, 133.8, 133.4, 131.2, 127.0, 60.5, 
35.6, 28.0, 14.2; IR (film / cm-1) ѵ = 1728 (C=O), 1694 (C=O) HRMS: m/z (ES) 
207.1009, C12H14O3 [M+H]
+ requires 207.1021. 





Methyl 3-(2-formylphenyl)propanoate 218 (0.036 g, 0.19 mmol) was dissolved in dry 
CH2Cl2 (3 mL) with MgSO4 and stirred under a nitrogen atmosphere. After 5 minutes, 
(S)-(-)-4-methoxy--methylbenzylamine (0.28 mL, 0.19 mmol) was added and the 
solution was stirred for 5 hours. The solution was filtered and the solvent was 
evaporated under reduced pressure, yielding a yellow oil (0.058 g, 96 %).  
1H NMR (300 MHz, CDCl3): H = 8.60 (1H, s, CHN), 7.79 (1H, dd, J = 1.5 and 7.5 Hz, 
Ar), 7.37-7.18 (5H, m, Ar), 6.91-6.84 (2H, m, Ar), 4.49 (1H, q, J = 7.0 Hz, CHCH3), 3.80 
(3H, s, ArOCH3), 3.67 (3H, s, COOCH3), 3.25 (2H, t, J = 8.0 Hz, CH2CH2), 2.61 (2H, t, J 
= 8.0 Hz, CH2CH2), 1.56 (3H, d, J = 7.0 Hz, CHCH3); IR (film / cm
-1) ѵ = 1735 (C=O), 
1639 (C=N); HRMS: m/z (ES) 326.1755, C20H23O3N [M+H]
+ requires 326.1756. 
(S,E)-Ethyl-3-(2-((1-(4-methoxyphenyl)ethylimino)methyl)phenyl)propanoate 221 
 
Ethyl 3-(2-formylphenyl)propanoate 219 (4.07 g, 19.8 mmol) was dissolved in dry 
CH2Cl2 (150 mL) with MgSO4 and stirred under a nitrogen atmosphere. After 5 minutes, 
(S)-(-)-4-methoxy--methylbenzylamine (2.92 mL, 19.8 mmol) was added and the 
solution was stirred for 5 hours. The solution was filtered and the solvent was 
evaporated under reduced pressure yielding a yellow oil (6.34 g, 95 %).  
1H NMR (400 MHz, CDCl3): H = 8.67 (1H, s, ArCHN), 7.86 (1H, dd, J = 7.5 and 1.5 Hz, 
Ar), 7.44-7.24 (5H, m, Ar), 6.96-6.92 (2H, m, Ar), 4.55 (1H, q, J = 6.5 Hz, CHCH3), 4.19 
(2H, q, J = 7.0 Hz, OCH2CH3), 3.85 (3H, s, OCH3), 3.30 (2H, t, J = 8.0 Hz, ArCH2CH2), 
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2.66 (2H, t, J = 8.0 Hz, ArCH2CH2), 1.62 (3H, d, J = 6.5 Hz, CHCH3), 1.29 (3H, t, J = 7.0 
Hz, CH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 173.0, 158.5, 157.9, 140.3, 137.5, 
134.1, 130.2, 130.1, 129.5, 127.6, 127.4, 126.7, 114.1, 113.8, 70.1, 60.4, 55.3, 35.9, 
28.4, 25.2, 14.2; IR (film / cm-1) ѵ = 1730 (C=O), 1639 (C=N), 1611 (C-O); HRMS: m/z 
(ES) 340.1912, C21H25O3N [M+H]
+ requires 340.1913;     
  = +15.2 (c 1.45, CHCl3).  
 





The title compound was prepared according to General Procedure 5 from (S,E)-ethyl 3-
(2-((1-(4-methoxyphenyl)ethylimino)methyl)phenyl)propanoate 221 (0.144 g, 0.42 
mmol), which was dissolved in THF (10 mL) under a nitrogen atmosphere. 15-Crown-5 
(0.09 mL, 0.46 mmol) and NaHMDS (1M in THF, 0.46 mL, 0.46 mmol) was added and 
the mixture was stirred for 8 hours at -40 °C and allowed to warm to room temperature. 
The crude product was purified using flash column chromatography [Petrol: EtOAc 
(60:40), Rf 0.47] yielding a white crystalline solid (0.088 g, 73 %). 
1H NMR (400 MHz, CDCl3): H = 7.34-7.28 (4H, m, Ar), 7.22-7.14 (2H, m, CH3OCHCH), 
6.98-6.94 (2H, m, CH3OCH), 5.00 (1H, q, J = 7.0 Hz, CHCH3), 4.83 (1H, d, J = 4.5 Hz, 
CHCHN), 3.92-3.89 (1H, m, CHCH2), 3.88 (3H, s, OCH3), 3.41 (1H, dd, J = 17.5 and 
2.0 Hz, CH2CH), 3.03 (1H, dd, J = 17.5 and 10.5 Hz, CH2CH), 1.44 (3H, d, J = 7.0 Hz, 
CHCH3); 
13C{1H} NMR (100 MHz, CDCl3): C = 169.8, 159.1, 145.1, 139.7, 132.0, 
128.8, 128.4, 126.5, 126.4, 126.2, 114.0, 61.4, 55.4, 51.7, 51.2, 30.1, 18.9; IR (film / 
cm-1) ѵ = 1731 (C=O) HRMS: m/z (ES) 316.1308, C19H19O2N [M+Na]
+ requires 
316.1313; mp 90-92 °C;     
   = -52 (c 1.15, CHCl3). 





(S,E)-Ethyl 3-(2-((1-(4-methoxyphenyl)ethylimino)methyl)phenyl)propanoate 221 (0.24 
g, 0.7 mmol) was dissolved in THF (23 mL). KHMDS (0.5 M in toluene, 1.5 mL, 0.78 
mmol) was added and the mixture was stirred for 8 hours at room temperature. The 
reaction was quenched with a saturated solution of NH4Cl (10 mL). The aqueous layer 
was extracted with Et2O (3 x 50 mL) and the organic layers were combined and washed 
with NH4Cl (50 mL) and water (50 mL). The organics were then dried using MgSO4 and 
filtered before being evaporated under reduced pressure. The crude product was 
purified using flash column chromatography [Hexane: Et2O (1:1), Rf 0.15] yielding a 
white crystalline solid (0.031 g, 15 %). 
1H NMR (400 MHz, CDCl3): H = 7.33-7.28 (2H, m, Ar), 7.24-7.19 (2H, m, Ar), 7.15-7.10 
(1H, m, Ar), 6.93-6.86 (3H, m, Ar), 4.82 (1H, d, J = 4.5 Hz, CHCHN), 4.48 (1H, q, J = 
7.0 Hz, CHCH3), 3.92-3.89 (1H, m, CHCH2), 3.86 (3H, s, OCH3), 3.40 (1H, dd, J = 17.5 
and 2.0 Hz, CH2CH), 3.07 (1H, dd, J = 17.5 and 10.5 Hz, CH2CH), 1.71 (3H, d, J = 7.0 
Hz, CHCH3); 
13C{1H} NMR (100 MHz, CDCl3): C = 170.3, 159.0, 144.9, 138.9, 133.4, 
128.8, 128.1, 126.5, 126.4, 125.8, 114.1, 61.1, 55.4, 53.9, 51.5, 30.3, 20.8; IR (film / 
cm-1) ѵ = 1737 (C=O); HRMS: m/z (ES) 294.1502, C19H19O2N [M+H]
+ requires 
294.1494; mp 93-95 °C;     
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one (0.035 g, 0.12 mmol) 223a was added to a solution of acetonitrile : water (7.5 mL : 
1.5 mL). Ammonium cerium(IV) nitrate (0.19 g, 0.35 mmol) was added portion-wise and 
the solution was left to stir for 16 hours. The reaction was then quenched with a 
saturated solution of NaHCO3 (30 mL) and diluted with diethyl ether (30 mL). The 
aqueous layer was extracted with diethyl ether (2 x 30 mL) and the organic layers 
combined and washed with a saturated solution of NaHCO3 (2 x 30 mL) The organics 
were dried using MgSO4 and filtered, before being evaporated under reduced pressure. 
The crude product was purified by recrystallisation from dichloromethane and hexane 
yielding a white crystalline solid (0.14 g, 76 %). 
1H NMR (500 MHz, CDCl3): H = 7.35-7.21 (4H, m, Ar), 6.25 (1H, br. s, NH), 5.03 (1H, 
d, J = 4.5 Hz, NCHCH), 4.06-4.00 (1H, m, CHCH2), 3.35 (1H, d, J = 17.5 Hz, CHCH2), 
3.07 (1H, dd, J = 17.5 and 10.5 Hz, CHCH2); 
13C{1H} NMR (75 MHz, CDCl3): C = 
170.5, 143.2, 139.5, 128.1, 126.1, 125.3, 124.1, 57.5, 53.2, 29.3; IR (film / cm-1) ѵ = 
3164 (N-H), 1695 (C=O); HRMS: m/z (ES) 182.0581, C10H9ON[M+Na]
+ requires 
181.0582; mp 191-192 °C    
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(1R,2R)-1-Amino-2,3-dihydro-1H-indene-2-carboxylic acid hydrochloride 189a 
 
(2aR,7bR)-2a,3-Dihydro-1H-indeno[1,2-b]azet-2(7bH)-one 198a (0.020 g, 0.13 mmol) 
was added to  18% HCl (5mL) and the solution was heated at reflux for 3 hours. The 
solvent was then evaporated under reduced pressure. The crude product was purified 
by recrystallisation from ethanol and diethyl ether yielding a white crystalline solid 
(0.022 g, 83 %). 
1H NMR (500 MHz, CDCl3): H = 7.45 (1H, d, J = 8.0 Hz, Ar), 7.40-7.34 (2H, m, Ar), 
7.31 (1H, t, J = 7.0 Hz, Ar), 4.94 (1H, d, J = 6.5 Hz, NCH), 3.69 (1H, q, J = 8.0 Hz, 
NCHCH), 3.30 (2H, d, J = 8.5 Hz, CHCH2); 
13C{1H} NMR (125 MHz, CDCl3): C = 175.4, 
142.1, 136.6, 130.3, 127.7, 125.4, 125.3, 55.3, 45.5, 33.3; IR (film / cm-1) ѵ = 3384 (O-
H), 1715 (C=O); HRMS: m/z (ES) 200.0680, C10H11O2N [M+Na]
+ requires 200.0687; mp 
210-214 °C;     
   = -2.5 (c 0.4, MeOH). 
4.5 Occurrence of a Minor -Amino Ester Side Product 
(1R,2R)-Ethyl-1-((S)-1-(4-methoxyphenyl)ethylamino)-2,3-dihydro-1H-indene-2-
carboxylate hydrochloride 242 
 
(2aR,7bR)-1-((S)-1-(4-Methoxyphenyl)ethyl)-2a,3-dihydro-1H-indeno[1,2-b]azet-2(7bH)-
one 223b (0.12 g, 0.40 mmol) was heated at reflux in ethanol (21 mL) with dry HCl (1 M 
in Et2O, 9 mL) for 2 hours. The solvent was then evaporated under reduced pressure. 
The crude product was purified by recrystallisation from ethanol and diethyl ether 
yielding a white crystalline solid (0.13 g, 94 %). 
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1H NMR (500 MHz, CDCl3): H = 10.56 (1H, s, NH), 9.81 (1H, s, NH), 8.13 (1H, app. t, 
Ar), 7.36-7.32 (2H, m, Ar), 7.32-7.28 (2H, m, Ar), 7.16 (1H, app. t, Ar), 6.88 (2H, d, J = 
8.5 Hz, Ar), 4.99 (1H, t, J = 6.5 Hz, NHCHCH), 4.24 (2H, q, J = 7.0 Hz, OCH2CH3), 4.13 
(1H, br. s, CHCH3), 3.82 (3H, s, OCH3), 3.45 (1H, q, J = 8.0 Hz, CH2CH), 3.10 (1H, dd, 
J= 16.0 and 8.5 Hz, CH2CH), 2.74 (1H, dd, J = 16.0 and 7.0 Hz, CH2CH), 1.79 (3H, d, J 
= 7.0 Hz, CHCH3), 1.31 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (125 MHz, CDCl3): 
C = 173.2, 160.4, 141.6, 134.9, 130.1, 129.9, 128.2, 127.9, 127.5, 124.6, 114.4, 62.3, 
60.3, 57.8, 55.4, 44.6, 34.5, 21.3, 14.0; IR (film / cm-1) ѵ = 1723 (C=O), 3651 (N-H); 
HRMS: m/z (ES) 340.1885, C21H25NO3 [M+H]





carboxylate hydrochloride 242 (0.13 g, 0.37 mmol) was dissolved in dry ethanol (10 
mL) under a nitrogen atmosphere. Sodium ethoxide (0.07 g, 0.97 mmol) was added 
and the reaction was heated at reflux for 7 hours. After cooling, the reaction was 
quenched with ammonium chloride (5 mL) and the aqueous layer extracted with 
dichloromethane (2 x 30 mL). The combined organics were collected and washed with 
water (2 x 30 mL) and then dried over MgSO4. The solvent was then evaporated under 
reduced pressure.The crude product was purified using flash column chromatography 
[Petrol : EtOAc (90:10), Rf 0.56] yielding a yellow oil (0.08 g, 62 %). 
1H NMR (500 MHz, CDCl3): H = 7.36 (2H, d, J = 8.5 Hz, Ar), 7.27-7.17 (4H, m, Ar), 
6.91 (2H, d, J = 8.5 Hz, Ar), 4.38 (1H, d, J = 7.5 Hz, NHCHCH), 4.24 (2H, q, J = 7.0 Hz, 
OCH2CH3), 3.96 (1H, q, J = 6.5 Hz, CHCH3), 3.83 (3H, s, OCH3), 3.48 (1H, q, J = 7.5 
Hz, CHCH2), 3.32 (1H, dd, J = 16.0 and 5.0 Hz, CHCH2), 2.98 (1H, dd, J = 16.0 and 8.0 
Hz), 1.38-1.33 (6H, m, OCH2CH3 and CHCH3); 
13C{1H} NMR (125 MHz, CDCl3): C = 
173.8, 158.7, 144.1, 141.0, 137.9, 127.9, 127.8, 126.7, 124.5, 124.2, 113.8, 62.6, 60.5, 
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55.7, 55.3, 48.7, 33.8, 24.8, 14.4; IR (film / cm-1) ѵ = 1723 (C=O); HRMS: m/z (ES) 
362.1797, C21H25NO3 [M+Na]
+ requires 362.1732;     
   = -28 (c 0.94, CHCl3). 
(1R,2S)-Ethyl-1-((S)-1-(4-methoxyphenyl)ethylamino)-2,3-dihydro-1H-indene-2-
carboxylate hydrochloride 243 
 
(1R,2S)-Ethyl-1-((S)-1-(4-methoxyphenyl)ethylamino)-2,3-dihydro-1H-indene-2-
carboxylate 241 (0.051 g, 0.15 mmol) was dissolved in HCl (1 M solution in Et2O, 0.15 
mL, 0.15 mmol) in Et2O (4 mL) for 30 minutes. The solvent was then evaporated under 
reduced pressure affording a white solid (0.056 g, 99 %). 
1H NMR (500 MHz, CDCl3): H = 10.43 (1H, br. s, HCl), 9.74 (1H, br. s, HCl), 7.88 (1H, 
d, J = 7.0 Hz, Ar), 7.36 (2H, d, J = 8.0 Hz, CHCHOCH3), 7.25 (2H, m, Ar), 7.10 (1H, d, J 
= 6.5 Hz, Ar), 6.85 (2H, d, J = 8.0 Hz, CHOCH3), 4.80 (1H, app. br. s, NHCHCH), 4.26-
4.17 (3H, m, OCH2CH3 and CHCH3), 3.77 (3H, s, OCH3), 3.38 (1H, q, J = 8.0 Hz, 
CHCH2), 3.32 (1H, dd, J = 16.0 and 8.5 Hz, CHCH2), 2.92 (1H, dd, J = 16.0 and 8.0 
Hz), 1.68 (3H, d, J = 7.0 Hz, CHCH3), 1.27 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR 
(125 MHz, CDCl3): C = 173.0, 160.3, 141.6, 135.0, 130.0, 129.9, 128.3, 127.8, 127.5, 
124.6, 114.4, 62.2, 60.3, 55.4, 55.4, 44.9, 34.5, 21.2, 14.0; IR (film / cm-1) ѵ = 1722 
(C=O); HRMS: m/z (ES) 362.1759, C21H25NO3 [M+Na]
+ requires 362.1732. 
(1S,2S)-Ethyl-1-(((S)-1-(4-methoxyphenyl)ethyl)amino)-2,3-dihydro-1H-indene-2-
carboxylate hydrochloride 244 
 
(2aS,7bS)-1-((S)-1-(4-Methoxyphenyl)ethyl)-2a,3-dihydro-1H-indeno[1,2-b]azet-2(7bH)-
one 223b (0.011 g, 0.037 mmol) was heated at reflux in ethanol (2.1 mL) with dry HCl 
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(1M in Et2O, 0.9 mL) for 5 hours. The solvent was then evaporated under reduced 
pressure yielding a yellow oil (0.0136 g, 96 %). 
1H NMR (500 MHz, MeOD): H = 7.60 (1H, d, J = 7.5 Hz, Ar), 7.54 (2H, d, J = 8.5 Hz, 
Ar), 7.46-7.35 (3H, m, Ar), 7.07 (2H, d, J = 8.5 Hz, Ar), 4.75 (1H, d, J = 6.5 Hz, 
NHCHCH), 4.66 (1H, q, J = 6.5 Hz CHCH3), 4.33-4.24 (2H, m, OCH2CH3), 3.84 (3H, s, 
OCH3), 3.69-3.62 (1H, m, CH2CH), 3.42-3.32 (2H, m, CH2CH), 1.72 (3H, d, J = 6.5 Hz, 
CHCH3), 1.32 (3H, t, J = 7.0Hz, OCH2CH3); 
13C{1H} NMR (125 MHz, CDCl3): C = 
173.9, 160.3, 143.6, 134.3, 130.7, 128.7, 128.4, 127.5, 126.2, 125.9, 115.3, 62.7, 59.3, 
56.6, 55.6, 45.6, 34.5, 22.4, 14.1; IR (film / cm-1) ѵ = 1727 (C=O); HRMS: m/z (ES) 
340.1968, C21H25NO3 [M+H]




(S,E)-Ethyl 3-(2-((1-(4-methoxyphenyl)ethylimino)methyl)phenyl)propanoate 221 (0.060 
g, 0.18 mmol) was dissolved in THF (6 mL). KHMDS (0.5 M in toluene, 0.39 mL, 0.19 
mmol) was added and the mixture was stirred for 8 hours at room temperature. The 
reaction was quenched with a saturated solution of NH4Cl (10 mL). The aqueous layer 
was extracted with Et2O (3 x 30 mL) and the organic layers were combined and washed 
with NH4Cl (50 mL) and water (50 mL), dried over MgSO4 and then evaporated under 
reduced pressure. The crude product was purified using flash column chromatography 
[Petrol: EtOAc (70:30), Rf 0.74] yielding a yellow oil (0.011 g, 18 %). 
1H NMR (500 MHz, CDCl3): H = 7.40 (3H, d, J = 7.5 Hz, Ar), 7.25-7.19 (2H, m, Ar), 
7.19-7.16 (1H, m, Ar), 6.91 (2H, d, J = 8.5 Hz), 4.45 (1H, br. d, J = 3.5 Hz, NHCHCH), 
4.19-4.06 (3H, m, CHCH3 and OCH2CH3), 3.82 (3H, s, OCH3), 3.36-3.25 (1H, br. s, 
CH2CH), 3.18-3.06 (2H, m, CH2CH), 1.35 (3H, d, J = 6.5 Hz, CHCH3), 1.24 (3H, t, J = 
7.0 Hz, OCH2CH3); 
13C{1H} NMR (125 MHz, CDCl3): C = 175.3, 158.7, 143.8, 140.7, 
137.2, 130.6, 127.9, 126.9, 124.6, 124.3, 113.8, 64.8, 60.7, 55.3, 53.3, 35.0, 26.4, 25.5, 
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14.2; IR (film / cm-1) ѵ = 1726 (C=O); HRMS: m/z (ES) 340.1899, C21H25O3N [M+H]
+ 
requires 340.1913;     
   = +21 (c 0.99, CHCl3). 
The stereochemistry was confirmed using the following experimental method: 
(1S,2S)-Ethyl-1-(((S)-1-(4-methoxyphenyl)ethyl)amino)-2,3-dihydro-1H-indene-2-
carboxylate hydrochloride 244 (0.015 g, 0.039 mmol) was dissolved in dry ethanol (3 
mL) under a nitrogen atmosphere. Sodium ethoxide (0.007 g, 0.10 mmol) was added 
and the reaction was heated at reflux for 48 hours. After cooling, the reaction was 
quenched with a saturated solution of NH4Cl (5 mL) and the aqueous layer extracted 
with dichloromethane (2 x 20 mL). The combined organics were collected and washed 
with water (2 x 20 mL) and then dried over MgSO4. The solvent was then evaporated 
under reduced pressure.124 The crude was purified using flash column chromatography 
[Petrol: EtOAc (70:30), Rf 0.74] yielding a yellow oil (0.011 g, 81 %). 
Data for this compound identical to that reported above. 
(1S,2R)-Ethyl-1-((S)-1-(4-methoxyphenyl)ethylamino)-2,3-dihydro-1H-indene-2-
carboxylate hydrochloride 245 
 
(1S,2R)-Ethyl-1-((S)-1-(4-methoxyphenyl)ethylamino)-2,3-dihydro-1H-indene-2-
carboxylate 240 (0.062 g, 0.18 mmol) was dissolved in HCl (1M solution in Et2O, 0.18 
mL, 0.18 mmol) and diluted in Et2O (4 mL) for 30 minutes. The solvent was then 
evaporated under reduced pressure affording a white solid (0.067 g, 98 %). 
1H NMR (500 MHz, CDCl3): H = 10.24 (1H, br. s, HCl), 9.74 (1H, br. s, HCl), 7.67 (3H, 
d, J = 7.0 Hz, Ar), 7.22-7.12 (3H, m, Ar), 6.96 (2H, d, J = 7.5 Hz), 4.68 (1H, d, J = 7.0 
Hz, NHCHCH), 4.21-4.08 (3H, m, CHCH3 and OCH2CH3), 3.83 (3H, s, OCH3), 3.80-
3.72 (1H, m, CH2CH), 3.16 (2H, m, CH2CH), 1.28 (3H, d, J = 6.0 Hz, CHCH3), 1.22 (3H, 
t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (125 MHz, CDCl3): C = 172.8, 160.2, 143.1, 
134.9, 129.8, 128.4, 127.5, 127.1, 124.5, 124.3, 114.6, 63.3, 61.5, 58.1, 55.3, 46.1, 
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35.4, 20.3, 14.2; IR (film / cm-1) ѵ = 1732 (C=O); HRMS: m/z (ES) 340.1897, C21H25O3N 
[M+H]+ requires 340.1913. 
4.6 Development of Benzocispentacin Analogues 
2-(2-Bromo-4-methylphenyl)-1,3-dioxane 275a 
 
The title compound was prepared according to General Procedure 1 from 2-bromo-4-
methylbenzaldehyde 274a (0.56 g, 2.8 mmol), 1,3-propanediol (0.30 mL, 4.2 mmol) and 
PTSA (0.05 g, 0.2 mmol). The crude product was purified by recrystallisation from 
diethyl ether, yielding a pale yellow oil (0.61 g, 85%). 
1H NMR (300 MHz, CDCl3): H = 7.47 (1H, d, J = 8.0 Hz, CBrCH), 7.26 (1H, d, J = 1.0 
Hz, Ar), 7.04 (1H, d, J = 8.0 Hz, Ar), 5.63 (1H, s, ArCH), 4.18-4.10 (2H, app. ddd, J = 
12.0, 5.0 and 1.0 Hz, OCH2), 3.95-3.85 (2H, m, OCH2), 2.21 (3H, s, ArCH3), 2.18-2.04 
(1H, m, OCH2CH2), 1.32 (1H, app. d of hep., J = 13.5 and 1.5 Hz, OCH2CH2); 
13C{1H 
NMR (75 MHz, CDCl3): C = 140.6, 134.7, 133.0, 128.3, 127.8, 122.1, 101.0, 67.6, 25.7, 
20.9; IR (film / cm-1) ѵ = 2851 (O-CH-O); HRMS: m/z (ES) 279.0002, C11H13O2Br 
[M+Na]+ requires 278.9997.  
2-(2-Bromo-5-(trifluoromethyl)phenyl)-1,3-dioxane 275b 
 
The title compound was prepared according to General Procedure 1 from 2-bromo-5-
(trifluoromethyl)benzaldehyde 274b (3.59 g, 14.2 mmol), 1,3-propanediol (1.5 mL, 21.3 
mmol) and PTSA (0.24 g, 1.4 mmol). The crude product was purified by column 
 Page | 160  
 
chromatography [Petrol : EtOAc (80:20), Rf 0.88] to afford the title compound as a pale 
yellow oil (3.50 g, 79 %). 
1H NMR (300 MHz, CDCl3): H = 7.89 (1H, d, J = 2.5 Hz, Ar), 7.56 (1H, d, J = 8.0 Hz, 
Ar), 7.37-7.32 (1H, dd, J = 8.5 and 2.5 Hz, Ar), 5.66 (1H, s, ArCH), 4.23-4.14 (2H, ddd, 
J = 12.0, 5.0 and 1.0 Hz, OCH2), 3.98-3.88 (2H, m, OCH2), 2.25-2.06 (1H, m, 
OCH2CH2), 1.37 (1H, m, OCH2CH2); 
13C{1H} NMR (75 MHz, CDCl3): C = 138.6, 133.2, 
130.1 (q, J = 33 Hz, CCF3), 126.9-126.8 (q, J = 3.5 Hz, CHCCF3), 126.18 (d, J = 1.5 
Hz, CHCCF3), 125.6-125.3 (q, J = 3.80 Hz, CBr), 125.6-122.0 (q, J = 272.0 Hz, CF3), 
100.0, 67.6, 25.6; IR (film / cm-1) ѵ = 2855 (O-CH-O). 
2-(2-Bromo-6-fluorophenyl)-1,3-dioxane 275c 
 
The title compound was prepared according to General Procedure 1 from 2-(2-bromo-
6-fluorophenyl)-1,3-dioxane 274c (0.93 g, 4.6 mmol), 1,3-propanediol (0.49 mL, 6.8 
mmol) and PTSA (0.09 g, 0.5 mmol). The crude product was purified by 
recrystallisation from diethyl ether, to afford the title compound as a white solid (0.60 g, 
50 %). 
1H NMR (300 MHz, CDCl3): H = 7.29 (1H, d, J = 8.0 Hz, CFCH), 7.13-7.04 (1H, app. 
td, J = 8.0 and 5.5 Hz, CBrCH), 7.02-6.93 (1H, m, CHCH), 5.96 (1H, s, ArCH), 4.25-
4.18 (2H, app. dd, J = 12.0 and 5.0 Hz, OCH2), 3.96-3.86 (2H, t, J = 12.5 Hz, OCH2), 
2.35-2.18 (1H, m, OCH2CH2), 1.37 (1H, d of app. hep., J = 13.5 and 1.0 Hz, OCH2CH2); 
13C{1H} NMR (75 MHz, CDCl3): C = 159.8, 131.1 (d, J = 9.5 Hz, CHCH), 129.0 (d, J = 
3.8 Hz, CBrCH), 123.0, 116.2, 115.9, 100.7, 67.8, 25.6; IR (film / cm-1) ѵ = 2851 (O-CH-
O); HRMS: m/z (ES) 282.9738, C10H10O2BrF [M+Na]








The title compound was prepared according to General Procedure 1 from 2-bromo-5-
methoxybenzaldehyde 274d (0.47 g, 2.2 mmol), propan-1,3,diol (0.24 mL, 3.3 mmol) 
and PTSA (0.04 g, 0.2 mmol). The crude product was purified by recrystallisation from 
diethyl ether, yielding a white solid (0.58 g, 96 %). 
1H NMR (300 MHz, CDCl3): H = 7.32 (1H, br. d, J = 9.0 Hz, Ar), 7.17 (1H, d, J = 3.0 Hz, 
Ar), 6.69 (1H, dd, J = 8.5 and 3.0 Hz, Ar), 5.64 (1H, s, CHO), 4.19 (2H, ddd, J = 12.0, 
5.0 and 1.0 Hz, OCH2CH2), 3.95 (2H, app. br. t, OCH2CH2), 3.73 (3H, s, OCH3), 2.30-
2.08 (1H, m, OCH2CH2), 1.37 (1H, app. d of hep., J = 13.5 and 1.5 Hz, OCH2CH2); 
13C{1H} NMR (75 MHz, CDCl3): C = 159.5, 138.7, 133.6, 117.5, 113.1, 113.0, 101.2, 
68.0, 55.9, 26.1; IR (film / cm-1) ѵ = 2853 (O-CH-O); HRMS: m/z (ES) 273.0129, 
C11H13O3Br [M+H]
+ requires 273.0126, mp 79-81 °C. 
2-(6-Bromo-2,3-dimethoxyphenyl)-1,3-dioxane 275e 
 
The title compound was prepared according to General Procedure 1 from 6-
bromoveratraldehyde 274e (2.03 g, 8.3 mmol), 1,3-propanediol (0.9 mL, 12.4 mmol) 
and PTSA (0.14 g, 0.8 mmol). The crude was purified by recrystallisation from diethyl 
ether, yielding a white solid (2.11 g, 84 %). 
1H NMR (300 MHz, CDCl3): H = 7.21 (1H, s, Ar), 6.99 (1H, s Ar), 5.70 (1H, s, CHO), 
4.27 (2H, ddd, J = 12.0, 6.5 and 1.5 Hz, OCH2CH2), 4.08-3.97 (2H, m, OCH2CH2), 3.91 
(3H, s, OMe), 3.87 (3H, s, OCH3), 2.35-2.16 (1H, m, OCH2CH2), 1.46 (1H, app. d of 
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hep., J = 13.5 and 1.5 Hz, OCH2CH2); 
13C{1H} NMR (75 MHz, CDCl3): C = 150.2, 
149.0, 130.2, 115.5, 112.9, 110.7, 101.4, 68.0, 56.6, 56.4, 26.0; IR (film / cm-1) ѵ = 
2855 (O-CH-O); HRMS: m/z (ES) 303.0232, C12H15O4Br [M+H]




The title compound was prepared according to General Procedure 1 from 2-(1-
bromonaphthalen-2-yl)-1,3-dioxane 274f (1.46 g, 6.2 mmol), propan-1,3-diol (0.67 mL, 
9.3 mmol) and PTSA (0.10 g, 0.6 mmol). The crude was purified by recrystallisation 
from diethyl ether, yielding a white solid (1.53 g, 84 %). 
1H NMR (300 MHz, CDCl3): 8.38 (1H, app. d, J = 8.5 Hz, Ar), 7.88 (3H, m, Ar), 7.50 
(2H, m, Ar), 6.11 (1H, s, ArCH), 4.36-4.28 (2H, ddd, J = 12.0, 5.0 and 1.5 Hz, OCH2), 
4.16-4.05 (2H, m, OCH2), 2.40-2.22 (1H, m, OCH2CH2), 1.49 (1H, app d of hep., J = 
13.5 and 1.5 Hz, OCH2CH2); 
13C{1H} NMR (75 MHz, CDCl3): C = 135.6, 134.8, 132.0, 
128.2, 128.0, 127.4, 127.3, 127.0, 124.6, 123.0, 102.0, 67.7, 25.8; IR (film / cm-1) ѵ = 
2864 (O-CH-O); HRMS: m/z (ES) 293.0164, C14H13O2Br [M+H]
+ requires 293.0177. 
(E)-Ethyl 3-(2-(1,3-dioxan-2-yl)-5-methylphenyl)acrylate 276a 
 
The title compound was prepared according to General Procedure 2 from 2-(2-bromo-
4-methylphenyl)-1,3-dioxane 275a (0.96 g, 3.7 mmol), ethyl acrylate (0.40 mL, 3.7 
mmol), palladium (II) acetate (0.04 g, 0.19 mmol), tri(o-tolyl)phosphine (0.11 g, 0.37 
mmol) and diisopropylethyl amine (1.95 mL, 11.2 mmol) in acetonitrile (30 mL). The 
crude product was purified by column chromatography [Petrol : EtOAc (90:10), Rf 0.20] 
yielding a yellow oil (0.74 g, 71%). 
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1H NMR (300 MHz, CDCl3): H = 8.14 (1H, d, J = 16.0 Hz, CHCHCO2), 7.42 (1H, d, J = 
8.0 Hz, Ar), 7.33 (1H, s, Ar), 7.12 (1H, d, J = 8.0 Hz, Ar), 6.28 (1H, d, J = 16.0 Hz, 
CHCHCO2), 5.60 (1H, s, ArCH), 4.23-4.16 (4H, m, OCH2CH3 and OCH2CH3), 3.98-3.89 
(2H, m, OCH2), 2.28 (3H, s, CCH3), 2.25-2.13 (1H, m, OCH2CH), 1.39 (1H, app. d, J = 
13.5 Hz, OCH2CH2), 1.27 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): 
C = 167.0, 142.4, 138.3, 134.5, 132.6, 130.6, 127.3, 127.0, 119.6, 100.4, 67.5, 60.4, 
25.7, 21.2, 14.3; IR (film / cm-1) ѵ = 2852 (O-CH-O), 1709 (C=O), 1636 (C=C), 1612 (C-
O); HRMS: m/z (ES) 277.1444, C16H20O4 [M+H]
+ requires 277.1440.  
(E)-Ethyl 3-(2-(1,3-dioxan-2-yl)-4-(trifluoromethyl)phenyl)acrylate 276b 
 
The title compound was prepared according to General Procedure 2 from 2-(2-bromo-
5-(trifluoromethyl)phenyl)-1,3-dioxane 275b (0.80 g, 2.6 mmol), ethyl acrylate (0.28 mL, 
2.6 mmol), palladium (II) acetate (0.03 g, 0.13 mmol), tri(o-tolyl)phosphine (0.08 g, 0.26 
mmol) and diisopropylethyl amine (1.34 mL, 7.7 mmol) in acetonitrile (25 mL). The 
crude product was purified by column chromatography [Petrol : EtOAc (80:20), Rf 0.48] 
yielding a yellow oil (0.57 g, 68 %). 
1H NMR (300 MHz, CDCl3): H = 8.05 (1H, d, J = 16.0 Hz, CHCHCO2), 7.83 (1H, app. s, 
Ar), 7.57-7.47 (2H, m, Ar), 6.30 (1H, d, J = 16.0 Hz, CHCHCO2), 5.62 (1H, s, ArCH), 
4.23-4.16 (4H, m, OCH2CH2 and OCH2CH3), 3.98-3.87 (2H, app. dd, J = 12.5 and 2.5 
Hz, OCH2CH2), 2.27-2.09 (1H, m, OCH2CH2 ), 1.39 (1H, app. d of hep., J = 13.5 and 
1.5 Hz, OCH2CH2), 1.26 (3H, t, J = 7.5 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): 
C = 166.4, 140.1 (d, J = 207.0 Hz, ArCHCH), 136.4 (q, J = 1.5 Hz, CCHCH), 132.0-
130.7 (q, J = 32.5 Hz, CCF3), 127.2, 125.8-125.7 (q, J = 3.5 Hz, CHCCF3), 124.2-124.0 
(q, J = 4.0 Hz, CF3), 122.2, 118.4, 100.4, 99.09, 67.5, 60.7, 25.5, 14.2; IR (film / cm
-1) ѵ 
= 2872 (O-CH-O), 1716 (C=O), 1630 (C=C), 1580 (C-O); HRMS: m/z (ES) 331.1147, 
C16H17O4F3 [M+H]
+ requires 331.1157. 
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(E)-Ethyl 3-(2-(1,3-dioxan-2-yl)-3-fluorophenyl)acrylate 276c 
 
The title compound was prepared according to General Procedure 2 from 2-(2-bromo-
6-fluorophenyl)-1,3-dioxane 275c (0.46 g, 1.8 mmol), ethyl acrylate (0.19 mL, 1.8 
mmol), palladium (II) acetate (0.02 g, 0.09 mmol), tri(o-tolyl)phosphine (0.05 g, 0.18 
mmol) and diisopropylethyl amine (0.92 mL, 5.3 mmol) in acetonitrile (15 mL). The 
crude product was purified by column chromatography [Petrol : EtOAc (80:20), Rf 0.48] 
yielding a yellow oil (0.40 g, 81 %). 
1H NMR (300 MHz, CDCl3): H = 8.68 (1H, d, J = 16.0 Hz, ArCHCH), 7.35 (1H, d, J = 
8.0 Hz, Ar), 7.26-7.19 (1H, m, Ar), 7.01-6.93 (1H, m, Ar), 6.24 (1H, d, J = 16.0 Hz, 
ArCHCH), 5.98 (1H, s, ArCHCO2), 4.25-4.16 (4H, m, OCH2CH2 and OCH2CH3), 3.95-
3.84 (2H, m, OCH2CH2), 2.40-2.23 (1H, m, OCH2CH2), 1.40 (1H, app. d of hep., J = 
13.5 and 1.0 Hz, OCH2CH2), 1.28 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, 
CDCl3): C = 166.9, 160 d, J = 248.5 Hz, CF), 143.3 (d, J = 3.0 Hz, ArCHCH), 136.3 (d, 
J = 3.0 Hz, CCHCH), 130.4 (d, J = 9.5 Hz, CFCHCH), 124.3 (d, J = 11.5 Hz, ArCHCH), 
123.3 (d, J = 3.5 Hz, CFCC), 119.6, 116.5 (d, J = 23.5 Hz, CFCH), 96.3 (d, J = 10.0 Hz, 
ArCHO2), 68.0, 60.4, 25.9, 14.3; IR (film / cm
-1) ѵ = 2856 (O-CH-O), 1710 (C=O), 1639 
(C=C), 1577 (C-O); HRMS: m/z (ES) 281.1179, C15H17O4F [M+H]
+ requires 281.1189. 
(E)-Ethyl 3-(2-(1,3-dioxan-2-yl)-4-methoxyphenyl)acrylate 276d 
 
The title compound was prepared according to General Procedure 2 from 2-(2-bromo-
5-methoxyphenyl)-1,3-dioxane 275d (0.58 g, 2.1 mmol), ethyl acrylate (0.23 mL, 2.1 
mmol), palladium (II) acetate (0.02 g, 0.11 mmol), tri(o-tolyl)phosphine (0.06 g, 0.21 
mmol) and diisopropylethyl amine (1.10 mL, 6.4 mmol) in acetonitrile (15 mL). The 
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crude product was purified by column chromatography [Petrol : EtOAc (85:15), Rf 0.25] 
yielding a yellow crystalline solid (0.36 g, 58 %). 
1H NMR (300 MHz, CDCl3): H = 8.04 (1H, br. d, J = 16.0 Hz, ArCHCH), 7.49 (1H, d, J = 
8.5 Hz, Ar), 7.11 (1H, d, J = 2.5 Hz, Ar), 6.81 (1H, dd, J = 8.5 and 2.5 Hz, Ar), 6.20 (1H, 
br. d, J = 16.0 Hz, ArCHCH), 5.64 (1H, s, CHO), 4.26-4.14 (4H, m, OCH2CH2 and 
OCH2CH3), 4.01-3.90 (2H, m, OCH2CH2), 3.77 (3H, s, OCH3), 2.31-2.12 (1H, m, 
OCH2CH2), 1.40 (1H, app. d of hep., J = 1.5 Hz, OCH2CH2) 1.26 (3H, t, J = 7.0 Hz, 
OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 167.7, 161.4, 141.9, 139.3, 128.6, 
125.5, 117.9, 115.8, 111.9, 100.0, 67.9, 60.7, 55.8, 26.0, 14.7; IR (film / cm-1) ѵ = 2855 
(O-CH-O), 1702 (C=O), 1605 (C=C); HRMS: m/z (ES) 315.1195, C16H20O5 [M+Na]
+ 
requires 315.1208; mp 43-44 °C. 
(E)-Ethyl 3-(2-(1,3-dioxan-2-yl)-3,4-dimethoxyphenyl)acrylate 276e 
 
The title compound was prepared according to General Procedure 2 from 2-(2-bromo-
4,5-dimethoxyphenyl)-1,3-dioxane 275e (1.02 g, 3.4 mmol), ethyl acrylate (0.36 mL, 3.4 
mmol), palladium (II) acetate (0.04 g, 0.17 mmol), tri(o-tolyl)phosphine (0.10 g, 0.34 
mmol) and diisopropylethyl amine (1.75 mL, 10.0 mmol) in acetonitrile (40 mL). The 
crude product was purified by column chromatography [Petrol : EtOAc (70:30), Rf 0.49] 
yielding a yellow oil (0.82 g, 76 %). 
1H NMR (300 MHz, CDCl3): H = 8.03 (1H, br. d, J = 16.0 Hz, ArCHCH), 7.11 (1H, s, 
Ar), 7.00 (1H, s, Ar), 6.22 (1H, br. d, J = 16.0 Hz, ArCHCH), 5.66 (1H, s, CHO), 4.26-
4.15 (4H, m, OCH2CH2 and CH2CH3), 4.02-3.90 (2H, m, OCH2CH2), 3.87 (3H, s, 
OCH3), 3.83 (3H, s, OCH3), 2.33-2.10 (1H, m, OCH2CH2), 1.41 (1H, br. d, J = 13.5 Hz, 
OCH2CH2), 1.28 (3H, t, J = 7.0 Hz, CH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 
167.6, 151.0, 149.5, 141.7, 131.6, 125.5, 118.1, 109.7, 109.0, 99.7, 67.9, 60.8, 56.4, 
26.0, 14.8; IR (film / cm-1) ѵ = 2853 (O-CH-O), 1703 (C=O), 1602 (C=C); HRMS: m/z 
(ES) 323.1495, C17H22O6 [M+H]
+ requires 323.1495. 
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(E)-Ethyl 3-(2-(1,3-dioxan-2-yl)naphthalen-1-yl)acrylate 276f 
 
The title compound was prepared according to General Procedure 2 from 2-(1-
bromonaphthalen-2-yl)-1,3-dioxane 275f (0.77 g, 2.6 mmol), ethyl acrylate (0.28 mL, 
2.6 mmol), palladium (II) acetate (0.03 g, 0.13 mmol), tri(o-tolyl)phosphine (0.08 g, 0.26 
mmol) and diisopropylethyl amine (1.37 mL, 7.8 mmol) in acetonitrile (20 mL). The 
crude product was purified using column chromatography [Petrol : EtOAc (85:15), Rf 
0.47] yielding a yellow oil (0.69 g, 84 %). 
1H NMR (300 MHz, CDCl3): H = 8.23 (1H, d, J = 16.0 Hz, ArCHCH), 7.96 (1H, m, Ar), 
7.80-7.74 (3H, m, Ar), 7.44 (2H, m, Ar), 6.22 (1H, d, J = 16.0 Hz, ArCHCH), 5.66 (1H, s, 
ArCHO2), 4.28 (2H, q, J = 7.0 Hz, OCH2CH3), 4.24-4.11 (2H, m, OCH2CH2), 3.99-3.88 
(2H, dd, J = 12.0 and 2.5 Hz, OCH2CH2), 2.33-2.14 (1H, m, OCH2CH2), 1.39 (1H, app. 
d of hep., J = 13.5 and 1.5 Hz, OCH2CH2), 1.32 (3H, t, J= 7.0 Hz, OCH2CH3); 
13C{1H} 
NMR (75 MHz, CDCl3): C = 166.4, 141.1, 134.0, 133.5, 131.2, 131.0, 129.2, 128.4, 
126.7, 126.6, 126.5, 125.3, 123.6, 99.9, 67.3, 60.8, 25.7, 14.4; IR (film / cm-1) ѵ = 2853 
(O-CH-O), 1713 (C=O), 1639 (C=C), 1597 (C-O); HRMS: m/z (ES) 313.1429, C19H20O4 
[M+H]+ requires 313.1440. 
Ethyl 3-(2-(1,3-dioxan-2-yl)-5-methylphenyl)propanoate 277a 
 
The title compound was prepared according to General Procedure 3 from (E)-ethyl 3-
(2-(1,3-dioxan-2-yl)-5-methylphenyl)acrylate 276a (0.64 g, 2.3 mmol), cobalt (II) 
chloride hexahydrate (0.05 g, 0.02 mmol) in ethanol (20 mL) with the addition of sodium 
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borohydride (0.17 g, 4.6 mmol). The crude product was purified using flash column 
chromatography [Petrol: EtOAc (80:20), Rf 0.54] yielding a colourless oil (0.44 g, 70 %). 
1H NMR (300 MHz, CDCl3): H = 7.38 (1H, d, J = 8.0 Hz, CH3CCHCH), 6.96 (1H, d, J = 
8.0 Hz, CH3CCHCH), 6.91 (1H, s, CH2CCH), 5.54 (1H, s, ArCHO2), 4.21-4.13 (2H, m, 
OCH2CH2), 4.07 (2H, q, J = 7.0 Hz, OCH2CH3), 3.95-3.84 (2H, m, OCH2CH2), 2.99-2.91 
(2H, diastereotopic m., ArCH2CH2), 2.58-2.50 (2H, diastereotopic m., ArCH2CH2), 2.20 
(3H, s, ArCH3), 2.20-2.07 (1H, m, OCH2CH2), 1.35 (1H, app. d of hep., J = 1.0 Hz, 
OCH2CH2), 1.18 (3H, t, J = 7.0 Hz, CH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 
173.3, 138.6, 138.3, 133.6, 130.2, 127.2, 126.5, 100.3, 67.5, 60.3, 36.2, 27.7, 25.8, 
21.2, 14.3; IR (film / cm-1) ѵ = 2854 (O-CH-O), 1730 (C=O), 1617 (C-O); HRMS: m/z 
(ES) 279.1587, C16H22O4 [M+H]
+ requires 279.1596. 
Ethyl 3-(2-(1,3-dioxan-2-yl)-4-(trifluoromethyl)phenyl)propanoate 277b 
 
The title compound was prepared according to General Procedure 3 from (E)-ethyl 3-
(2-(1,3-dioxan-2-yl)-4-(trifluoromethyl)phenyl)acrylate 276b (0.32 g, 1.0 mmol), cobalt 
(II) chloride hexahydrate (0.002 g, 0.01 mmol) in ethanol (10 mL) with the addition of 
sodium borohydride (0.07 g, 1.9 mmol). The crude product was purified using flash 
column chromatography [Petrol: EtOAc (80:20), Rf 0.49] yielding a colourless oil (0.17 
g, 54 %). 
1H NMR (300 MHz, CDCl3): H = 7.25 (1H, app. dd, J = 10.0 and 2.5 Hz, Ar), 7.07 (1H, 
app. dd, J = 5.5 and 8.5 Hz, Ar), 6.88 (1H, app. td, J = 8.5 and 3.0 Hz, Ar), 5.54 (1H, s, 
CHO2), 4.22-4.14 (2H, m, OCH2CH2), 4.07 (2H, q, J = 7.0 Hz, OCH2CH3), 3.97-3.89 
(2H, m, OCH2CH2), 2.93 (2H, app. t, J = 8.0 Hz, OCH2CH2), 2.55-2.48 (2H, 
diastereotopic m., ArCH2CH2), 2.24-2.06 (1H, diastereotopic m., OCH2CH2), 1.37 (1H, 
app. d of hep., J = 1.5 Hz, OCH2CH2), 1.17 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR 
(75 MHz, CDCl3): C = 172.8, 142.6, 137.3, 129.9, 128.7 (d, J = 33.0 Hz, CCF3), 124 (d, 
J = 271.5 Hz, CF3), 125.6 (q, J = 4.0 Hz, CHCCF3), 123.8 (q, J = 4.0 Hz, CHCCF3), 
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99.1, 67.4, 60.5, 53.4, 35.5, 27.5, 25.6, 14.2; IR (film / cm-1) ѵ = 2856 (O-CH-O), 1731 
(C=O), 1624 (C-O); HRMS: m/z (ES) 333.1300, C16H19O4F3 [M+H]
+ requires 333.1314.  
Ethyl 3-(2-(1,3-dioxan-2-yl)-3-fluorophenyl)propanoate 277c 
 
The title compound was prepared according to General Procedure 3 from (E)-ethyl 3-
(2-(1,3-dioxan-2-yl)-3-fluorophenyl)acrylate 276b (0.38 g, 1.4 mmol), cobalt (II) chloride 
hexahydrate (0.003 g, 0.01 mmol) in ethanol (10 mL) with the addition of sodium 
borohydride (0.10 g, 2.7 mmol) for 72 hours. The crude product was purified using flash 
column chromatography [Petrol: EtOAc (75:25), Rf 0.69] yielding a colourless oil (0.19 
g, 49 %). 
1H NMR (300 MHz, CDCl3): H = 7.19-7.08 (1H, m, Ar), 6.93 (1H, app. d, J = 7.5 Hz, 
Ar), 6.87-6.76 (1H, m, Ar), 5.92 (1H, s, CHO2), 4.23-4.14 (2H, m, OCH2CH2), 4.08 (2H, 
q, J = 7.0 Hz, OCH2CH3), 3.89 (2H, app. td, J = 12.0 and 2.0 Hz, OCH2CH2), 3.33-3.28 
(2H, diastereotopic m., ArCH2CH2), 2.64-2.54 (2H, diastereotopic m., ArCH2CH2), 2.31-
2.10 (1H, diastereotopic m., OCH2CH2), 1.37 (1H, app. d of hep., J = 1.5 Hz, 
OCH2CH2), 1.20 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 
173.4, 160 d, J = 247.5 Hz, CF), 143.0 (d, J = 2.0 Hz, CCH2), 130.2 (d, J = 9.5 Hz, 
CFCHCH), 126.5 (d, J = 3.5 Hz, CFCHCHCH), 123.8 (d, J = 10.5 Hz, CFCCHO2), 
113.4 (d, J = 23.5 Hz, CHCF), 97.0 (d, J = 10.0 Hz, CHO2), 67.7, 60.3, 36.6, 28.6 (d, J 
= 2.0 Hz, ArCH2), 25.8, 14.3; IR (film / cm
-1) ѵ = 2856 (O-CH-O), 1729 (C=O), 1619 (C-
O); HRMS: m/z (ES) 283.1351, C15H19O4F [M+H]
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Ethyl 3-(2-(1,3-dioxan-2-yl)-4-methoxyphenyl)propanoate 277d 
 
The title compound was prepared according to General Procedure 3 from ethyl 3-(2-
(1,3-dioxan-2-yl)-4-methoxyphenyl)acrylate 276d (0.36 g, 1.2 mmol), cobalt (II) chloride 
hexahydrate (0.003 g, 0.01 mmol) in ethanol (10 mL) with the addition of sodium 
borohydride (0.09 g, 2.4 mmol) for 48 hours. The crude product was purified using flash 
column chromatography [Petrol: EtOAc (80:20), Rf
 0.44] yielding a colourless oil (0.26 
g, 71 %). 
1H NMR (300 MHz, CDCl3): H = 7.08 (1H, d, J = 3.0 Hz, Ar), 7.01 (1H, br. d, J = 8.5 Hz, 
Ar), 6.73 (1H, dd, J = 8.5 and 3.0 Hz, Ar), 5.55 (1H, s, ArCHO2), 4.18 (2H, dd, J = 11.0 
and 5.0 Hz, OCH2CH2), 4.06 (2H, q, J = 7.5 Hz, OCH2CH3), 3.91 (2H, td, J = 12.5 and 
2.0 Hz, OCH2CH2), 3.71 (3H, s, OCH3), 2.91 (2H, t, J = 8.0 Hz, ArCH2CH2), 2.50 (2H, t, 
J = 7.5 Hz, ArCH2CH2), 2.16 (1H, m, OCH2CH2), 1.36 (1H, m, OCH2CH2), 1.17 (3H, t, J 
= 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C =173.7, 158.6, 137.8, 131.0, 
130.8, 115.6, 111.6, 100.2, 67.8, 60.7, 55.7, 36.7, 27.4, 26.1, 14.6; IR (film / cm-1) ѵ = 
2852 (O-CH-O), 1729 (C=O); HRMS: m/z (ES) 295.1551, C16H22O5 [M+H]
+ requires 
295.1545. 
Ethyl 3-(2-(1,3-dioxan-2-yl)-3,4-dimethoxyphenyl)propanoate 277e 
 
The title compound was prepared according to General Procedure 3 from ethyl 3-(2-
(1,3-dioxan-2-yl)-4,5-dimethoxyphenyl)acrylate  276e (0.82 g, 2.6 mmol), cobalt (II) 
chloride hexahydrate (0.01 g, 0.03 mmol) in ethanol (20 mL) with the addition of sodium 
borohydride (0.19 g, 5.1 mmol) for 48 hours. The crude product was purified using flash 
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column chromatography [Petrol: EtOAc (80:20), Rf
 0.11] yielding a pale yellow 
crystalline solid (0.73 g, 87 %). 
1H NMR (300 MHz, CDCl3): H = 7.07 (1H, s, Ar), 6.61 (1H, s, Ar), 5.54 (1H, s, CHO2), 
4.19 (2H, dd, J = 12.0 and 5.0 Hz, OCH2CH2), 4.08 (2H, q, J = 7.0 Hz, OCH2CH3), 3.92 
(2H, td, J = 12.5 and 2.5 Hz, OCH2CH2), 3.82 (3H, s, OCH3), 3.78 (3H, s, OCH3), 2.95-
2.87 (2H, m, ArCH2CH2), 2.56-2.49 (2H, m, ArCH2CH2), 2.26-2.09 (1H, m, OCH2CH2), 
1.37 (1H, app. d of hep., J = 13.5 and 1.5 Hz, OCH2CH2), 1.19 (3H, t, J = 7.0 Hz, 
OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 173.6, 149.4, 147.8, 131.3, 129.2, 
112.8, 109.8, 100.1, 67.9, 60.8, 56.3, 36.8, 27.8, 26.1, 14.6; IR (film / cm-1) ѵ = 2858 
(O-CH-O), 1729 (C=O); HRMS: m/z (ES) 325.1667, C17H25O6 [M+H]
+ requires 
325.1651; mp 58-60 °C. 
Ethyl 3-(2-(1,3-dioxan-2-yl)naphthalen-1-yl)propanoate 277f 
 
The title compound was prepared according to General Procedure 3 from (E)-ethyl 3-
(2-(1,3-dioxan-2-yl)naphthalen-1-yl)acrylate 276f (1.31 g, 4.2 mmol), cobalt (II) chloride 
hexahydrate (0.01 g, 0.04 mmol) in ethanol (40 mL) with the addition of sodium 
borohydride (0.32 g, 8.4 mmol) for 96 hours. The crude product was purified using flash 
column chromatography [Petrol: EtOAc (75:25), Rf 0.51] yielding a colourless oil (0.75 
g, 75 %). 
1H NMR (300 MHz, CDCl3): H = 8.01 (1H, d, J = 8.5 Hz, Ar), 7.81-7.72 (1H, m, Ar), 
7.69 (2H, s, Ar), 7.43 (2H, app. pent. of d, J = 1.5 and 8.0 Hz, Ar), 5.82 (1H, s, CHO2), 
4.23 (2H, app dd, J = 5.0 and 11.0 Hz, OCH2CH2), 4.13 (2H, q, J= 7.0 Hz, OCH2CH3), 
3.99 (2H, td, J = 12.0 and 2.0 Hz, OCH2CH2), 3.50-3.42 (2H, diastereotopic m., 
ArCH2CH2), 2.67-2.58 (2H, diastereotopic m., ArCH2CH2), 2.31-2.14 (1H, diastereotopic 
m., OCH2CH2), 1.41 (1H, d, J = 13.5 Hz, OCH2CH2), 1.22 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 173.4, 134.6, 134.0, 133.9, 131.7, 128.8, 127.2, 
126.3, 125.9, 124.0, 100.5, 67.6, 60.5, 35.6, 25.8, 23.5, 14.3; IR (film / cm-1) ѵ = 2854 
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(O-CH-O), 1727 (C=O), 1600 (C-O); HRMS: m/z (ES) 315.1581, C19H22O4 [M+H]
+ 
requires 315.1596. 
Ethyl 3-(2-formyl-5-methylphenyl)propanoate 278a 
 
The title compound was prepared according to General Procedure 4 from ethyl 3-(2-
(1,3-dioxan-2-yl)-5-methylphenyl)propanoate 277a (0.26 g, 1.0 mmol), which was 
added to a solution of acetic acid : water (14 mL : 6 mL) and stirred open to the air 
overnight. The product was obtained as a white crystalline solid (0.16 g, 73 %). 
1H NMR (300 MHz, CDCl3): H = 10.07 (1H, s, CHO), 7.63 (1H, d, J = 8.0 Hz, 
CHCCOH), 7.14 (1H, br. d, J = 8.0 Hz, CHCCH3), 7.06 (1H, br. s, CHCCH3), 4.04 (2H, 
q, J = 7.0 Hz, OCH2CH3), 3.24 (2H, app. t, J = 8.0 Hz, ArCH2CH2), 2.55 (2H, app. t, J = 
8.0 Hz, ArCH2CH2), 2.32 (3H, s, ArCH3), 1.15 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} 
NMR (75 MHz, CDCl3): C = 192.3, 172.8, 144.9, 142.9, 133.9, 132.0, 131.5, 127.8, 
60.5, 35.6, 28.1, 21.8, 14.2; IR (film / cm-1) ѵ = 1729 (C=O), 1690 (C=O), 1610 (C-O); 
HRMS: m/z (ES) 243.0989, C13H16O3 [M+Na]
+ requires 243.0997, mp 37-39 °C. 
Ethyl 3-(2-formyl-4-(trifluoromethyl)phenyl)propanoate 278b 
 
The title compound was prepared according to General Procedure 4 from ethyl 3-(2-
(1,3-dioxan-2-yl)-4-(trifluoromethyl)phenyl)propanoate 277b (0.15 g, 0.46 mmol), which 
was added to a solution of acetic acid : water (14 mL : 6 mL) and stirred open to the air 
for 36 hours. The product was obtained as a colourless oil (0.09 g, 69 %). 
1H NMR (300 MHz, CDCl3): H = 10.21 (1H, s, CHO), 8.01 (1H, br. s, CHCCHO), 7.69 
(1H, dd, J = 8.0 and 1.5 Hz, CCHCH), 7.43 (1H, d, J = 8.0 Hz, CHCCH2), 4.05 (2H, q, J 
= 7.0 Hz, OCH2CH3), 3.34 (2H, t, J = 7.5 Hz, ArCH2CH2), 2.60 (2H, t, J = 7.5 Hz, 
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ArCH2CH2), 1.15 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 
191.1, 172.2, 146.8, 134.1, 132.0, 130.1, 130.0, 129.7, 60.7, 35.2, 27.8, 14.2; IR (film / 
cm-1) ѵ = 1731 (C=O), 1704 (C=O), 1618 (C-O); HRMS: m/z (ES) 275.0868, C13H13O3F3 
[M+H]+ requires 275.0895. 
Ethyl 3-(3-fluoro-2-formylphenyl)propanoate 278c 
 
The title compound was prepared according to General Procedure 4 from ethyl 3-(2-
(1,3-dioxan-2-yl)-3-fluorophenyl)propanoate 277c (0.19 g, 0.68 mmol), which was 
added to a solution of acetic acid : water (7 mL : 3 mL) and stirred open to the air 
overnight. The product was obtained as a colourless oil (0.12 g, 79 %). 
1H NMR (300 MHz, CDCl3): H = 10.46 (1H, s, CHO), 7.41 (1H, td, J = 8.0 and 6.0 Hz, 
Ar), 7.07-6.94 (2H, m, Ar), 4.04 (2H, q, J = 7.0 Hz, OCH2CH3), 3.23 (2H, t, J = 7.5 Hz, 
ArCH2), 2.55 (2H, t, J = 7.5 Hz, ArCH2CH2), 1.15 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} 
NMR (75 MHz, CDCl3): C = 189.0 (d, J = 11.0 Hz, CHO), 172.8, 166.64 (d, J = 257.5 
Hz, CF), 144.7, 135.40 (d, J = 10.5 Hz, CFCHCH), 127.2 (d, J = 3.5 Hz, CH2CCH), 
122.19 (d, J = 5.5 Hz, CFC), 114.6 (d, J = 22.0 Hz, CFCH), 60.5, 35.0, 29.03 (d, J = 2.0 
Hz, ArCH2), 14.2; IR (film / cm
-1) ѵ = 1730 (C=O), 1695 (C=O), 1610 (C-O). 
Ethyl 3-(2-formyl-4-methoxyphenyl)propanoate 278d 
 
The title compound was prepared according to General Procedure 4 from ethyl-3-(2-
(1,3-dioxan-2-yl)-4-methoxyphenyl)propanoate 277d (0.15 g, 0.5 mmol), which was 
added to a solution of acetic acid : water (14 mL : 6 mL) and stirred open to the air 
overnight. The product was obtained as an orange oil (0.12 g, 86 %). 
1H NMR (300 MHz, CDCl3): H = 10.16 (1H, s, CHO), 7.27 (1H, d, J = 2.5 Hz, Ar), 7.19 
(1H, d, J = 5.0 Hz, Ar), 6.99 (1H, dd, J = 8.5 and 3.0 Hz, Ar), 4.04 (2H, q, J = 7.0 Hz, 
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OCH2CH3), 3.78 (3H, s, OCH3), 3.21 (2H, t, J = 7.5 Hz, ArCH2CH2), 2.51 (2H, t, J = 7.5 
Hz, ArCH2CH2) 1.15 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 
192.3, 173.0, 158.9, 135.7, 134.9, 132.7, 120.9, 116.2, 60.9, 55.9, 36.5, 27.2, 14.6; IR 
(film / cm-1) ѵ = 1728 (C=O), 1686 (C=O); HRMS: m/z (ES) 259.0941, C13H16O4 
[M+Na]+ requires 259.0946. 
Ethyl 3-(2-formyl-3,4-dimethoxyphenyl)propanoate 278e 
 
The title compound was prepared according to General Procedure 4 from ethyl-3-(2-
(1,3-dioxan-2-yl)-4,5-dimethoxyphenyl)propanoate 277e (0.47 g, 1.5 mmol), which was 
added to a solution of acetic acid : water (14 mL : 6 mL) and stirred open to the air 
overnight. The product was obtained as a white solid (0.30 g, 77 %). 
1H NMR (300 MHz, CDCl3): H = 10.10 (1H, s, CHO), 7.28 (1H, s, Ar), 6.71 (1H,s, Ar), 
4.05 (2H, q, J = 7.0 Hz, OCH2CH3), 3.88 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.24 (2H, t, 
J = 7.5 Hz, ArCH2CH2), 2.57 (2H, t, J = 7.5 Hz, ArCH2CH2), 1.16 (3H, t, J = 7.5 Hz, 
OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 190.4, 172.9, 154.1, 148.3, 138.7, 
127.1, 113.5, 112.9, 61.0, 56.5, 56.4, 36.8, 27.4, 14.6; IR (film / cm-1) ѵ = 1727 (C=O), 
1673 (C=O); HRMS: m/z (ES) 289.1035, C14H18O5 [M+Na]
+ requires 289.1052; mp 121-
123 °C. 
Ethyl 3-(2-formylnaphthalen-1-yl)propanoate 278f 
 
The title compound was prepared according to General Procedure 4 from ethyl 3-(2-
(1,3-dioxan-2-yl)naphthalen-1-yl)propanoate 277f (0.25 g, 0.80 mmol), which was 
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added to a solution of acetic acid : water (14 mL : 6 mL) and stirred open to the air 
overnight. The product was obtained as a yellow oil (0.14 g, 71 %).  
1H NMR (300 MHz, CDCl3): 10.53 (1H, s, CHO), 8.20-8.13 (1H, m, Ar), 7.88-7.72 (3H, 
m, Ar), 7.59-7.51 (2H, m, Ar), 4.08 (2H, q, J= 7.0 Hz, OCH2CH3), 3.80 (2H, t, J= 8.0 Hz, 
ArCH2CH2), 2.70-2.63 (2H, diastereotopic m., ArCH2CH2), 1.16 (3H, t, J= 7.0 Hz, 
OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 192.0, 172.4, 142.2, 136.3, 131.7, 
131.0, 129.1, 128.7, 127.7, 127.3, 125.0, 124.8, 60.8, 35.8, 22.0, 14.2; IR (film / cm-1) ѵ 






Ethyl 3-(2-formyl-5-methylphenyl)propanoate 278a (0.07 g, 0.30 mmol) was dissolved 
in dry CH2Cl2 (15 mL) with MgSO4 and stirred under a nitrogen atmosphere. After 5 
minutes, (S)-(-)-4-methoxy--methylbenzylamine (0.04 mL, 0.30 mmol) was added and 
the solution was stirred for 5 hours. The solution was then filtered and the solvent 
evaporated under reduced pressure, yielding a hygroscopic white solid (0.10 g, 82 %).  
1H NMR (300 MHz, CDCl3): H = 8.45 (1H, s, ArCHN), 7.61 (1H, d, J = 8.0 Hz, Ar), 
7.31-7.24 (2H, m, Ar), 7.02-6.93 (2H, m, Ar), 6.84 -6.77 (2H, m, Ar), 4.39 (1H, q, J = 4.5 
Hz, CHCH3), 4.06 (2H, q, J = 7.0 Hz, OCH2CH3), 3.72 (3H, s, OCH3), 3.14 (2H, t, J = 
8.5 Hz, ArCH2CH2), 2.51 (2H, t, J = 8.0 Hz, ArCH2CH2), 2.26 (3H, s, ArCH3), 1.48 (3H, 
d, J = 6.5 Hz, CHCH3), 1.17 (3H, t, J =7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, 
CDCl3): C = 173.0, 158.4, 157.9, 140.3, 140.2, 137.7, 131.4, 131.0, 129.7, 127.6, 
127.5, 126.9, 113.9, 113.8, 70.1, 60.4, 55.3, 36.0, 28.5, 25.3, 21.4, 14.3; HRMS: m/z 
(ES) 354.2071, C22H27O3N [M+H]
+ requires 354.2069. 
 






Ethyl 3-(2-formyl-4-(trifluoromethyl)phenyl)propanoate 278b (0.11 g, 0.39 mmol) was 
dissolved in dry CH2Cl2 (20 mL) with MgSO4 and stirred under a nitrogen atmosphere. 
After 5 minutes, (S)-(-)-4-methoxy--methylbenzylamine (0.06 mL, 0.39 mmol) was 
added and the solution was stirred for 5 hours. The solution was then filtered and the 
solvent evaporated under reduced pressure, yielding a yellow oil (0.14 g, 85 %). 
1H NMR (300 MHz, CDCl3): H = 8.55 (1H, s, ArCHN), 8.01 (1H, s, CHCCHN), 7.48 
(1H, app. dd, J = 8.0 and 1.5 Hz, Ar), 7.30-7.23 (3H, m, Ar), 6.85-6.78 (2H, m, Ar), 4.46 
(1H, q, J = 6.5 Hz, CHCH3), 4.06 (2H, q, J = 7.0 Hz), 3.73 (3H, s, OCH3), 3.20 (2H, t, J 
= 8.0 Hz, ArCH2CH2), 2.57-2.50 (2H, diastereotopic m., ArCH2CH2), 1.51 (3H, d, J = 6.5 
Hz, CHCH3), 1.16 (3H, t, J = 7.0 Hz, OCH2CH3); HRMS: m/z (ES) 408.1802, 
C22H24O3NF3 [M+H]




Ethyl 3-(3-fluoro-2-formylphenyl)propanoate 278c (0.06 g, 0.27 mmol) was dissolved in 
dry CH2Cl2 (15 mL) with MgSO4 and stirred under a nitrogen atmosphere. After 5 
minutes, (S)-(-)-4-methoxy--methylbenzylamine (0.04 mL, 0.27 mmol) was added and 
the solution was stirred for 5 hours. The solution was then filtered and the solvent 
evaporated under reduced pressure, yielding a yellow oil (0.08 g, 82 %).  
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1H NMR (300 MHz, CDCl3): H = 8.65 (1H, s, ArCHN), 7.35-7.15 (2H, m, Ar), 7.02-6.72 
(5H, m, Ar), 4.38 (1H, q, J = 6.5 Hz, CHCH3), 4.06 (2H, q, J = 7.0 Hz, OCH2CH3), 3.72 
(3H, s, OCH3), 3.26 (2H, t, J = 8.0 Hz, ArCH2CH2), 2.55 (2H, t, J = 8.0 Hz, ArCH2CH2), 
1.49 (3H, d, J = 6.5 Hz, CHCH3), 1.17 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 
MHz, CDCl3): C = 173.3, 158.5, 153.4, 143.2, 137.4, 130.9, 130.8, 127.6, 127.3, 126.7, 
122.5, 113.8, 113.5, 71.4, 60.3, 55.3, 35.6, 29.7, 25.6, 14.3; HRMS: m/z (ES) 
258.1815, C21H24O3NF [M+H]




Ethyl-3-(2-formyl-4-methoxyphenyl)propanoate 278d (0.18 g, 0.75 mmol) was dissolved 
in dry CH2Cl2 (20 mL) with MgSO4 and stirred under a nitrogen atmosphere. After 5 
minutes, (S)-(-)-4-methoxy--methylbenzylamine (0.11 mL, 0.75 mmol) was added and 
the solution was stirred for 5 hours. The solution was then filtered and the solvent 
evaporated under reduced pressure, yielding a yellow oil (0.23 g, 85 %).  
1H NMR (300 MHz, CDCl3): H = 8.50 (1H, s, ArCHN), 7.34-7.24 (3H, m, Ar), 7.04 (1H, 
d, J = 8.5 Hz, Ar), 6.82-6.76 (3H, m, Ar), 4.42 (1H, q, J = 6.5 Hz, CHCH3), 4.03 (2H, q, J 
= 7.0 Hz, OCH2CH3), 3.72 (3H, s, OCH3), 3.70 (3H, s, OCH3), 3.07 (2H, br. t, J = 7.5 
Hz, ArCH2CH2), 2.47 (2H, t, J = 7.5 Hz, ArCH2CH2), 1.48 (3H, d, J = 6.5 Hz, CHCH3), 
1.15 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 172.9, 158.5, 
158.3, 157.5, 137.4, 135.0, 132.7, 131.3, 127.7, 116.7, 114.1, 113.8, 113.2, 69.9, 60.4, 
55.4, 55.3, 36.3, 29.7, 27.5, 25.2, 14.3; HRMS: m/z (ES) 370.2021, C22H27O4N [M+H]
+ 
requires 370.2018.  
 
 





Ethyl 3-(2-formyl-3,4-dimethoxyphenyl)propanoate 278e (0.49 g, 1.9 mmol) was 
dissolved in dry CH2Cl2 (35 mL) with MgSO4 and stirred under a nitrogen atmosphere. 
After 5 minutes, (S)-(-)-4-methoxy--methylbenzylamine (0.28 mL, 1.9 mmol) was 
added and the solution was stirred for 5 hours. The solution was then filtered and the 
solvent evaporated under reduced pressure, yielding a yellow oil (0.68 g, 93 %).  
1H NMR (400 MHz, CDCl3): H = 8.60 (1H, s, ArCHN), 7.53 (1H, br. s, Ar), 7.42-7.38 
(2H, m, Ar), 6.96-6.91 (2H, m, Ar), 6.74 (1H, s, Ar), 4.55 (1H, q, J = 6.5 Hz, CHCH3), 
4.18 (2H, q, J = 7.0 Hz, CH2CH3), 3.97 (3H, s, OCH3), 3.94 (3H, s, OCH3), 3.85 (3H, s, 
OCH3), 3.19 (2H, t, J = 8.0 Hz, ArCH2CH2), 2.64-2.59 (2H, diastereotopic m., 
ArCH2CH2), 1.62 (3H, d, J = 6.5 Hz, CHCH3), 1.29 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 172.8, 158.5, 156.7, 150.7, 147.7, 137.6, 133.9, 
127.7, 126.5, 113.8, 112.6, 110.7, 69.6, 60.5, 56.0, 55.9, 55.3, 36.5, 27.6, 25.1, 14.3; 
HRMS: m/z (ES) 400.2143, C23H30O5N [M+H]




Ethyl 3-(2-(1,3-dioxan-2-yl)naphthalen-1-yl)propanoate 278e (0.04 g, 0.16 mmol) was 
dissolved in dry CH2Cl2 (10 mL) with MgSO4 and stirred under a nitrogen atmosphere. 
After 5 minutes, (S)-(-)-4-methoxy--methylbenzylamine (0.02 mL, 0.16 mmol) was 
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added and the solution was stirred for 5 hours. The solution was then filtered and the 
solvent evaporated under reduced pressure, yielding a yellow oil (0.068 g, 92 %).  
1H NMR (400 MHz, CDCl3): H = 8.97 (1H, s, ArCHN), 8.19 (1H, d, J= 8.5 Hz, 
CHCCHN), 8.14 (1H, d, J= 9.0 Hz, Ar), 7.90 (1H, d, J= 8.0 Hz, Ar), 7.79 (1H, d, J= 8.5 
Hz, Ar), 7.59 (2H, d J= 8.0 Hz, Ar), 7.46 (2H, d, J= 8.5 Hz, Ar), 6.96 (2H, d, J= 8.5 Hz, 
Ar), 4.66 (1H, q, J= 6.5 Hz, CHCH3), 4.23 (1H, q, J= 7.5 Hz, OCH2CH3), 3.86 (3H, s, 
OCH3), 3.73 (2H, t, J= 7.5 Hz, ArCH2CH2), 2.74 (2H, t, J= 8.0 Hz, ArCH2CH2), 1.68 (3H, 
d, J= 6.5 Hz, CHCH3), 1.31 (3H, t, J= 7.5 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, 
CDCl3): C = 172.9, 158.5, 157.7, 137.5, 137.0, 134.7, 131.8, 131.5, 128.9, 127.7, 
127.2, 126.7, 126.6, 125.3, 124.0, 114.1, 113.9, 70.0, 60.7, 55.3, 35.6, 25.2, 22.8, 14.3; 
HRMS: m/z (ES) 390.2053, C25H27O3N [M+H]




The title compound was prepared according to General Procedure 5 from (S,E)-ethyl 3-
(2-((1-(4-methoxyphenyl)ethylimino)methyl)-5-methylphenyl)propanoate 279a (0.087 g, 
0.25 mmol), which was dissolved in THF (7 mL) under a nitrogen atmosphere. 15-
Crown-5 (0.05 mL, 0.27 mmol) and NaHMDS (1M in THF, 0.27 mL, 0.27 mmol) were 
added and the mixture was stirred for 8 hours at -40 °C and allowed to warm to room 
temperature. The crude product was purified using flash column chromatography 
[Petrol : EtOAc (60:40), Rf 0.35] yielding a white crystalline solid (0.045 g, 60 %). 
1H NMR (400 MHz, CDCl3): H = 7.34-7.29 (2H, m, Ar), 7.11 (1H, s, Ar), 7.06 (1H, d, J = 
8.0 Hz, Ar), 7.02-6.98 (1H, m, Ar), 6.98-6.95 (2H, m, Ar), 5.00 (1H, q, J = 7.0 Hz, 
CHCH3), 4.86 (1H, d, J = 4.5 Hz, CHCHN), 3.91-3.86 (4H, m, CHCH2 and OCH3), 3.36 
(1H, d, J = 17.5 Hz, CHCH2), 2.99 (1H, dd, J = 17.5 and 10.5 Hz, CHCH2), 2.38 (3H, s, 
ArCH3), 1.44 (3H, d, J = 7.0 Hz, CHCH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 169.9, 
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159.0, 145.4, 138.8, 136.9, 132.1, 128.4, 127.4, 126.9, 125.9, 114.0, 61.1, 55.4, 51.9, 
50.9, 29.9, 21.4, 18.9; IR (film / cm-1) ѵ = 1738 (C=O); HRMS: m/z (ES) 208.1642, 
C20H21O2N [M+H]
+ requires 308.1651; mp 71-73 °C;     




The title compound was prepared according to General Procedure 5 from (S,E)-ethyl 3-
(2-((1-(4-methoxyphenyl)ethylimino)methyl)-4-(trifluoromethyl)phenyl)propanoate 279b 
(0.086 g, 0.21 mmol), which was dissolved in THF (6 mL) under a nitrogen atmosphere. 
15-Crown-5 (0.05 mL, 0.23 mmol) and NaHMDS (1M in THF, 0.23 mL, 0.23 mmol) 
were added and the mixture was stirred for 8 hours at -40 °C and allowed to warm to 
room temperature. The crude product was purified using flash column chromatography 
[Petrol : EtOAc (60:40), Rf 0.24] yielding a white crystalline solid (0.053 g, 69 %). 
1H NMR (400 MHz, CDCl3): H = 7.53 (1H, d, J = 7.5 Hz, Ar), 7.39 (1H, d, J = 8.0 Hz, 
Ar), 7.24 (2H, d, J = 8.5 Hz, Ar), 7.14 (1H, s, Ar), 6.92 (2H, d, J = 8.5 Hz, Ar), 4.89 (1H, 
q, J = 7.0 Hz, CHCH3), 4.84 (1H, d, J = 4.0 Hz, NCHCH), 3.96 (1H, dq, J = 10.5 and 2.0 
Hz, CHCH2), 3.87 (3H, s, OCH3), 3.45 (1H, d, J = 18.0 Hz, CHCH2), 3.08 (1H, dd, J = 
17.5 and 10.5 Hz, CHCH2), 1.51 (3H, d, J = 7.0 Hz, CHCH3); 
13C{1H} NMR (75 MHz, 
CDCl3): C = 169.3, 159.3, 149.1, 140.4, 131.7, 128.7 (q, J = 31.0 Hz, CF3C), 128.4, 
126.7, 125.8 (q, J = 4.0 Hz, CHCCH), 124.1 (q, J = 273.0 Hz, CF3), 123.2 (q, J = 4.0 
Hz, CF3CCH), 122.7, 114.1, 61.2, 55.3, 52.8, 51.7, 30.2, 19.3; IR (film / cm
-1) ѵ = 1742 
(C=O); HRMS: m/z (ES) 362.1358, C20H18O2NF3 [M+H]
+ requires 362.1368; mp 108-
110 °C;     
   = -14 (c 0.5825, CHCl3). 
 
 





The title compound was prepared according to General Procedure 5 from (S,E)-ethyl 3-
(3-fluoro-2-((1-(4-methoxyphenyl)ethylimino)methyl)phenyl)propanoate 279c (0.070 g, 
0.20 mmol), which was dissolved in THF (6 mL) under a nitrogen atmosphere. 15-
Crown-5 (0.04 mL, 0.22 mmol) and NaHMDS (1M in THF, 0.22 mL, 0.22 mmol) were 
added and the mixture was stirred for 8 hours at -40 °C and allowed to warm to room 
temperature. The crude product was purified using flash column chromatography 
[Petrol : EtOAc (60:40), Rf 0.30] yielding a white crystalline solid (0.048 g, 79 %). 
1H NMR (400 MHz, CDCl3): H = 7.37-7.26 (3H, m, Ar), 7.08 (1H, s, Ar), 6.94-6.86 (3H, 
m, Ar), 5.02-4.95 (2H, m, NCHCH and CHCH3), 3.98-3.92 (1H, m, CHCH2), 3.85 (3H, s, 
OCH3), 3.44 (1H, d, J = 17.5 Hz, CHCH2), 3.05 (1H, dd, J = 18.0 and 11.0 Hz, CHCH2), 
1.51 (3H, d, J = 7.0 Hz, CHCH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 169.2, 163.2 (d, J 
= 247 Hz, CF), 158.9, 148.7 (d, J = 4.5 Hz, CH2C), 132.6, 131.1 (d, J = 7.5 Hz, 
CFCCH), 128.2 (d, J = 1.0 Hz, CFCHCH), 127.2, 127.0, 122.0 (d, J = 3.5 Hz, 
CFCHCHCH), 113.9, 113.2 (d, J = 20.5 Hz, CFCH), 57.7, 55.3, 52.5, 51.4, 30.2, 18.2 
(d, J = 3.5Hz); IR (film / cm-1) ѵ = 1743 (C=O); HRMS: m/z (ES) 334.1225, C19H18O2NF 
[M+Na]+ requires 334.1219; mp 75-77 °C;     











The title compound was prepared according to General Procedure 5 from (S,E)-ethyl 3-
(4-methoxy-2-((1-(4-methoxyphenyl)ethylimino)methyl)phenyl)propanoate 279d (0.105 
g, 0.28 mmol), which was dissolved in THF (7 mL) under a nitrogen atmosphere. 15-
Crown-5 (0.06 mL, 0.31 mmol) and NaHMDS (1M in THF, 0.31 mL, 0.31 mmol) were 
added and the mixture was stirred for 8 hours at -40 °C and allowed to warm to room 
temperature. The crude product was purified using flash column chromatography 
[Petrol : EtOAc (60:40), Rf 0.25] yielding a white crystalline solid (0.057 g, 62 %). 
1H NMR (400 MHz, CDCl3): H = 7.30 (2H, d, J = 8.0 Hz, Ar), 7.19 (1H, d, J = 8.5 Hz, 
Ar), 6.98-6.94 (2H, m, Ar), 6.86 (1H, dd, J = 8.0 and 2.5 Hz, Ar), 6.60 (1H, d, J = 2.5 
Hz, Ar), 4.98 (1H, q, J = 7.0 Hz, CHCH3), 4.77 (1H, d, J = 4.5 Hz, NCHCH), 3.91 (1H, 
dq, J = 10.5 and 2.5 Hz, CHCH2), 3.88 (3H, s, OCH3), 3.79 (3H, s, OCH3), 3.33 (1H, d, 
J = 17.0 Hz, CHCH2), 2.96 (1H, dd, J = 17.0 and 10.5 Hz, CHCH2), 1.48 (3H, d, J = 7.0 
Hz, CHCH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 170.0, 159.1, 158.5, 140.9, 136.9, 
132.0, 128.5, 126.9, 114.9, 114.0, 111.4, 61.5, 55.5, 55.3, 52.4, 51.5, 29.3, 19.1; IR 
(film / cm-1) ѵ = 1730 (C=O); HRMS: m/z (ES) 324.1601, C20H21O3N [M+H]
+ requires 
324.1600; mp 128-130 °C;     











The title compound was prepared according to General Procedure 5 from (S,E)-ethyl 3-
(3,4-dimethoxy-2-((1-(4-methoxyphenyl)ethylimino)methyl)phenyl)propanoate 279e 
(0.054 g, 0.14 mmol), which was dissolved in THF (5 mL) under a nitrogen atmosphere. 
15-Crown-5 (0.03 mL, 0.15 mmol) and NaHMDS (1M in THF, 0.15 mL, 0.15 mmol) 
were added and the mixture was stirred for 8 hours at -40 °C and allowed to warm to 
room temperature.  The crude product was purified using flash column chromatography 
[Petrol : EtOAc (60:40), Rf 0.15] yielding a white crystalline solid (0.029 g, 60 %). 
1H NMR (400 MHz, CDCl3): H = 7.32-7.27 (2H, m, Ar), 6.95 (2H, d, J = 8.5 Hz, Ar), 
6.77 (1H, s, CHCOCH3), 6.47 (1H, s, CHCOCH3), 4.95 (1H, q, J = 7.0 Hz, CHCH3), 
4.76 (1H, d, J = 4.0 Hz, CHCHN), 3.92-3.95 (1H, m, CHCH2), 3.90 (3H, s, ArOCH3), 
3.87 (3H, s, ArOCH3), 3.82 (3H, s, ArOCH3), 3.34 (1H, d, J = 17.0 Hz, CHCH2), 2.97 
(1H, dd, J = 17.0 and 10.5 Hz, CHCH2), 1.49 (3H, d, J = 7.0 Hz, CHCH3); 
13C{1H} NMR 
(75 MHz, CDCl3): C = 170.2, 159.1, 149.9, 147.9, 137.2, 132.1, 131.4, 128.5, 114.0, 
108.8, 108.5, 61.9, 56.0, 55.9, 55.3, 52.4, 51.6, 30.0, 19.2; IR (film / cm-1) ѵ = 1720 
(C=O); HRMS: m/z (ES) 354.1692, C21H23O4N [M+H]
+ requires 354.1701;  mp 142-144 
°C;     











The title compound was prepared according to General Procedure 5 from (S,E)-ethyl 3-
(2-((1-(4-methoxyphenyl)ethylimino)methyl)naphthalen-1-yl)propanoate 279f (0.068 g, 
0.17 mmol), which was dissolved in dry THF (6 mL) under a nitrogen atmosphere. 15-
crown-5 (0.04 mL, 0.19 mmol) and NaHMDS (1M in THF, 0.19 mL, 0.19 mmol) were 
added and the mixture was stirred for 8 hours at -40 °C and allowed to warm to room 
temperature. The crude product was purified using flash column chromatography 
[Petrol : EtOAc (60:40), Rf 0.39] yielding a white crystalline solid (0.034 g, 57 %). 
1H NMR (400 MHz, CDCl3): H = 7.88 (1H, d, J = 8.0 Hz, Ar), 7.82 (1H, d, J = 8.0 Hz, 
Ar), 7.69 (1H, d, J = 8.0 Hz, Ar), 7.58-7.50 (2H, m, Ar), 7.32 (2H, d, J = 8.5 Hz, Ar), 7.23 
(1H, d, J = 8.5 Hz, Ar), 6.95 (2H, d, J = 8.5 Hz, Ar), 5.02 (1H, q, J = 7.0 Hz, CHCH3), 
4.94 (1H, d, J = 4.0 Hz, NCHCH), 4.05 (1H, dq, J = 10.5 and 2.5 Hz, CHCH2), 3.85 (3H, 
s, OCH3), 3.75 (1H, d, J = 17.5 Hz, CHCH2), 3.28 (1H, dd, J = 17.5 and 10.5 Hz, 
CHCH2), 1.40 (3H, d, J = 7.0 Hz, CHCH3); 
13C{1H}NMR (75 MHz, CDCl3): C = 170.0, 
159.0, 141.8, 136.9, 133.5, 132.0, 131.0, 128.4, 127.4, 126.6, 126.3, 124.4, 123.4, 
114.1, 62.3, 55.3, 51.8, 51.0, 28.7, 19.1; IR (film / cm-1) ѵ = 1738 (C=O); HRMS: m/z 
(ES) 344.1648, C23H21O2N [M+H]
+ requires 344.1650; mp 149-151 °C;     












b]azet-2(7bH)-one (0.019 g, 0.06 mmol) 280a was added to a solution of acetonitrile : 
water (5 mL : 1 mL). Ammonium cerium (IV) nitrate (0.10 g, 0.18 mmol) was added 
portion-wise and the solution was stirred for 16 hours. The reaction was quenched with 
a saturated solution of NaHCO3 (30 mL) and diluted with diethyl ether (30 mL). The 
aqueous layer was extracted with diethyl ether (2 x 30 mL) and the organic layers 
combined and washed with a saturated solution of NaHCO3 (2 x 30 mL). The organics 
were then dried using MgSO4 and filtered before being evaporated under reduced 
pressure. The crude was purified using flash column chromatography [Petrol : EtOAc 
(65:45), Rf 0.17] yielding a white crystalline solid (0.007 g, 66 %). 
1H NMR (500 MHz, CDCl3): H = 7.23 (1H, d, J = 7.5 Hz, CH3CCHCH), 7.12 (1H, s, 
CH3CCHC), 7.06 (1H, d, J = 7.5 Hz, CH3CCHCH), 6.19 (1H, br. s, NH), 5.01 (1H, d, J = 
4.0 Hz, CHNH), 4.04 (1H, d, J = 10.5 Hz, CHCH2), 3.33 (1H, dd, J = 17.5 Hz, CHCH2), 
3.05 (1H, dd, J = 17.5 and 10.5 Hz, CHCH2 ), 2.37 (3H, s, CH3); 
13C{1H} NMR (125 
MHz, CDCl3): C = 171.5, 144.5, 139.1, 137.7, 128.0, 126.9, 124.8, 58.3, 54.5, 30.3, 
21.4; IR (film / cm-1) ѵ = 3194 (N-H), 1701 (C=O); HRMS: m/z (ES) 174.0903, 
C11H11ON [M+H]
+ requires 174.0910; mp 97-100 °C;     












indeno[1,2-b]azet-2(7bH)-one (0.024 g, 0.07 mmol) 280b was added to a solution of 
acetonitrile : water (5 mL : 1 mL). Ammonium cerium (IV) nitrate (0.11 g, 0.20 mmol) 
was added portion-wise and the solution was stirred for 16 hours. The reaction was 
quenched with a saturated solution of NaHCO3 (30 mL) and diluted with diethyl ether 
(30 mL).  The aqueous layer was extracted with diethyl ether (2 x 30 mL) and the 
organic layers combined and washed with a saturated solution of NaHCO3 (2 x 30 mL). 
The organics were then dried using MgSO4 and filtered before being evaporated under 
reduced pressure. The crude was purified using flash column chromatography [Petrol : 
EtOAc (70:30), Rf 0.15] yielding a white crystalline solid (0.009 g, 61 %). 
1H NMR (500 MHz, CDCl3): H = 7.62 (1H, s, CF3CHC), 7.59 (1H, d, J = 8.0 Hz, 
CF3CHCH), 7.42 (1H, d, J = 18.0 Hz CF3CHCH), 6.35 (1H, br. s, NH), 5.09 (1H, d, J = 
4.5 Hz, NCHCH), 4.12 (1H, m, CHCH2), 3.42 (1H, d, J = 18.0 Hz, CHCH2), 3.14 (1H, 
dd, J = 17.5 and 10.5 Hz, CHCH2); 
13C{1H} NMR (125 MHz, CDCl3): C = 170.5, 148.4, 
141.3, 129.9 (q, J = 33.0 Hz, CF3C) 126.8, 126.2 (q, J = 4.0 Hz, CHCCH), 124.0 (q, J = 
272.0 Hz, CF3), 122.3 (q, J = 4.0 Hz, CCHCH), 58.0, 54.6, 30.4; IR (film / cm
-1) ѵ = 
3201 (N-H), 1755 (C=O); HRMS: m/z (ES) 228.0639, C11H8ONF3 [M+H]
+ requires 
228.0636; mp 138-139 °C;     












b]azet-2(7bH)-one (0.024 g, 0.08 mmol) 280c was added to a solution of acetonitrile : 
water (5 mL : 1 mL). Ammonium cerium (IV) nitrate (0.13 g, 0.23 mmol) was added 
portion-wise and the solution was stirred for 16 hours. The reaction was quenched with 
a saturated solution of NaHCO3 (30 mL) and diluted with diethyl ether (30 mL). The 
aqueous layer was extracted with diethyl ether (2 x 30 mL) and the organic layers 
combined and washed with a saturated solution of NaHCO3 (2 x 30 mL). The organics 
were then dried using MgSO4 and filtered before being evaporated under reduced 
pressure. The crude was purified using flash column chromatography [Petrol : EtOAc 
(70:30), Rf 0.25] yielding a white crystalline solid (0.0085 g, 62 %). 
1H NMR (500 MHz, CDCl3): H = 7.33-7.28 (1H, m, CFCHCH), 7.07 (1H, d, J = 7.5 Hz, 
CFCHCHCH), 6.92 (1H, app. t, J = 9.0 Hz, CFCH), 6.30 (1H, br. s, NH), 5.18 (1H, d, J 
= 4.5 Hz, NCHCH), 4.14-4.10 (1H, m, CHCH2), 3.40 (1H, d, J = 17.5 Hz, CHCH2), 3.10 
(1H, dd, J = 17.5 and 10.5 Hz, CHCH2); 
13C{1H} NMR (125 MHz, CDCl3): C = 170.7, 
160.1 (d, J = 248.0 Hz, CF), 147.8 (d, J = 4.5 Hz, CFCCCH), 131.4 (d, J = 7.0 Hz, 
CFCHCH), 127.6 (d, J = 19.0 Hz, CFCCCH), 121.9 (d, J = 19.0 Hz, CFCCCH), 113.5 
(d, J = 19.0 Hz, CFCH), 55.2, 55.1, 30.6; IR (film / cm-1) ѵ = 3225 (N-H), 1786 (C=O); 
HRMS: m/z (ES) 200.0472, C10H8ONF [M+Na]
+ requires 200.0488; mp 151-153 °C; 
    











indeno[1,2-b]azet-2(7bH)-one 280d (0.020 g, 0.06 mmol) was added to a solution of 
acetonitrile : water (5 mL : 1 mL). Ammonium cerium (IV) nitrate (0.093 g, 0.17 mmol) 
was added portion-wise and the solution was stirred for 16 hours. The reaction was 
quenched with a saturated solution of NaHCO3 (30 mL) and diluted with diethyl ether 
(30 mL). The aqueous layer was extracted with diethyl ether (2 x 30 mL) and the 
organic layers combined and washed with a saturated solution of NaHCO3 (2 x 30 mL) 
The organics were then dried using MgSO4 and filtered before being evaporated under 
reduced pressure yielding a yellow oil (0.004 g, 19%). 
1H NMR (300 MHz, CDCl3): H = 7.18-7.12 (3H, m, Ar), 6.86-6.80 (2H, d, J = 8.5 Hz, 
Ar), 6.25 (1H, s, Ar), 4.82 (1H, q, J = 7.0 Hz, CH3CH), 4.65 (1H, d, J = 3.5 Hz, COCH), 
4.15 (1H, d, J = 3.5 Hz, NHCHCH), 3.84 (3H, s, OCH3), 3.76 (3H, s, OCH3), 3.75 (3H, 
s, OCH3), 1.44 (3H, d, J = 7.0 Hz, CH3CH); 
13C{1H} NMR (75 MHz, CDCl3): C = 193.6, 
161.7, 159.4, 155.0, 150.9, 144.3, 131.4, 131.3, 128.6, 114.2, 108.2, 105.4, 63.1, 56.3, 
56.2, 55.4, 53.5, 53.3, 19.4;  IR (film / cm-1) ѵ = 1729 (C=O); HRMS: m/z (ES) 
370.1651, C21H23O5N [M+H]
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4.7 Synthesis and Optimization of Benzocishexacin 
Ethyl 4-(2-formylphenyl)butanoate 291169 
 
To a Schlenk flask flushed with nitrogen, anhydrous LiCl (0.75 g, 17.6 mmol) was 
added and dried under vacuum. Zinc dust (1.15 g, 17.6 mmol) was added and the 
resultant mixture was further dried under high vacuum. THF (10 mL) was added and 
the suspension was stirred for 10 minutes before dibromoethane (0.076 mL, 0.58 
mmol), Me3SiCl (0.015 mL, 0.12 mmol), iodine (0.09 g, 0.35 mmol) and ethyl 4-
bromobutyrate (1.68 mL, 11.8 mmol) were added and the solution was stirred for 12 
hours at 50 °C. The resultant grey suspension was cooled to room temperature and 2-
bromobenzaldehyde (1.10 mL, 9.4 mmol), PEPPSI (0.04 g, 0.06 mmol) and DMI (5 mL) 
were added to the solution, which was stirred at room temperature for 12 hours. The 
reaction was quenched with a saturated solution of NH4Cl (20 mL) and then filtered 
through cotton wool. The aqueous layer was extracted with diethyl ether (2 x 10 mL). 
The combined organics were collected, washed with brine (2 x 10 mL) and dried over 
MgSO4. The solution was then filtered and the solvent evaporated under reduced 
pressure. The crude compound was purified using flash column chromatography [Petrol 
: EtOAc (90:10), Rf  0.50] yielding a yellow oil (0.90 g, 51 %).  
1H NMR (300 MHz, CDCl3): H = 10.19 (1H, s, CHO), 7.77 (1H, app. dd, J = 7.5 and 1.5 
Hz, Ar), 7.45 (1H, td, J = 7.5 and 1.5 Hz, Ar), 7.32 (1H, td, J = 7.5 and 1.5 Hz, Ar), 7.28-
7.20 (1H, m, Ar), 4.06 (2H, q, J = 7.0 Hz, OCH2CH3), 3.01 (2H, t, J = 7.5 Hz, 
ArCH2CH2), 2.31 (2H, t, J = 7.5 Hz, CH2CH2CH2), 1.93-1.82 (2H, pent., J = 7.5 Hz, 
ArCH2CH2), 1.19 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 
192.5, 173.3, 144.3, 133.8, 133.7, 132.5, 131.2, 126.8, 60.4, 33.8, 31.8, 27.0, 14.3; IR 
(film / cm-1) ѵ = 1728 (C=O), 1695 (C=O), 1600 (C-O); HRMS: m/z (ES) 243.0984, 
C13H16O3 [M+Na]
+ requires 243.0997. 
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(S,E)-Ethyl 4-(2-((1-(4-methoxyphenyl)ethylimino)methyl)phenyl)butanoate 285 
 
Ethyl 4-(2-formylphenyl)butanoate (0.84 g, 3.8 mmol) 291 was dissolved in dry CH2Cl2 
(50 mL) with MgSO4 and stirred under a nitrogen atmosphere. After 5 minutes, (S)-(-)-
4-methoxy--methylbenzylamine (0.56 mL, 3.8 mmol) was added and stirring was 
continued for 5 hours. The solution was then filtered and the solvent evaporated under 
reduced pressure yielding a colourless oil (1.10 g, 82 %).  
1H NMR (300 MHz, CDCl3): H = 8.57 (1H, s, ArCHN), 7.82 (1H, app. dd, J = 7.5 and 
1.5 Hz, CHCCHN), 7.28 (2H, d, J = 8.5 Hz, Ar), 7.24-7.13 (2H, m, Ar), 7.09 (1H, d, J = 
7.0 Hz, CH3OCCHCH), 6.81 (2H, d, J = 8.5 Hz, CH3OCCH), 4.44 (1H, q, J = 6.5 Hz, 
CHCH3), 4.06 (2H, q, J = 7.0 Hz, OCH2CH3), 3.71 (3H, s, OCH3), 2.82 (2H, t, J = 7.5 
Hz, ArCH2CH2), 2.25 (2H, t, J = 7.5 Hz, ArCH2CH2CH2), 1.82 (2H, p, J = 7.5 Hz, 
ArCH2CH2), 1.50 (3H, d, J = 6.5 Hz, CHCH3), 1.18 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 173.4, 158.5, 157.8, 141.2, 137.5, 134.1, 130.2, 
130.1, 128.6, 127.7, 126.5, 113.8, 69.7, 60.3, 55.3, 33.8, 32.2, 26.9, 25.0, 14.3; HRMS: 
m/z (ES) 354.2074, C22H27O3N [M+H]




The title compound was prepared according to General Procedure 5 from (S,E)-ethyl 4-
(2-((1-(4-methoxyphenyl)ethylimino)methyl)phenyl)butanoate 285 (0.064 g, 0.18 mmol), 
which was dissolved in THF (6 mL) under a nitrogen atmosphere. 15-Crown-5 (0.07 
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mL, 0.36 mmol) and NaHMDS (1 M in THF, 0.36 mL, 0.36 mmol) were added and the 
mixture was strirred for 8 hours at -40 °C and allowed to warm to room temperature. 
The crude was purified using flash column chromatography [Petrol : EtOAc (60:40), Rf 
0.36] yielding a colourless oil (0.032 g, 57 %). 
Major Diastereomer: 1H NMR (400 MHz, CDCl3): H = 7.31-7.25 (1H, m, Ar), 7.22-7.17 
(4H, m, Ar), 6.97-6.89 (3H, m, Ar), 4.99 (1H, q, J = 7.0 Hz, CHCH3), 4.42 (1H, d, J = 5.0 
Hz, NCHCH), 3.87 (3H, s, OCH3), 3.59-3.55 (1H, m, NCHCH), 2.85-2.70 (2H, m, 
ArCH2), 2.40 (1H, app. d of hep., J = 13.5 and 1.5 Hz, CHCH2CH2), 1.61-1.50 (1H, m, 
CHCH2CH2), 1.18 (3H, d, J = 7.0 Hz, CHCH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 
169.1, 158.9, 139.9, 133.7, 131.6, 130.1, 128.8, 128.7, 128.3, 126.2, 113.8, 55.3, 52.8, 
50.6, 49.4, 26.8, 23.1, 18.2.  
Minor Diastereomer: 1H NMR (400 MHz, CDCl3): H = 7.31-7.25 (1H, m, Ar), 7.22-7.17 
(2H, m, Ar), 7.10-7.07 (2H, m, Ar), 7.03 (1H, d, J = 7.5 Hz, Ar), 6.82-6.78 (2H, m, Ar), 
4.50 (1H, d, J = 5.0 Hz, NCHCH), 4.32 (1H, q, J = 7.0 Hz, CHCH3), 3.82 (3H, s, OCH3), 
3.59-3.55 (1H, m, NCHCH), 2.85-2.70 (2H, m, ArCH2), 2.40 (1H, app. d of hep., J = 
13.5 and 1.5 Hz, CHCH2CH2), 1.67 (3H, d, J = 7.0 Hz, CHCH3), 1.47-1.40 (1H, m, 
CHCH2CH2); 
13C{1H} NMR (75 MHz, CDCl3): C = 169.4, 158.7, 139.9, 132.7, 131.6, 
130.3, 128.8, 128.6, 128.3, 127.8, 114.0, 55.3, 52.8, 50.6, 49.2, 26.8, 22.9, 19.9.  






2(2aH)-one 292 (0.027 g, 0.09 mmol) was added to a solution of acetonitrile : water (5 
mL : 1 mL). Ammonium cerium (IV) nitrate (0.15 g, 0.27 mmol) was added portion-wise 
and the solution was stirred for 16 hours. The reaction was quenched with a saturated 
solution of NaHCO3 (30 mL) and diluted with diethyl ether (30 mL). The aqueous layer 
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was extracted with diethyl ether (2 x 30 mL) and the organic layers combined and 
washed with a saturated solution of NaHCO3 (2 x 30 mL). The organics were then dried 
using MgSO4 and filtered before being evaporated under reduced pressure. The crude 
product was purified using flash column chromatography [Petrol : EtOAc (70:30), Rf 
0.29] yielding a white crystalline solid (0.011 g, 72 %). 
1H NMR (500 MHz, CDCl3): H = 7.32-7.20 (4H, m, Ar), 6.06 (1H, br. s, NH), 4.70 (1H, 
d, J = 5.0 Hz, NCHCH), 3.74 (1H, s, CHCH2CH2), 2.88-2.73 (2H, m, CHCH2CH2), 2.35 
(1H, d, J = 13.5 Hz, CHCH2CH2), 1.68-1.59 (1H, m, CHCH2CH2); 
13C{1H} NMR (75 
MHz, CDCl3): C = 170.6, 139.3, 134.0, 129.6, 129.0, 128.5, 126.6, 51.5, 50.2, 26.9, 
22.9; IR (film / cm-1) ѵ = 3235 (N-H), 1737 (C=O); HRMS: m/z (ES) 196.0721, 
C11H11ON [M+Na]
+ requires 196.0738; mp 103-105 °C. 
4.8 Chiral Imino Ester Synthesis 
Ethyl 6-oxohexanoate 333 
 
Ethyl-6-hydrohexanoate (0.50 mL, 3.1 mmol) was added to pyridinium chlorochromate 
(1.00 g, 3.1 mmol) in CH2Cl2 (14 mL) and allowed to stir at room temperature for 2 
hours. The reaction mixture was filtered through a pad of Celite® and Fluorosil® and 
then evaporated under reduced pressure. The crude product was purified using flash 
column chromatography [Petrol : EtOAc (80:20), Rf 0.51] yielding a colourless liquid 
(0.44 g, 89 %). 
1H NMR (300 MHz, CDCl3): H = 9.76 (1H, br. s, CHO), 4.13 (2H, q, J = 7.0 Hz, 
OCH2CH3), 2.46 (2H, app. q, CH2CHO), 2.32 (2H, m, CH2CO2Et), 1.67 (4H, m, 
CH2CH2CH2), 1.25 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 
201.9, 173.1, 60.1, 43.3, 33.8, 24.3, 21.4, 14.1; IR (film / cm-1) ѵ = 1721 (C=O); HRMS: 
m/z (ES) 159.1013, C8H14O3 [M+H]
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(S,E)-Ethyl 6-((1-(4-methoxyphenyl)ethyl)imino)hexanoate 334 
 
Ethyl-6-oxohexanoate 333 (0.193 g, 1.22 mmol) was dissolved in dry CH2Cl2 (20 mL) 
with MgSO4. After 5 minutes, (S)-(−)-4-Methoxy-α-methylbenzylamine (0.180 mL, 1.22 
mmol) was added and the reaction was stirred for 3 hours. The solution was then 
filtered and the solvent evaporated under reduced pressure yielding a pale yellow oil 
(0.318 g, 90 %). 
1H NMR (300 MHz, CDCl3): H = 7.71 (1H, t, J = 5.0 Hz, CHN), 7.29-7.20 (2H, m, Ar), 
6.85 (2H, d, J = 8.5 Hz, Ar), 4.24 (1H, q, J = 6.5 Hz, CH3CH), 4.11 (2H, q, J = 7.0 Hz, 
OCH2CH3), 3.78 (3H, s, OCH3), 2.34-2.22 (4H, m, CH2CH2CH2CH2), 1.71-1.52 (4H, m, 
CH2CH2CH2), 1.46 (3H, d, J = 6.5 Hz, CH3CH), 1.24 (3H, t, J = 7.0 Hz, CH2CH3); 
HRMS: m/z (ES) 292.1911, C17H25O3N [M+H]




(S,E)-Ethyl 6-((1-(4-methoxyphenyl)ethyl)imino)hexanoate 334 was stored under 
nitrogen for 14 days, resulting in the formation of the title compound as a dark brown 
oil.   
1H NMR (300 MHz, CDCl3): H = 7.82 (1H, s, CHN), 7.31 (2H, m, Ar), 6.90 (2H, m, Ar), 
5.84 (1H, t, J = 7.5 Hz, CH2CHCHN), 4.33 (1H, q, J = 6.5 Hz, CHCH3), 4.16 (2H, q, J = 
7.0 Hz, OCH2CH3), 4.15 (2H, q, J = 7.0 Hz, OCH2CH3), 3.82 (3H, s, OCH3), 2.49 (2H, 
m, CCH2), 2.35 (4H, m, O2CCH2), 2.28 (2H, m, CH2CH), 1.81 (2H, m, CCH2CH2), 1.70 
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(2H, m, CH2CH2CH2CH), 1.51 (2H, m, CH2CH2CH2CH), 1.49 (3H, d, J = 6.5 Hz, 
CHCH3), 1.29 (3H, t, J = 7.0 Hz, OCH2CH3), 1.28 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} 
NMR (75 MHz, CDCl3): C = 173.7, 173.4, 162.3, 158.2, 141.5, 139.9, 137.9, 127.4, 
113.7, 68.5, 60.1, 60.0, 55.2, 34.1, 34.0, 28.7, 27.9, 25.2, 25.1, 24.6, 24.0, 14.2, 14.1; 
HRMS: m/z (ES) 432.2752, C25H37O5N [M+H]
+ requires 432.2744. 
(1R,5S)-6-((S)-1-(4-Methoxyphenyl)ethyl)-6-azabicyclo[3.2.0]heptan-7-one 336 
 
Ethyl 6-oxohexanoate 333 (0.28 g, 1.75 mmol) was dissolved in dry THF (35 mL) with 
MgSO4 and left stirring under a nitrogen atmosphere. After 5 minutes, (S)-(−)-4-
Methoxy-α-methylbenzylamine (0.26 mL, 1.75 mmol) was added to the reaction and 
stirred for 10 minutes, the solution was subsequently cooled to -40 °C. 15-Crown-5 
(0.69 mL, 3.5 mmol) and NaHMDS (1M in THF, 3.5 mL, 3.5 mmol) were added and the 
mixture was stirred for 6 hours allowing to warm to room temperature. The reaction was 
quenched with a saturated solution of NH4Cl (5 mL) and the THF was removed under 
reduced pressure. The resulting solution was further diluted with a saturated solution of 
NH4Cl (20 mL) and the aqueous layer was extracted with Et2O (3 x 30 mL). The organic 
layers were combined and washed with water (50 mL). The organics were then dried 
using MgSO4 and filtered before being evaporated under reduced pressure. The crude 
product was purified using flash column chromatography [Petrol : EtOAc (60:40), Rf 
0.41] yielding a pale yellow oil (0.23 g, 52 %). 
1H NMR (300 MHz, CDCl3): H = 7.26 (2H, m, Ar), 6.88 (2H, d, J = 8.5 Hz, Ar), 4.81 
(1H, q, J = 7.0 Hz, CH3CH), 3.83 (4H, m, OCH3 and CHNH), 3.32 (1H, dd, J = 3.5 and 
8.0 Hz, CHCHNH), 2.07-1.99 (1H, m, CH2CH2), 1.87-1.62 (3H, m, CH2CH2CH2), 1.58 
(3H, d, J = 7.0 Hz, CH3CH), 1.38-1.13 (2H, m, CH2CH2); 
13C{1H} NMR (75 MHz, CDCl3): 
C = 168.9, 159.0, 132.9, 128.2, 114.0, 57.2, 55.3, 53.8, 51.5, 29.2, 24.8, 22.7, 19.6; IR 
(film / cm-1) ѵ = 1731 (C=O); HRMS: m/z (ES) 246.1489, C15H19O2N [M+H]
+ requires 
246.1494.     
   = -14 (c 1.09, CHCl3). 
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4.9 Synthesis of Cispentacin and Transpentacin Ethyl Ester 
(1R,5S)-6-Azabicyclo[3.2.0]heptan-7-one 338 
 
(1R,5S)-6-((S)-1-(4-Methoxyphenyl)ethyl)-6-azabicyclo[3.2.0]heptan-7-one 336 (0.297 
g, 1.2 mmol) was added to a solution of acetonitrile : water (15 mL : 15 mL). 
Ammonium cerium (IV) nitrate (2.63 g, 4.8 mmol) was added portion-wise and the 
solution was stirred for 4 hours. The reaction was quenched with a saturated solution of 
NaHCO3 (30 mL) and diluted with CH2Cl2 (30 mL). The aqueous layer was extracted 
with EtOAc (2 x 30 mL) and the organic layers combined and washed with a saturated 
solution of NaHCO3 (2 x 30 mL) The organics were then dried using MgSO4 and filtered 
before being evaporated under reduced pressure. The crude product was purified by 
recrystallisation from dichloromethane and hexane yielding a white solid (0.095 g, 71 
%). 
1H NMR (500 MHz, CDCl3): H = 6.17 (1H, br. s, NH), 4.01 (1H, t, J = 4.0Hz, CHCHNH), 
3.47-3.43 (1H, m, CHCHNH), 1.99 (1H, dd, J = 13.5 and 6.0 Hz, CH2CH2CH2), 1.85-
1.69 (3H, m, CH2CH2CH2), 1.44-1.28 (2H, m, CH2CH2CH2); 
13C{1H} NMR (125 MHz, 
CDCl3): C = 171.0, 55.9, 54.0, 30.0, 25.2, 22.4; IR (film / cm
-1) ѵ = 3250 (N-H), 1716 
(C=O); HRMS: m/z (ES) 112.0778, C6H9ON [M+H]
+ requires 112.0762; mp 49-50 °C; 
    
   = -33 (c 0.87, CHCl3). 
(1R,2S)-2-Aminocyclopentanecarboxylic acid hydrochloride 300a 
 
(1R,5S)-6-Azabicyclo[3.2.0]heptan-7-one 338 (0.028 g, 0.25 mmol) was heated at 
reflux in 18% HCl solution for 3 hours. The solvent was then evaporated under reduced 
pressure. The crude product was purified by recrystallisation from water and diethyl 
ether yielding a white crystalline solid (0.040 g, 97 %). 
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1H NMR (500 MHz, D2O): H = 3.84 (1H, q, J = 6.0 Hz, CHCHNH2), 3.14 (1H, q, J = 8.5 
Hz, CHCHNH2), 2.17-2.09 (2H, m, CH2CH2CH2), 1.98-1.69 (4H, m, CH2CH2CH2). 
13C{1H} NMR (125 MHz, D2O): C = 176.3, 52.7, 45.4, 29.7, 27.2, 21.2; IR (film / cm
-1) ѵ 
= 3341 (O-H), 2974 (N-H), 1694 (C=O); HRMS: m/z (ES) 152.0710, C6H11O2N [M+Na]
+ 
requires 152.0687; mp 164-166 °C;     
   = -5.0 (c 0.5, H2O). 
(1R,2S)-Ethyl 2-aminocyclopentanecarboxylate hydrochloride 338 
 
(1R,5S)-6-Azabicyclo[3.2.0]heptan-7-one 339 (0.031 g, 0.28 mmol) was heated at 
reflux in ethanol (9 ml) with dry hydrogen chloride (1 M in Et2O, 3 mL) for 3 hours. The 
solvent was then evaporated under reduced pressure. The crude product was purified 
by recrystallisation from diethyl ether yielding a white solid (0.052 g, 96 %); 
1H NMR (500 MHz, MeOD): H = 4.27-4.16 (2H, m, OCH2CH3), 3.77 (1H, m, 
CHCHNH2), 3.10 (1H, q, J = 8.0 Hz, CHCHNH2), 2.19-2.08 (2H, m, CH2CH2CH2), 2.03-
1.73 (4H, m, CH2CH2CH2), 1.28 (3H, t, J = 7.0 Hz, OCH2CH3). 
13C{1H} NMR (100 MHz, 
CDCl3): C = 172.9, 61.0, 52.7, 45.4, 29.9, 27.3, 21.3, 13.0; IR (film / cm
-1) ѵ = 2957 (N-
H), 1716 (C=O); HRMS: m/z (ES) 180.0998, C8H15O2N [M+Na]
+ requires 180.1000; 
    
   = -7.77 (c 1.03, EtOH); mp 68-70 °C. 
(1R,5S)-6-((S)-1-Phenylethyl)-6-azabicyclo[3.2.0]heptan-7-one 343 
 
Ethyl 6-oxohexanoate 333 (0.69 g, 4.3 mmol) was dissolved in dry THF (80 mL) with 
MgSO4 and stirred under a nitrogen atmosphere. After 5 minutes, (S)--
methylbenzylamine (0.55 mL, 4.3 mmol) was added to the reaction and stirred for 10 
minutes, the solution was subsequently cooled to -40 °C. 15-Crown-5 (1.72 mL, 8.6 
mmol) and NaHMDS (1M in THF, 8.6 mL, 8.6 mmol) were added and the mixture was 
stirred for 8 hours allowing to warm to room temperature. The reaction was quenched 
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with a saturated solution of NH4Cl (5 mL) and the THF was removed under reduced 
pressure. The resulting solution was further diluted with a saturated solution of NH4Cl 
(20 mL) and the aqueous layer was extracted with Et2O (3 x 30 mL). The organic layers 
were combined and washed with water (50 mL). The organics were then dried using 
MgSO4 and filtered before being evaporated under reduced pressure. The crude 
product was purified using flash column chromatography [Petrol : EtOAc (60:40), Rf 
0.56] yielding a pale yellow oil (0.50 g, 53 %). 
1H NMR (300 MHz, CDCl3): H = 7.29-7.17 (5H, m, Ar), 4.76 (1H, q, J = 7.0Hz, CHCH3), 
3.76 (1H, t, J = 4.0 Hz, CHNH), 3.26 (1H, dd, J = 8.0 and 3.5 Hz, CHCHNH), 1.96 (1H, 
dd, J = 13.0 and 6.0 Hz, CH2CH2CH2), 1.80-1.56 (3H, m, CH2CH2CH2), 1.54 (3H, d, J = 
7.0 Hz, CHCH3), 1.33-1.04 (2H, m, CH2CH2CH2); 
13C{1H} NMR (100 MHz, CDCl3): C = 
168.9, 140.8, 128.6, 127.6, 127.0, 57.33, 53.9, 52.1, 29.2, 24.8, 22.7, 19.5; IR (film / 
cm-1) ѵ = 1726 (C=O); HRMS: m/z (ES) 238.1309, C14H17ON [M+Na]
+ requires 
238.1208;  = -11.0 (c 0.64, CHCl3). 
(1R,2S)-Ethyl 2-(((S)-1-phenylethyl)amino)cyclopentanecarboxylate 344 
 
(1R,5S)-6-((S)-1-Phenylethyl)-6-azabicyclo[3.2.0]heptan-7-one 343 (0.13 g, 0.60 mmol) 
was heated at reflux in ethanol (18 ml) with dry hydrogen chloride (1 M in Et2O , 6 mL) 
for 12 hours. The solvent was then evaporated under reduced pressure yielding the title 
compound as a brown oil (0.17 g, 95 %). 
1H NMR (300 MHz, MeOD): H = 7.58-7.53 (3H, m, Ar), 7.51-7.42 (2H, m, Ar), 4.45 (1H, 
q, J = 7.0 Hz, CHCH3), 4.29-4.17 (2H, m, OCH2CH3), 3.42 (1H, q, J = 7.5 Hz, CHNH), 
3.18 (1H, m, CHCHNH), 2.07-1.72 (5H, m, CH2CH2CH2), 1.69 (3H, d, J = 7.0 Hz, 
CHCH3), 1.64-1.54 (1H, m, CH2CH2CH2), 1.29 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} 
NMR (75 MHz, MeOD): C = 175.3, 137.9, 131.3, 131.0, 129.4, 63.1, 60.4, 59.7, 45.6, 
29.6, 22.6, 20.5, 14.8; IR (film / cm-1) ѵ = 3391 (N-H), 1725 (C=O); HRMS: m/z (ES) 
284.1604, C16H23O2N [M+Na]
+ requires 284.1626;     
   = -47.4 (c 1.31, MeOH). 
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(1S,2S)-Ethyl 2-(((S)-1-phenylethyl)amino)cyclopentanecarboxylate 345 
 
(1R,2S)-Ethyl 2-(((S)-1-phenylethyl)amino)cyclopentanecarboxylate 344 (0.16 g, 0.55 
mmol) was dissolved in dry ethanol (8 mL) under a nitrogen atmosphere. Potassium 
tert-butoxide (0.12g, 1.10 mmol) was added and the reaction was heated at reflux for 4 
hours. After cooling, the reaction was quenched with NH4Cl (5 mL) and the aqueous 
layer extracted with dichloromethane (2 x 30 mL). The combined organics were 
collected and washed with water (2 x 30 mL) and then dried over MgSO4. The solvent 
was then evaporated under reduced pressure. The crude product was purified using 
flash column chromatography [Petrol : EtOAc (90:10), Rf 0.15] yielding a colourless oil 
(0.79 g, 55 %) in accordance with the literature.213  
1H NMR (500 MHz, CDCl3): H = 7.33-7.30 (4H, m, Ar), 7.26-7.21 (1H, m, Ar), 4.16-4.08 
(2H, m, OCH2CH3), 3.86 (1H, q, J = 7.0 Hz, CHCH3), 3.23 (1H, q, J = 7.0 Hz, CHNH), 
2.60 (1H, q, J = 7.0 Hz, CHCHNH), 2.01-1.92 (1H, m, CH2CHNH), 1.81 (2H, hep., J = 
7.5 Hz, CH2CH2CH2), 1.72- 1.57 (2H, m, CH2CH2CH2), 1.36 (3H, d, J = 6.5 Hz, 
CHCH3), 1.33-1.27 (1H, m, CH2CH2CH2), 1.24 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} 
NMR (75 MHz, CDCl3): C = 176.0, 128.3, 126.9, 126.7, 61.6, 60.3, 56.8, 51.3, 34.3, 
28.9, 24.6, 23.7, 14.1; IR (film / cm-1) ѵ = 1727 (C=O); HRMS: m/z (ES) 262.1562, 
C16H23O2N [M+H]
+ requires 262.1807;     
   = -1.4 (c 0.71, CHCl3). 
4.10 Methyl-Substituted Cispentacin Synthesis 
Ethyl 6-((triethylsilyl)oxy)hexanoate 350 
 
A solution of ethyl 6-hydroxyhexanoate 332 (1.5 mL, 9.2 mmol) in CH2Cl2 (90 mL) was 
cooled to 0 °C under a nitrogen atmosphere. 2,6-Lutidine (2.1 mL, 18.4 mmol) was 
added followed by a dropwise addition of TES-triflate (3.1 mL, 13.7 mmol), the resulting 
solution was then stirred for 3 hours at 0 °C. Following this, the reaction was quenched 
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with water (30 mL) and extracted with Et2O (3 x 30 mL), the organic layers were 
combined and further washed with water (30 mL). The organics were dried using 
MgSO4 and filtered; the solvent was then removed under reduced pressure. The crude 
product was purified using flash column chromatography [Petrol : EtOAc (95:5), Rf 0.71] 
yielding a colourless oil (1.95 g, 77 %). 
1H NMR (300 MHz, CDCl3): H = 4.09 (2H, q, J = 7.0 Hz, OCH2CH3), 3.57 (2H, t, J = 6.5 
Hz, CH2OSi), 2.27 (2H, t, J = 7.5 Hz, EtOOCCH2), 1.67-1.56 (2H, pent., J = 7.5 Hz, 
CH2CH2CH2O), 1.54-1.46 (2H, q, J = 7.0 Hz, CH2CH2CH2O), 1.40-1.28 (2H, m, 
CH2CH2CH2O), 1.22 (3H, t, J = 7.0 Hz, OCH2CH3), 0.92 (9H, t, J = 8.0 Hz, SiCH2CH3), 
0.56 (6H, q, J = 8.0 Hz, SiCH2CH3); 
13C{1H} NMR (100 MHz, CDCl3): C = 173.7, 62.6, 
60.1, 34.3, 32.5, 25.4, 24.8, 14.2, 6.7, 4.6; IR (film / cm-1) ѵ = 1737 (C=O) 1095 (Si-O); 
HRMS: m/z (ES) 297.1724, C14H30O3Si [M+Na]
+ requires 297.1862. 
Ethyl 2-methyl-6-((triethylsilyl)oxy)hexanoate 351 
 
A solution of NaHMDS (1M in THF, 1.5 mL, 1.5 mmol) in THF (15 mL) was cooled to -
78 °C, followed by a dropwise addition of ethyl 6-((triethylsilyl)oxy)hexanoate 350 (0.35 
g, 1.2 mmol). The reaction was left for 4 hours and allowed to warm to -40 °C, methyl 
iodide (0.13 mL, 2.04 mmol) was subsequently added and the resulting solution was 
left overnight to warm to room temperature. The reaction was quenched with a 
saturated solution of NH4Cl (20 mL) and the aqueous layer was extracted with Et2O (3 x 
30 mL). The organic layers were combined and washed with brine (30 mL). The 
organics were then dried using MgSO4 and filtered before the solvent was removed 
under reduced pressure. The crude product was purified using flash column 
chromatography [Petrol : EtOAc (95:5), Rf 0.74] yielding a yellow oil (0.24 g, 65 %). 
1H NMR (300 MHz, CDCl3): H = 4.12 (2H, q, J = 7.0 Hz, OCH2CH3), 3.59 (2H, t, J = 6.5 
Hz, CH2OSi), 2.41 (1H, sextet, J = 7.0 Hz, CHCH3), 1.73-1.28 (6H, m, CH2CH2CH2), 
1.24 (3H, t, J = 7.0 Hz, OCH2CH3), 1.13 (3H, d, J = 7.0 Hz, CH3CH) 0.95 (9H, t, J = 8.0 
Hz, SiCH2CH3), 0.58 (6H, q, J = 8.0 Hz, SiCH2CH3). 
13C{1H} NMR (75 MHz, CDCl3): C 
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= 176.9, 62.7, 60.1, 39.6, 33.6, 32.8, 23.6, 17.0, 14.3, 6.8, 4.4; IR (film / cm-1) ѵ = 1736 
(C=O) 1096 (Si-O); HRMS: m/z (ES) 289.2186, C15H32O3Si [M+H]
+ requires 289.2199.  
Ethyl 6-hydroxy-2-methylhexanoate 352 
 
TBAF (1M in THF, 1.85 mL, 1.85 mmol) was slowly added to a solution of ethyl 2-
methyl-6-((triethylsilyl)oxy)hexanoate 351 (0.27 mL, 0.92 mmol) in THF (15 mL) and left 
for 30 minutes. The reaction was quenched with a saturated solution of NH4Cl (20 mL) 
and the aqueous layer was extracted with CH2Cl2 (2 x 30 mL). The organics were then 
dried using MgSO4 and filtered before the solvent was removed under reduced 
pressure. The crude product was purified using flash column chromatography [Petrol : 
EtOAc (95:5), Rf 0.10] yielding a yellow oil (0.11 g, 67 %). 
1H NMR (300 MHz, CDCl3): H = 4.12 (2H, q, J = 7.0 Hz, OCH2CH3), 3.64 (2H, t, J = 6.5 
Hz, CH2OH), 2.48-2.36 (1H, sextet, J = 7.0 Hz, CHCH3), 1.76-1.30 (6H, m, J = 7.0 Hz, 
CH2CH2CH2), 1.25 (3H, t, J = 7.0 Hz, OCH2CH3), 1.15 (3H, d, J = 7.0 Hz, CHCH3); 
13C{1H} NMR (100 MHz, CDCl3): C = 176.8, 62.7, 60.2, 39.5, 33.4, 32.6, 23.4, 17.1, 
14.3; IR (film / cm-1) ѵ = 3404 (O-H), 1733 (C=O); HRMS: m/z (ES) 175.1347, C9H18O3 
[M+H]+ requires 175.1334. 
Ethyl 2-methyl-6-oxohexanoate 353 
 
Ethyl 6-hydroxy-2-methylhexanoate 352 (0.062 mL, 0.35 mmol) was added to 
pyridinium chlorochromate (0.11 g, 0.51 mmol) in CH2Cl2 (5 mL) and allowed to stir at 
room temperature for 3 hours. The reaction mixture was filtered through a pad of 
Celite® and Fluorosil® and the solvent evaporated under reduced pressure. The crude 
product was purified using flash column chromatography [Petrol : EtOAc (80:20), Rf 
0.80] yielding a colourless oil (0.037 g, 60 %). 
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1H NMR (300 MHz, CDCl3): H = 9.76 (1H, t, J = 1.5 Hz, CHO), 4.13 (2H, q, J = 7.0 Hz, 
OCH2), 2.48-2.38 (3H, m, CHCH3 and CH2CHO), 1.69-1.27 (4H, m, CH2CH2CH2), 1.22 
(3H, m, OCH2CH3), 1.16 (3H, d, J = 7.0 Hz, CHCH3); 
13C{1H} NMR (75 MHz, CDCl3): C 
= 201.2, 175.5, 59.4, 42.8, 38.5, 32.2, 18.9, 16.2, 13.4; IR (film / cm-1) ѵ = 1726 (C=O); 
HRMS: m/z (ES) 173.1191, C9H16O3 [M+H]
+ requires 173.1178.  
(E)-Ethyl 6-(((S)-1-(4-methoxyphenyl)ethyl)imino)-2-methylhexanoate 354 
 
Ethyl 2-methyl-6-oxohexanoate 353 (0.038 g, 0.22 mmol) was dissolved in dry CH2Cl2 
(6 mL) with MgSO4. After 5 minutes (S)-(−)-4-Methoxy-α-methylbenzylamine (0.032 mL, 
0.22 mmol) was added and the reaction was stirred for 3 hours. The solution was then 
filtered and the solvent evaporated under reduced pressure yielding a pale yellow oil 
(0.061 g, 91 %). 
1H NMR (300 MHz, CDCl3): H = 7.71 (1H, t, J = 4.5 Hz, CHN), 7.29-7.20 (2H, m, Ar), 
6.90-6.83 (2H, m, Ar), 4.23 (1H, q, J = 6.5 Hz, ArCHCH3), 4.11 (2H, q, J = 7.0 Hz, 
OCH2CH3), 3.78 (3H, s, OCH3), 2.48-2.22 (2H, m, CH2CHN), 1.73-1.49 (4H, m, 
CHCH3), 1.48-1.43 (3H, d, ArCHCH3), 1.43-1.10 (7H, m, CH2CH2 and OCH2CH3). 
4.11  Synthesis of Cishexacin 
Ethyl 7-hydroxyheptanoate 357 
 
Potassium persulfate (5.00 g, 18.50 mmol) was added to a solution of H2SO4 (4.60 mL), 
ethanol (10 mL) and water (2 mL), which had been cooled to 15 °C. A solution of 
cycloheptanone 356 (0.73 g, 6.17 mmol) in ethanol (3 mL) was added dropwise and the 
reaction was left to stir overnight. The reaction was diluted with water (30 mL) and the 
aqueous layer was extracted with Et2O (3 x 30 mL). The organics were collected, dried 
using MgSO4 and filtered before being evaporated under reduced pressure. The crude 
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product was purified by distillation (bp0.2 = 114-116 °C) yielding a colourless oil (0.838 
g, 74 %) in accordance with the literature.203 
1H NMR (300 MHz, CDCl3): H = 4.02 (2H, q, J = 7.0 Hz, OCH2CH3), 3.52 (2H, t, J = 6.5 
Hz, CH2OH), 2.38 (1H, br. s, OH), 2.20 (2H, t, J = 7.5 Hz, EtOOCCH2), 1.60-1.40 (4H, 
m, CH2CH2CH2CH2), 1.33-1.21 (4H, m, CH2CH2CH2CH2), 1.51 (3H, t, J = 7.0 Hz, 
OCH2CH3); 
13C{1H} NMR (75 MHz, CDCl3): C = 173.9, 62.6, 60.2, 34.2, 32.4, 28.6, 
25.4, 24.8, 14.2; IR (film / cm-1) ѵ = 3389 (O-H), 1732 (C=O); HRMS: m/z (ES) 
175.1323, C9H18O3 [M+H]
+ requires 175.1334.  
Ethyl 7-oxoheptanoate 358 
 
Ethyl 7-hydroxyheptanoate 357 (0.737 mL, 4.23 mmol) was added to pyridinium 
chlorochromate (1.37 g, 6.34 mmol) in CH2Cl2 (20 mL) and allowed to stir at room 
temperature for 2 hours. The reaction mixture was filtered through a pad of Celite® and 
Fluorosil® and then evaporated under reduced pressure. The crude product was 
purified by distillation (bp0.2 = 96-98°C) yielding a colourless oil (0.714 g, 98 %) in 
accordance with the literature.203 
1H NMR (300 MHz, CDCl3): H = 9.69 (1H, s, CHO), 4.05 (2H, q, J = 7.0 Hz, OCH2CH3), 
2.38 (2H, t, J = 7.0 Hz, CH2CHO), 2.23 (2H, t, J = 7.0 Hz, EtOCOCH2), 1.66-1.49 (4H, 
m, CH2CH2CH2), 1.37-1.23 (2H, m, CH2CH2CH2), 1.18 (3H, t, J = 6.5 Hz, OCH2CH3); 
13C{1H} NMR (100 MHz, CDCl3): C = 202.5, 173.5, 60.2, 43.6, 34.1, 28.5, 24.7, 21.6, 
14.2; IR (film / cm-1) ѵ = 1725 (C=O). 
4.12  Gem-Di-Methyl Substituted Cispentacin Synthesis 
Ethyl 6-hydroxy-4,4-dimethylhexanoate 369 
 
Potassium persulfate (2.40 g, 8.87 mmol) was added to a solution of H2SO4 (5 mL), 
ethanol (10 mL) and water (2 mL), which has been cooled to 15 °C. A solution of 4,4’-
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dimethylcyclohexanone 364 (0.373 g, 2.96 mmol) in ethanol (3 mL) was added 
dropwise and the reaction was left to stir overnight. The reaction was diluted with water 
(30 mL) and the aqueous layer was extracted with Et2O (3 x 30 mL). The organics were 
collected, dried using MgSO4 and filtered before being evaporated under reduced 
pressure. The crude product was purified using flash column chromatography [Petrol : 
EtOAc (80:20), Rf- 0.23] yielding a colourless oil (0.445 g, 80 %).
203 
1H NMR (300 MHz, CDCl3): H = 4.05 (2H, q, J = 7.0 Hz, OCH2), 3.61 (2H, t, J = 7.0 Hz, 
CH2OH), 2.68 (1H, br. s, OH), 2.25-2.17 (2H, m, CH2CO2Et), 1.54-1.40 (4H, m, 
CH2C(CH3)2CH2), 1.19 (3H, t, J = 7.0 Hz, OCH2CH3), 0.83 (6H, s, C (CH3)2); 
13C{1H} 
NMR (75 MHz, CDCl3): C = 174.4, 60.4, 59.5, 44.0, 36.9, 31.9, 29.6, 27.1, 14.2; IR 
(film / cm-1) ѵ = 3413 (O-H), 1733 (C=O); HRMS: m/z (ES) 189.1486, C10H20O3 [M+H]
+ 
requires 189.1490.  
Ethyl 4,4-dimethyl-6-oxohexanoate 370 
 
Pyridinium chlorochromate (0.589 g, 2.73 mmol) was added to ethyl 6-hydroxy-4,4-
dimethylhexanoate 369 (0.343 mL, 1.82 mmol) in CH2Cl2 (15 mL) and allowed to stir at 
room temperature for 2 hours. The reaction mixture was filtered through a pad of 
Celite® and Fluorosil® and then evaporated under reduced pressure. The crude 
product was purified using flash column chromatography [Petrol : EtOAc (80:20), Rf - 
0.79] yielding a colourless oil (0.295 g, 87 %). 
1H NMR (300 MHz, CDCl3): H = 9.80 (1H, s, CHO), 4.15-4.01 (2H, br. s, OCH2CH3), 
2.34-2.18 (4H, br. s, CH2CHO and CH2CO2), 1.75-1.59 (2H, br. s, CH2C(CH3)2), 1.30-
1.15 (3H, br. s, OCH2CH3), 1.10-0.95 (6H, s, C(CH3)2); 
13C{1H} NMR (75 MHz, CDCl3): 
C = 202.9, 173.6, 60.5, 54.5, 37.1, 33.1, 29.4, 27.0, 14.2; IR (film / cm
-1) ѵ = 1732 
(C=O); HRMS: m/z (ES) 187.1340, C10H18O3 [M+H]
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(S,E)-Ethyl 6-((1-(4-methoxyphenyl)ethyl)imino)-4,4-dimethylhexanoate 371 
 
Ethyl 4,4-dimethyl-6-oxohexanoate 370 (0.183 g, 0.98 mmol) was dissolved in dry 
CH2Cl2 (20 mL) with MgSO4. After 5 minutes (S)-(−)-4-Methoxy-α-methylbenzylamine 
(0.145 mL, 0.98 mmol) was added and the reaction was stirred for 3 hours. The 
solution was then filtered and the solvent evaporated under reduced pressure yielding a 
pale yellow oil (0.272 g, 87 %). 
1H NMR (300 MHz, CDCl3): H = 7.72 (1H, t, J = 5.5 Hz, CNH), 7.17 (2H, d, J = 8.5 Hz, 
Ar), 6.78 (2H, d, J = 8.5 Hz, Ar), 4.20 (1H, q, J = 6.5 Hz, CHCH3), 4.04 (2H, q, J = 7.0 
Hz, OCH2CH3), 3.71 (3H, s, OCH3), 2.26-2.19 (2H, m, CH2CO), 2.11 (2H, d, J = 5.5 Hz, 
CH2C(CH3)2), 1.57-1.50 (2H, m, CH2CHN), 1.41 (3H, d, J = 6.5 Hz, CHCH3), 1.17 (3H, 
t, J = 7.0 Hz, OCH2CH3), 0.87 (6H, s, C(CH3)2); 
13C{1H} NMR (75 MHz, CDCl3): C = 
174.0, 161.5, 158.4, 137.0, 127.6, 114.1, 113.8, 69.3, 60.3, 55.3, 47.0, 37.0, 33.3, 29.5, 




(S,E)-Ethyl 6-((1-(4-methoxyphenyl)ethyl)imino)-4,4-dimethylhexanoate 371 (0.378 g, 
1.18 mmol) was dissolved in THF (40 mL). 15-Crown-5 (0.47 mL, 2.36 mmol) and 
NaHMDS (1 M in THF, 2.36 mL, 2.36 mmol) were added and the mixture was stirred for 
8 hours at room temperature. The reaction was quenched with a saturated solution of 
NH4Cl (5 mL) and the THF was removed under reduced pressure. The resulting 
solution was further diluted with a saturated solution of NH4Cl (20 mL) and the aqueous 
 Page | 204  
 
layer was extracted with Et2O (3 x 30 mL). The organic layers were combined and 
washed with water (50 mL). The organics were then dried using MgSO4 and filtered 
before being evaporated under reduced pressure. The crude product was purified using 
flash column chromatography [Petrol : EtOAc (60:40), Rf 0.57] yielding a pale yellow oil 
(0.252 g, 78 %). 
1H NMR (300 MHz, CDCl3): H = 7.19-7.14 (2H, m, Ar), 6.84-6.78 (2H, m, Ar), 4.85 (1H, 
q, J = 7.0 Hz, CHCH3), 3.80-3.75 (1H, m, CHCHN), 3.74 (3H, s, OCH3), 3.36 (1H, ddd, 
J = 9.0, 4.5 and 2.0 Hz, CHCHN), 1.81 (1H, dd, J = 14.0 and 2.0 Hz, CH2C(CH3)CH2), 
1.67 (1H, d, J = 14.5 Hz, CH2C(CH3)CH2), 1.49 (3H, d, J = 7.0 Hz, CHCH3), 1.39-1.27 
(2H, m, CH2C(CH3)CH2), 1.08 (3H, s, C(CH3)2), 0.94 (3H, s, C(CH3)2); 
13C{1H} NMR (75 
MHz, CDCl3): C = 170.3, 158.9, 132.7, 128.3, 113.9, 57.9, 55.3, 55.2, 50.6, 43.2, 42.0, 
38.3, 31.2, 30.1, 18.8; IR (film / cm-1) ѵ = 1737 (C=O); HRMS: m/z (ES) 296.1644, 
C17H23O2N [M+Na]
+ requires 296.1626;     




373 (0.227 g, 0.83 mmol) was added to a solution of acetonitrile : water (20 mL : 20 
mL). Ammonium cerium (IV) nitrate (1.82 g, 3.32 mmol) was added portion-wise and 
the solution was stirred for 4 hours. The reaction was then quenched with a saturated 
solution of NaHCO3 (30 mL) and diluted with CH2Cl2 (30 mL). The aqueous layer was 
extracted with CH2Cl2 (2 x 30 mL) and the organic layers combined and washed with a 
saturated solution of NaHCO3 (2 x 30 mL) The organics were then dried using MgSO4 
and filtered before being evaporated under reduced pressure. The crude product was 
purified by recrystallisation from Et2O and petrol yielding a white crystalline solid (0.100 
g, 87 %). 
1H NMR (400 MHz, CDCl3): H = 5.99 (1H, br. s, NH), 4.17 (1H, t, J = 5.0 Hz, CHNH), 
3.64-3.59 (1H, m, CHCH), 1.99 (1H, dd, J = 14.0 and 5.0 Hz, CH2C(CH3)CH2), 1.76 
(1H, d, J = 14.5 Hz, CH2C(CH3)CH2), 1.61-1.53 (2H, m, CH2C(CH3)CH2), 1.25 (3H, s, 
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C(CH3)2), 1.10 (3H, s, C(CH3)2); 
13C{1H} NMR (75 MHz, CDCl3): C = 172.3, 57.4, 55.9, 
44.1, 41.9, 39.5, 31.5, 30.1; IR (film / cm-1) ѵ = 3218 (N-H), 1735 (C=O); HRMS: m/z 
(ES) 140.1056, C8H13ON [M+H]
+ requires 140.1075; mp 95-97 °C;     
   = -2 (c 1.01, 
CHCl3). 
(1R,2S)-Ethyl 2-amino-4,4-dimethylcyclopentanecarboxylate hydrochloride 374 
 
(1R,5S)-3,3-Dimethyl-6-azabicyclo[3.2.0]heptan-7-one 373 (0.017 g, 0.12 mmol) was 
heated at reflux in ethanol (4 ml) with dry hydrogen chloride (1 M in Et2O, 2 mL) for 3 
hours. The solvent was then evaporated under reduced pressure. The crude product 
was purified by recrystallisation from CH2Cl2 and hexane yielding a white crystalline 
solid (0.024 g, 90 %). 
1H NMR (500 MHz, MeOD): H = 4.29-4.18 (2H, m, OCH2CH3), 3.89 (1H, q, J = 7.5 Hz, 
CHCHNH2), 3.33 (1H, m, CHCHNH2), 2.06 (1H, dd, J = 13.5 and 7.5 Hz, CHCH2), 1.94 
(2H, d, J = 8.5 Hz, CH2CHCHCH2), 1.71 (1H, dd, J = 13.5 and 8.0 Hz, NH2CHCHCH2), 
1.31 (3H, t, J = 7.0 Hz, OCH2CH3), 1.18 (3H, s, C(CH3)2), 1.08 (3H, s, C(CH3)2); 
13C{1H} 
NMR (100 MHz, CDCl3): C = 173.3, 61.7, 52.3, 44.8, 44.6, 43.3, 37.2, 29.9, 29.8, 14.2; 
IR (film / cm-1) ѵ = 3417 (N-H) 1721 (C=O) 1208 (C-O); HRMS: m/z (ES) 208.1297, 
C10H19O2N [M+Na]
+ requires 208.1313;     
   = -4.6 (c 0.86, MeOH). 
4.13  Cyclisation of Acetal Substrate 
1,4,8-Trioxaspiro[4.6]undecan-9-one 376 
 
To a stirred solution of 1,4-cyclohexadione monoethylene acetal 375 (2.1 g, 13.3 mmol) 
in CH2Cl2 (20 mL), mCPBA (3.4 g, 19.9 mmol) was added and heated at reflux for 6 
hours. The reaction was allowed to cool to room temperature, dried using MgSO4 and 
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the solvent evaporated under reduced pressure.214 The crude product was purified 
using flash column chromatography [Petrol : EtOAc (70:30), Rf 0.50] yielding a 
translucent white solid (1.8 g, 80 %).  
1H NMR (400 MHz, CDCl3): H = 4.29 (2H, m, COOCH2), 3.98 (4H, m, OCH2CH2O), 
2.70 (2H, m, OCOCH2), 2.00 (2H, m, OCOCH2CH2), 1.90 (2H, m, COOCH2CH2); 
13C{1H} NMR (100 MHz, CDCl3): C = 175.4, 107.8, 64.8, 64.3, 39.0, 32.7, 28.8; IR (film 
/ cm-1) ѵ = 1725 (C=O); HRMS: m/z (ES) 173.0804, C8H13O4 [M+H]
+ requires 173.0808; 
mp 48-50 °C. 
Ethyl 3-(2-(2-hydroxyethyl)-1,3-dioxolan-2-yl)propanoate 377 
 
The lactone 1,4,8-trioxaspiro[4.6]undecan-9-one 376 (0.15 g, 0.87 mmol) was dissolved 
in ethanol (5 mL) and cooled to 0 °C. K2CO3 (0.024 g, 0.17 mmol) was added and the 
reaction was stirred for 1 hour at 0 °C. The reaction was then filtered and the filtrate 
was concentrated under reduced pressure.207 The crude product was purified using 
flash column chromatography [Petrol : EtOAc (30:70), Rf 0.38] yielding a translucent 
white liquid (0.16 g, 87 %).  
1H NMR (400 MHz, CDCl3): H = 4.11 (2H, q, J = 7.0 Hz, CH2CH3), 3.97 (4H, m, 
OCH2CH2O), 3.73 (2H, t, J = 5.5 Hz, CH2OH), 2.70 (1H, br. s, OH), 2.35 (2H, m, 
O2CCH2), 2.02 (2H, t, J = 7.5 Hz, O2CCH2CH2), 1.89 (2H, t, J = 5.5 Hz, CH2CH2OH), 
1.24 (3H, t, J = 7.0 Hz, CH2CH3); 
13C{1H} NMR (100 MHz, CDCl3): C = 173.3, 111.2, 
64.9, 60.4, 58.7, 38.4, 32.0, 28.9, 14.2; IR (film / cm-1) ѵ = 3439 (O-H), 1732 (C=O); 
HRMS: m/z (ES) 241.1169, C10H18O5 [M+Na]
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Ethyl 3-(2-(2-oxoethyl)-1,3-dioxolan-2-yl)propanoate 378 
 
Ethyl 3-(2-(2-hydroxyethyl)-1,3-dioxolan-2-yl)propanoate 377 (0.81 mL, 3.71 mmol) was 
added to pyridinium chlorochromate (1.20 g, 5.57 mmol) in CH2Cl2 (20 mL) and allowed 
to stir at room temperature for 2 hours. The reaction mixture was filtered through a pad 
of Celite® and Fluorosil® and the solvent was evaporated under reduced pressure. The 
crude product was purified using flash column chromatography [Petrol : EtOAc (30:70), 
Rf 0.70] yielding a pale yellow liquid (0.72 g, 89 %). 
1H NMR (400 MHz, CDCl3): H = 9.73 (1H, t, J = 3.0 Hz, CHO), 4.13 (2H, q, J = 7.0 Hz, 
OCH2CH3), 4.00 (4H, m, OCH2CH2O), 2.68 (2H, d, J = 3.0 Hz, CH2CHO), 2.39 (2H, m, 
O2CCH2), 2.09 (2H, m, O2CCH2CH2), 1.25 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H} NMR 
(100 MHz, CDCl3): C = 199.9, 173.0, 108.5, 65.3, 60.5, 50.7, 33.3, 28.6, 14.2; IR (film / 
cm-1) ѵ = 1722 (C=O); HRMS: m/z (ES) 217.1070, C10H16O5 [M+H]




Ethyl 3-(2-(2-oxoethyl)-1,3-dioxolan-2-yl)propanoate 378 (0.421 g, 1.95 mmol) was 
dissolved in dry CH2Cl2 (20 mL) with MgSO4. After 5 minutes (S)-(−)-4-Methoxy-α-
methylbenzylamine (0.288 mL, 1.95 mmol) was added and the reaction was stirred for 
3 hours. The solution was then filtered and the solvent evaporated under reduced 
pressure yielding a colourless oil (0.668 g, 98 %). 
1H NMR (400 MHz, CDCl3): H = 7.74 (1H, td, J = 5.5 and 0.5 Hz, CHN), 7.30-7.23 (2H, 
m, Ar), 6.90-6.84 (2H, m, Ar), 4.29 (1H, q, J = 6.5 Hz, CHCH3), 4.12 (2H, q, J = 7.0 Hz, 
OCH2CH3), 3.93 (4H, m, OCH2CH2O), 3.79 (3H, s, OCH3), 2.61 (2H, d, J = 5.5 Hz, 
CH2CHN), 2.38 (2H, m, O2CCH2), 2.02 (2H, m, O2CCH2CH2), 1.49 (3H, d, J = 6.5 Hz, 
 Page | 208  
 
CHCH3), 1.25 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C{1H}c NMR (100 MHz, CDCl3): C = 
173.3, 159.1, 158.5, 136.8, 127.6, 113.8, 109.6, 69.2, 65.2, 60.3, 55.3, 43.9, 32.9, 28.6, 




The title compound was prepared according to General Procedure 5 from (S,E)-Ethyl 3-
(2-(2-((1-(4-methoxyphenyl)ethyl)imino)ethyl)-1,3-dioxolan-2-yl)propanoate 379 (0.12 g, 
0.33 mmol), which was dissolved in dry THF (10 mL) under a nitrogen atmosphere. 15-
crown-5 (0.13 mL, 0.67 mmol) and NaHMDS (1M in THF, 0.67 mL, 0.67 mmol) were 
added and the mixture was stirred for 8 hours at -40 °C and allowed to warm to room 
temperature. The crude product was purified using flash column chromatography 
[Petrol : EtOAc (40:60), Rf 0.13] yielding a white crystalline solid (0.060 g, 59 %). 
1H NMR (400 MHz, CDCl3): H = 7.26 (2H, m, Ar), 6.89 (2H, m, Ar), 4.94 (1H, q, J = 7.0 
Hz, CHCH3) 4.03-3.78 (8H, m, COCH3, OCH2CH2 and NCH), 3.44 (1H, ddd, J = 9.0, 4.5 
and 1.0 Hz, NCHCH), 2.20 (1H, dt, J = 14.0 and 1.0 Hz, O2CCH2), 2.03 (1H, dd, J = 
14.5 and 1.0 Hz, O2CCH2), 1.84-1.67 (2H, m, O2CCH2), 1.60 (3H, d, J = 7.0 Hz, 
CHCH3); 
13C{1H} NMR (100 MHz, CDCl3): C = 168.4, 158.9, 132.5, 128.4, 116.5, 
113.9, 64.6, 64.3, 55.3, 53.5, 51.2, 50.9, 38.0, 34.6, 19.0; IR (film / cm-1) ѵ = 1740 
(C=O); HRMS: m/z (ES) 304.1543, C17H21O4N [M+H]
+ requires 304.1542; mp 49-51 °C; 
    










dioxolan]-7-one 380 (0.043 g, 0.14 mmol) and iodine (0.004 g, 0.014 mmol) was stirred 
in acetone (5 mL) at room temperature for 30 minutes. The acetone was evaporated 
under reduced pressure and the residue dissolved in CH2Cl2. The organic layer was 
separated, washed with Na2S2O3 (10 mL) and brine (20 mL), dried with MgSO4 and the 
solvent evaporated under reduced pressure. The crude product was purified using flash 
column chromatography [Petrol : EtOAc (20:80), Rf 0.33] yielding a colourless oil (0.029 
g, 79 %). 
1H NMR (400 MHz, CDCl3): H = 7.22 (2H, m, Ar), 6.88 (2H, m, Ar), 4.83 (1H, q, J = 8.5 
Hz, CHCH3) 4.05 (1H, m, NCH), 3.79 (3H, s, OCH3), 3.66 (1H, ddd, J = 10.5, 5.0 and 
2.0 Hz, NCHCH), 2.62 (1H, m, COCH2), 2.46-2.23 (3H, m, CH2COCH2 ), 1.58 (3H, d, J 
= 7.5 Hz, CHCH3); 
13C{1H} NMR (100 MHz, CDCl3): C = 214.3, 167.9, 159.2, 131.9, 
128.4, 114.2, 55.3, 52.0, 51.8, 49.1, 41.7, 37.0, 19.5; IR (film / cm-1) ѵ = 1738 (C=O), 
1671 (C=O); HRMS: m/z (ES) 282.1078, C15H17O3N [M+H]
+ requires 282.1106;     
   = 
-30.6 (c 1.18, CHCl3). 
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4.14  Future Work - Enantioselective Cyclisation 
6-Benzyl-6-azabicyclo[3.2.0]heptan-7-one 388 
 
Ethyl 6-oxohexanoate 333 (0.95 g, 5.97 mmol) was dissolved in dry THF (100 mL) with 
MgSO4 and left stirring under a nitrogen atmosphere. After 5 minutes benzylamine 
(0.65 mL, 5.97 mmol) was added to the reaction and stirred for 10 minutes, the solution 
was subsequently cooled to -40 °C. NaHMDS (1 M in THF, 12.0 mL, 12.0 mmol) was 
added and the mixture was stirred for 8 hours, allowing to warm to room temperature. 
The reaction was quenched with a saturated solution of NH4Cl (5 mL) and the THF was 
removed under reduced pressure. The resulting solution was further diluted with a 
saturated solution of NH4Cl (20 mL) and the aqueous layer was extracted with Et2O (3 x 
30 mL). The organic layers were combined and washed with water (50 mL). The 
organics were then dried using MgSO4 and filtered before being evaporated under 
reduced pressure. The crude product was purified using flash column chromatography 
[Petrol : EtOAc (60:40), Rf 0.35] yielding a colourless oil (0.70 g, 58 %). 
1H NMR (400 MHz, CDCl3): H = 7.37-7.24 (5H, m, Ar), 4.48 (1H, dd, J = 15.0 and 2.0 
Hz, NCH2), 4.09 (1H, dd, J = 15.0 and 1.0 Hz, NCH2), 3.90 (1H, t, J = 5.0 Hz, NCH), 
3.45 (1H, dd, J= 7.5 and 3.0 Hz, NCHCH), 2.03 (1H, m, CH2CH2CH2), 1.75 (2H, m, 
CH2CH2CH2), 1.57 (1H, m, CH2CH2CH2), 1.38 (1H, m, CH2CH2CH2), 1.18 (1H, m, 
CH2CH2CH2); 
13C{1H} NMR (100 MHz, CDCl3): C = 169.4, 136.2, 128.7, 128.2, 127.6, 










H NMR Spectrum of Dimer Impurity 335  
Acquisition Time (sec) 4.6399 Comment Caroline Evans/CE-5-054/ID Date 01 Nov 2011 21:43:28
Date Stamp 01 Nov 2011 21:43:28
File Name \\UKMCDILSNEEZY.RD.ASTRAZENECA.NET\NMRDATADATA\MCUS02PDD\NMR\111101032\11\PDATA\1\1R
Frequency (MHz) 400.13 Nucleus 1H Number of Transients 8 Origin A400
Original Points Count 32768 Owner ian Points Count 65536 Pulse Sequence sthq.z
Receiver Gain 256.00 SW(cyclical) (Hz) 7062.15 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2486.0417 Sweep Width (Hz) 7062.04 Temperature (degree C) 27.000























































































































C NMR Spectrum of Dimer Impurity 335 
Acquisition Time (sec) 1.3282 Comment Caroline Evans/CE-5-054/ID Date 01 Nov 2011 21:32:48
Date Stamp 01 Nov 2011 21:32:48
File Name \\UKMCDILSNEEZY.RD.ASTRAZENECA.NET\NMRDATADATA\MCUS02PDD\NMR\111101032\10\PDATA\1\1R
Frequency (MHz) 100.61 Nucleus 13C Number of Transients 800 Origin A400
Original Points Count 32768 Owner ian Points Count 65536 Pulse Sequence stc.z
Receiver Gain 2050.00 SW(cyclical) (Hz) 24671.05 Solvent CHLOROFORM-d Spectrum Offset (Hz) 10054.2598
Sweep Width (Hz) 24670.68 Temperature (degree C) 27.000






























































































H NMR Spectrum of -lactam 336 
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5.4 X-ray Crystal Structure Data for Trifluoro-aryl--lactam 280b 
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Table 18- Crystal data & structure refinement for (2aR,7bR)-1-((S)-1-(4-Methoxyphenyl)ethyl)-6-
(trifluoromethyl)-2a,3-dihydro-1H-indeno[1,2-b]azet-2(7bH)-one 280b 
Empirical formula C20 H18 F3 N O2 
Formula weight 361.35 
Temperature 150(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P21 
Unit cell dimensions a = 7.1850(1)Å = 90
o
 
 b = 6.2670(1)Å  = 99.040(1)
o
 







Density (calculated) 1.453 Mg/m
3
 




Crystal size 0.35 x 0.25 x 0.2 mm 
Theta range for data collection 4.04 to 27.50
o
 
Index ranges -9<=h<=9; -8<=k<=7; -24<=l<=24 
Reflections collected 15805 
Independent reflections 3741 [R(int) = 0.0331] 
Reflections observed (>2) 3570 
Data Completeness 0.990 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.966 and 0.920 
Refinement method Full-matrix least-squares on F
2
 




Final R indices [I>2(I)] R1 = 0.0295   wR2 = 0.0746 
R indices (all data) R1 = 0.0316  wR2 = 0.0763 
Absolute structure parameter -0.4(5) 
Largest diff. peak and hole 0.157 and -0.148 eÅ
-3
 
Notes: 50:50 disorder of the fluorine positions was readily modeled with inclusion of of C-F and F…F distance restraints. 
Absolute stereochemistry not definitive from structural results; assignment made on the basis of know stereochemistry at 
C12. 
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Table 19- Atomic coordinates ( x 10
4





for trifluoro-aryl--lactam 280b  U(eq) is defined  as one third of the trace of the orthogonalized Uij 
tensor.                                                      
Atom x y z U(eq) 
F(1) 6643(9) 11436(10) 9504(5) 57(1) 
F(2) 5152(14) 8750(10) 9057(4) 72(2) 
F(3) 3730(7) 11165(14) 9544(4) 61(2) 
F(1A) 6745(9) 11188(14) 9411(5) 89(3) 
F(2A) 4747(14) 8823(10) 9040(5) 80(2) 
F(3A) 3968(10) 11528(16) 9590(4) 79(2) 
O(1) 6543(1) 14035(2) 5199(1) 40(1) 
O(2) 9978(1) 7311(2) 9081(1) 36(1) 
N(1) 6360(1) 11395(2) 6097(1) 23(1) 
C(1) 5766(2) 13022(2) 5624(1) 27(1) 
C(2) 3784(2) 13037(2) 5831(1) 25(1) 
C(3) 4505(2) 11169(2) 6349(1) 22(1) 
C(4) 4385(2) 11992(2) 7099(1) 23(1) 
C(5) 4846(2) 10938(2) 7763(1) 25(1) 
C(6) 4544(2) 11985(2) 8395(1) 29(1) 
C(7) 3814(2) 14051(2) 8369(1) 33(1) 
C(8) 3361(2) 15096(2) 7705(1) 32(1) 
C(9) 3648(2) 14054(2) 7068(1) 26(1) 
C(10) 3198(2) 14871(2) 6294(1) 30(1) 
C(11) 5008(2) 10863(2) 9111(1) 36(1) 
C(12) 7819(2) 9742(2) 6121(1) 24(1) 
C(13) 9449(2) 10526(2) 5757(1) 33(1) 
C(14) 8435(2) 9031(2) 6902(1) 23(1) 
C(15) 8029(2) 7003(2) 7126(1) 25(1) 
C(16) 8496(2) 6341(2) 7852(1) 28(1) 
C(17) 9427(2) 7761(2) 8360(1) 27(1) 
C(18) 9877(2) 9797(2) 8142(1) 28(1) 
C(19) 9389(2) 10429(2) 7424(1) 26(1) 
C(20) 9349(2) 5349(3) 9347(1) 41(1) 
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Table 20- Bond lengths [Å] and angles [
o
] for trifluoro-aryl--lactam 280b 
Bond Length (Å) Bond Length (Å) 
F(1)-C(11) 1.331(6) F(2)-C(11) 1.333(6) 
F(3)-C(11) 1.325(5) F(1A)-C(11) 1.300(6) 
F(2A)-C(11) 1.296(6) F(3A)-C(11) 1.315(6) 
O(1)-C(1) 1.2157(15) O(2)-C(17) 1.3667(14) 
O(2)-C(20) 1.4252(18) N(1)-C(1) 1.3697(15) 
N(1)-C(12) 1.4698(15) N(1)-C(3) 1.4869(14) 
C(1)-C(2) 1.5327(16) C(2)-C(10) 1.5334(18) 
C(2)-C(3) 1.5517(16) C(2)-H(2) 1.0000 
C(3)-C(4) 1.5027(16) C(3)-H(3) 1.0000 
C(4)-C(5) 1.3918(17) C(4)-C(9) 1.3946(17) 
C(5)-C(6) 1.3914(16) C(5)-H(5) 0.9500 
C(6)-C(7) 1.395(2) C(6)-C(11) 1.4956(19) 
C(7)-C(8) 1.390(2) C(7)-H(7) 0.9500 
C(8)-C(9) 1.3946(17) C(8)-H(8) 0.9500 
C(9)-C(10) 1.5140(17) C(10)-H(10A) 0.9900 
C(10)-H(10B) 0.9900 C(12)-C(14) 1.5159(16) 
C(12)-C(13) 1.5223(16) C(12)-H(12) 1.0000 
C(13)-H(13A) 0.9800 C(13)-H(13B) 0.9800 
C(13)-H(13C) 0.9800 C(14)-C(15) 1.3830(17) 
C(14)-C(19) 1.4034(16) C(15)-C(16) 1.4006(17) 
C(15)-H(15) 0.9500 C(16)-C(17) 1.3893(17) 
C(16)-H(16) 0.9500 C(17)-C(18) 1.3917(18) 
C(18)-C(19) 1.3823(17) C(18)-H(18) 0.9500 
C(19)-H(19) 0.9500 C(20)-H(20A) 0.9800 
C(20)-H(20B) 0.9800 C(20)-H(20C) 0.9800 
C(17)-O(2)-C(20) 117.36(11) C(1)-N(1)-C(12) 133.82(9) 
C(1)-N(1)-C(3) 93.91(9) C(12)-N(1)-C(3) 126.45(9) 
O(1)-C(1)-N(1) 132.64(12) O(1)-C(1)-C(2) 134.37(11) 
N(1)-C(1)-C(2) 92.98(9) C(1)-C(2)-C(10) 119.54(10) 
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Table 20 continued 
Bond Length (Å) Bond Length (Å) 
C(1)-C(2)-C(3) 85.27(8) C(10)-C(2)-C(3) 108.19(9) 
C(1)-C(2)-H(2) 113.5 C(10)-C(2)-H(2) 113.5 
C(3)-C(2)-H(2) 113.5 N(1)-C(3)-C(4) 116.35(9) 
N(1)-C(3)-C(2) 87.83(8) C(4)-C(3)-C(2) 104.74(9) 
N(1)-C(3)-H(3) 114.8 C(4)-C(3)-H(3) 114.8 
C(2)-C(3)-H(3) 114.8 C(5)-C(4)-C(9) 120.83(11) 
C(5)-C(4)-C(3) 128.26(11) C(9)-C(4)-C(3) 110.87(10) 
C(6)-C(5)-C(4) 118.46(11) C(6)-C(5)-H(5) 120.8 
C(4)-C(5)-H(5) 120.8 C(5)-C(6)-C(7) 121.10(12) 
C(5)-C(6)-C(11) 119.13(12) C(7)-C(6)-C(11) 119.77(12) 
C(8)-C(7)-C(6) 120.12(12) C(8)-C(7)-H(7) 119.9 
C(6)-C(7)-H(7) 119.9 C(7)-C(8)-C(9) 119.17(12) 
C(7)-C(8)-H(8) 120.4 C(9)-C(8)-H(8) 120.4 
C(4)-C(9)-C(8) 120.31(12) C(4)-C(9)-C(10) 112.07(11) 
C(8)-C(9)-C(10) 127.60(12) C(9)-C(10)-C(2) 104.08(10) 
C(9)-C(10)-H(10A) 110.9 C(2)-C(10)-H(10A) 110.9 
C(9)-C(10)-H(10B) 110.9 C(2)-C(10)-H(10B) 110.9 
H(10A)-C(10)-
H(10B) 
109.0 F(2A)-C(11)-F(1A) 108.2(6) 
F(2A)-C(11)-F(3A) 107.0(6) F(1A)-C(11)-F(3A) 105.7(5) 
F(2A)-C(11)-F(3) 95.7(6) F(1A)-C(11)-F(3) 115.3(6) 
F(3A)-C(11)-F(3) 12.6(7) F(2A)-C(11)-F(1) 115.0(6) 
F(1A)-C(11)-F(1) 10.9(8) F(3A)-C(11)-F(1) 95.2(6) 
F(3)-C(11)-F(1) 105.4(5) F(2A)-C(11)-F(2) 12.6(8) 
F(1A)-C(11)-F(2) 96.1(6) F(3A)-C(11)-F(2) 115.1(6) 
F(3)-C(11)-F(2) 104.9(5) F(1)-C(11)-F(2) 103.7(5) 
F(2A)-C(11)-C(6) 111.4(4) F(1A)-C(11)-C(6) 111.9(5) 
F(3A)-C(11)-C(6) 112.4(5) F(3)-C(11)-C(6) 113.2(4) 
F(1)-C(11)-C(6) 114.5(4) F(2)-C(11)-C(6) 114.1(4) 
N(1)-C(12)-C(14) 109.55(9) N(1)-C(12)-C(13) 110.74(10) 
C(14)-C(12)-C(13) 113.01(9) N(1)-C(12)-H(12) 107.8 
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Table 20 continued 
   
Bond Length (Å) Bond Length (Å) 

















C(15)-C(14)-C(19) 117.91(11) C(15)-C(14)-C(12) 121.01(10) 
C(19)-C(14)-C(12) 121.06(11) C(14)-C(15)-C(16) 122.20(11) 
C(14)-C(15)-H(15) 118.9 C(16)-C(15)-H(15) 118.9 
C(17)-C(16)-C(15) 118.72(12) C(17)-C(16)-H(16) 120.6 
C(15)-C(16)-H(16) 120.6 O(2)-C(17)-C(16) 124.60(12) 
O(2)-C(17)-C(18) 115.46(11) C(16)-C(17)-C(18) 119.93(11) 
C(19)-C(18)-C(17) 120.53(11) C(19)-C(18)-H(18) 119.7 
C(17)-C(18)-H(18) 119.7 C(18)-C(19)-C(14) 120.70(12) 
C(18)-C(19)-H(19) 119.7 C(14)-C(19)-H(19) 119.7 
O(2)-C(20)-H(20A) 109.5 O(2)-C(20)-H(20B) 109.5 
H(20A)-C(20)-
H(20B) 
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) for trifluoro-aryl--lactam 280b. The 






 U11 + ... + 2 h k a* b* U                                                                               
Atom U11 U22 U33 U23 U13 U12 
F(1) 58(3) 59(2) 46(2) 15(2) -16(2) -29(2) 
F(2) 158(5) 35(2) 27(2) 4(2) 25(3) 13(3) 
F(3) 38(1) 116(5) 32(2) 16(2) 17(1) 0(2) 
F(1A) 43(2) 149(6) 69(4) 53(4) -12(2) -14(3) 
F(2A) 148(5) 47(3) 38(3) 8(2) -7(2) -46(3) 
F(3A) 123(5) 87(3) 36(2) -6(2) 39(3) 23(3) 
O(1) 40(1) 38(1) 44(1) 16(1) 15(1) -1(1) 
O(2) 42(1) 37(1) 26(1) 4(1) -2(1) -3(1) 
N(1) 22(1) 24(1) 26(1) 2(1) 6(1) -1(1) 
C(1) 27(1) 24(1) 28(1) 2(1) 4(1) -2(1) 
C(2) 24(1) 23(1) 29(1) 2(1) 3(1) -1(1) 
C(3) 20(1) 19(1) 26(1) 0(1) 5(1) -1(1) 
C(4) 20(1) 21(1) 29(1) -3(1) 7(1) -3(1) 
C(5) 23(1) 24(1) 28(1) -2(1) 7(1) -3(1) 
C(6) 28(1) 32(1) 28(1) -5(1) 10(1) -7(1) 
C(7) 33(1) 32(1) 37(1) -12(1) 14(1) -8(1) 
C(8) 29(1) 23(1) 45(1) -8(1) 13(1) -2(1) 
C(9) 22(1) 22(1) 36(1) -3(1) 8(1) -3(1) 
C(10) 29(1) 21(1) 38(1) 1(1) 5(1) 2(1) 
C(11) 40(1) 41(1) 26(1) -4(1) 8(1) -9(1) 
C(12) 21(1) 25(1) 26(1) -2(1) 5(1) 0(1) 
C(13) 26(1) 42(1) 33(1) 1(1) 11(1) 0(1) 
C(14) 17(1) 26(1) 27(1) -2(1) 3(1) 2(1) 
C(15) 23(1) 23(1) 29(1) -5(1) 3(1) -1(1) 
C(16) 27(1) 23(1) 33(1) 0(1) 4(1) -1(1) 
C(17) 24(1) 30(1) 25(1) 0(1) 2(1) 2(1) 
C(18) 25(1) 29(1) 28(1) -5(1) 1(1) -4(1) 
C(19) 25(1) 22(1) 32(1) -3(1) 5(1) -3(1) 
C(20) 50(1) 40(1) 31(1) 8(1) 6(1) -1(1) 
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Table 22- Hydrogen coordinates ( x 10
4





for trifluoro-aryl--lactam 280b.                                   
Atom x y z U(eq) 
H(2) 2777 12607 5422 30 
H(3) 3857 9774 6225 26 
H(5) 5355 9536 7784 30 
H(7) 3626 14745 8807 40 
H(8) 2863 16503 7685 38 
H(10A) 3924 16181 6229 35 
H(10B) 1837 15185 6162 35 
H(12) 7243 8484 5838 29 
H(13A) 10053 11747 6028 49 
H(13B) 8971 10960 5255 49 
H(13C) 10370 9375 5753 49 
H(15) 7413 6027 6776 30 
H(16) 8182 4947 7995 33 
H(18) 10525 10759 8489 33 
H(19) 9702 11824 7283 31 
H(20A) 9897 4154 9112 61 
H(20B) 7971 5274 9237 61 
H(20C) 9746 5269 9876 61 
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Table 23- Dihedral angles for trifluoro-aryl--lactam 280b. 
Atom1  -  Atom2  -  Atom3  -  Atom4 Dihedral (°) 
C(12) - N(1) - C(1) - O(1) -25.3(2) 
C(3) - N(1) - C(1) - O(1) -178.26(16) 
C(12) - N(1) - C(1) - C(2) 154.04(12) 
C(3) - N(1) - C(1) - C(2) 1.06(9) 
O(1) - C(1) - C(2) - C(10) -73.46(19) 
N(1) - C(1) - C(2) - C(10) 107.24(11) 
O(1) - C(1) - C(2) - C(3) 178.28(16) 
N(1) - C(1) - C(2) - C(3) -1.02(9) 
C(1) - N(1) - C(3) - C(4) -106.43(11) 
C(12) - N(1) - C(3) - C(4) 97.62(13) 
C(1) - N(1) - C(3) - C(2) -1.04(9) 
C(12) - N(1) - C(3) - C(2) -157.00(11) 
C(1) - C(2) - C(3) - N(1) 0.93(8) 
C(10) - C(2) - C(3) - N(1) -118.64(10) 
C(1) - C(2) - C(3) - C(4) 117.64(9) 
C(10) - C(2) - C(3) - C(4) -1.94(12) 
N(1) - C(3) - C(4) - C(5) -85.76(14) 
C(2) - C(3) - C(4) - C(5) 179.27(11) 
N(1) - C(3) - C(4) - C(9) 96.43(11) 
C(2) - C(3) - C(4) - C(9) 1.47(12) 
C(9) - C(4) - C(5) - C(6) 0.38(17) 
C(3) - C(4) - C(5) - C(6) -177.23(11) 
C(4) - C(5) - C(6) - C(7) -0.62(17) 
C(4) - C(5) - C(6) - C(11) 179.19(10) 
C(5) - C(6) - C(7) - C(8) 0.46(18) 
C(11) - C(6) - C(7) - C(8) -179.35(12) 
C(6) - C(7) - C(8) - C(9) -0.04(18) 
C(5) - C(4) - C(9) - C(8) 0.03(17) 
C(3) - C(4) - C(9) - C(8) 178.02(10) 
C(5) - C(4) - C(9) - C(10) -178.42(11) 
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Table 23 continued  
Atom1  -  Atom2  -  Atom3  -  Atom4 Dihedral (°) 
C(3) - C(4) - C(9) - C(10) -0.43(13) 
C(7) - C(8) - C(9) - C(4) -0.20(18) 
C(7) - C(8) - C(9) - C(10) 177.99(12) 
C(4) - C(9) - C(10) - C(2) -0.81(13) 
C(8) - C(9) - C(10) - C(2) -179.13(11) 
C(1) - C(2) - C(10) - C(9) -93.27(12) 
C(3) - C(2) - C(10) - C(9) 1.69(12) 
C(5) - C(6) - C(11) - F(2A) -32.1(5) 
C(7) - C(6) - C(11) - F(2A) 147.8(5) 
C(5) - C(6) - C(11) - F(1A) 89.1(5) 
C(7) - C(6) - C(11) - F(1A) -91.1(5) 
C(5) - C(6) - C(11) - F(3A) -152.2(4) 
C(7) - C(6) - C(11) - F(3A) 27.6(4) 
C(5) - C(6) - C(11) - F(3) -138.6(4) 
C(7) - C(6) - C(11) - F(3) 41.2(4) 
C(5) - C(6) - C(11) - F(1) 100.6(4) 
C(7) - C(6) - C(11) - F(1) -79.6(4) 
C(5) - C(6) - C(11) - F(2) -18.7(5) 
C(7) - C(6) - C(11) - F(2) 161.1(5) 
C(1) - N(1) - C(12) - C(14) 154.93(12) 
C(3) - N(1) - C(12) - C(14) -59.36(14) 
C(1) - N(1) - C(12) - C(13) 29.62(17) 
C(3) - N(1) - C(12) - C(13) 175.32(10) 
N(1) - C(12) - C(14) - C(15) 111.89(12) 
C(13) - C(12) - C(14) - C(15) -124.12(12) 
N(1) - C(12) - C(14) - C(19) -66.36(13) 
C(13) - C(12) - C(14) - C(19) 57.63(15) 
C(19) - C(14) - C(15) - C(16) 1.61(17) 
C(12) - C(14) - C(15) - C(16) -176.69(10) 
C(14) - C(15) - C(16) - C(17) -1.13(17) 
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Table 23 continued  
Atom1  -  Atom2  -  Atom3  -  Atom4 Dihedral (°) 
C(20) - O(2) - C(17) - C(16) -8.16(18) 
C(15) - C(16) - C(17) - O(2) -179.30(11) 
C(15) - C(16) - C(17) - C(18) -0.03(17) 
O(2) - C(17) - C(18) - C(19) 179.98(11) 
C(16) - C(17) - C(18) - C(19) 0.64(18) 
C(17) - C(18) - C(19) - C(14) -0.13(18) 
C(15) - C(14) - C(19) - C(18) -0.97(17) 
C(12) - C(14) - C(19) - C(18) 177.33(10) 
                                         
















 Page | 225  
 
5.5 X-ray Crystal Structure Data for Gem-Dimethyl -lactam 373 
 














 Page | 226  
 
Table 24- Crystal data and structure refinement for gem-dimethyl -lactam 373     
Identification code k11sdb1 
Empirical formula C8 H13 N O 
Formula weight 139.19 
Temperature 150(2) K 
Wavelength 0.71073 Å 
Crystal system Orthorhombic 
Space group P212121 
Unit cell dimensions a = 5.7340(1)Å = 90
o
 
 b = 6.4170(1)Å  = 90
o
 







Density (calculated) 1.170 Mg/m
3
 




Crystal size 0.50 x 0.40 x 0.40 mm 
Theta range for data collection 3.70 to 27.40 
o
. 
Index ranges -7<=h<=7; -8<=k<=8; -27<=l<=26 
Reflections collected 11687 
Independent reflections 1784 [R(int) = 0.0527] 
Reflections observed (>2) 1425 
Data Completeness 0.995 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.970 and 0.898 
Refinement method Full-matrix least-squares on F
2
 




Final R indices [I>2(I)] R1 = 0.0400   wR2 = 0.0949 
R indices (all data) R1 = 0.0581  wR2 = 0.1042 
Absolute structure parameter 1.5(19) 




Notes: Intermolecular hydrogen-bonding present in the gross structure. 
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Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 
deg. 
D-H        d(D-H)   d(H..A)   <DHA    d(D..A)   A 
N1-H1A      0.880    2.021   166.89    2.885    O1 [ -x+2, y+1/2, -
z+1/2 ] 
 
Table 25- Atomic coordinates ( x 10
4





) for gem-dimethyl -lactam 373. U(eq) is definedas one third of the trace of the 
orthogonalized Uij tensor. 
Atom x y z U(eq) 
O(1) 9553(2) 9615(2) 1820(1) 41(1) 
N(1) 7665(2) 12529(2) 2251(1) 34(1) 
C(1) 7997(3) 10913(2) 1864(1) 31(1) 
C(2) 5740(3) 11349(2) 1503(1) 30(1) 
C(3) 5505(3) 13254(2) 1949(1) 31(1) 
C(4) 5722(3) 15198(2) 1550(1) 29(1) 
C(5) 6838(3) 14522(2) 924(1) 27(1) 
C(6) 6025(3) 12242(3) 849(1) 29(1) 
C(7) 9514(3) 14667(3) 945(1) 35(1) 
C(8) 5969(3) 15884(3) 390(1) 38(1) 
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 Table 26- Bond lengths and angles for gem-dimethyl -lactam 373  
Bond Length (Å) Bond Length (Å) 
O(1)-C(1) 1.224(2) N(1)-C(1) 1.343(2) 
N(1)-C(3) 1.473(2) N(1)-H(1A) 0.8800 
C(1)-C(2) 1.534(2) C(2)-C(6) 1.526(2) 
C(2)-C(3) 1.559(2) C(2)-H(2) 1.0000 
C(3)-C(4) 1.519(2) C(3)-H(3) 1.0000 
C(4)-C(5) 1.550(2) C(4)-H(4A) 0.9900 
C(4)-H(4B) 0.9900 C(5)-C(8) 1.526(2) 
C(5)-C(7) 1.538(2) C(5)-C(6) 1.544(2) 
C(6)-H(6A) 0.9900 C(6)-H(6B) 0.9900 
C(7)-H(7A) 0.9800 C(7)-H(7B) 0.9800 
C(7)-H(7C) 0.9800 C(8)-H(8A) 0.9800 
C(8)-H(8B) 0.9800 C(8)-H(8C) 0.9800 
C(1)-N(1)-C(3) 95.23(12) C(1)-N(1)-H(1A) 132.4 
C(3)-N(1)-H(1A) 132.4 O(1)-C(1)-N(1) 132.60(15) 
O(1)-C(1)-C(2) 134.40(14) N(1)-C(1)-C(2) 92.99(13) 
C(6)-C(2)-C(1) 116.32(13) C(6)-C(2)-C(3) 106.33(12) 
C(1)-C(2)-C(3) 84.57(11) C(6)-C(2)-H(2) 115.2 
C(1)-C(2)-H(2) 115.2 C(3)-C(2)-H(2) 115.2 
N(1)-C(3)-C(4) 116.01(13) N(1)-C(3)-C(2) 87.14(11) 
C(4)-C(3)-C(2) 106.82(12) N(1)-C(3)-H(3) 114.5 
C(4)-C(3)-H(3) 114.5 C(2)-C(3)-H(3) 114.5 
C(3)-C(4)-C(5) 107.06(12) C(3)-C(4)-H(4A) 110.3 
C(5)-C(4)-H(4A) 110.3 C(3)-C(4)-H(4B) 110.3 
C(5)-C(4)-H(4B) 110.3 H(4A)-C(4)-H(4B) 108.6 
C(8)-C(5)-C(7) 108.23(14) C(8)-C(5)-C(6) 111.42(13) 
C(7)-C(5)-C(6) 111.19(14) C(8)-C(5)-C(4) 110.92(13) 
C(7)-C(5)-C(4) 111.68(13) C(6)-C(5)-C(4) 103.40(12) 
C(2)-C(6)-C(5) 106.93(12) C(2)-C(6)-H(6A) 110.3 
C(5)-C(6)-H(6A) 110.3 C(2)-C(6)-H(6B) 110.3 
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Table 26 continued 
Bond Length (Å) Bond Length (Å) 
C(5)-C(6)-H(6B) 110.3 H(6A)-C(6)-H(6B) 108.6 
C(5)-C(7)-H(7A) 109.5 C(5)-C(7)-H(7B) 109.5 
H(7A)-C(7)-H(7B) 109.5 C(5)-C(7)-H(7C) 109.5 
H(7A)-C(7)-H(7C) 109.5 H(7B)-C(7)-H(7C) 109.5 
C(5)-C(8)-H(8A) 109.5 C(5)-C(8)-H(8B) 109.5 
H(8A)-C(8)-H(8B) 109.5 C(5)-C(8)-H(8C) 109.5 
H(8A)-C(8)-H(8C) 109.5 H(8B)-C(8)-H(8C) 109.5 
                                              
 
                                                           




) for gem-dimethyl -lactam 373. 






 U11 + ... + 2 h 
k a* b* U                  
Atom U11 U22 U33 U23 U13 U12 
O(1) 49(1) 31(1) 42(1) 4(1) -12(1) 6(1) 
N(1) 42(1) 35(1) 26(1) 0(1) -6(1) -4(1) 
C(1) 41(1) 25(1) 28(1) 6(1) -4(1) -5(1) 
C(2) 32(1) 26(1) 32(1) 1(1) -3(1) -4(1) 
C(3) 33(1) 32(1) 27(1) -1(1) 1(1) -2(1) 
C(4) 30(1) 25(1) 31(1) -3(1) 0(1) -1(1) 
C(5) 27(1) 26(1) 28(1) 1(1) 0(1) -3(1) 
C(6) 33(1) 28(1) 26(1) -4(1) -5(1) 0(1) 
C(7) 30(1) 37(1) 37(1) 1(1) 4(1) -3(1) 











   
 Page | 230  
 
 Table 28- Hydrogen coordinates ( x 10
4





for gem-dimethyl -lactam 373 
Atom x y z U(eq) 
H(1A) 8461 12994 2572 57(6) 
H(2) 4499 10265 1547 36 
H(3) 4095 13222 2223 37 
H(4A) 6717 16245 1760 34 
H(4B) 4166 15820 1477 34 
H(6A) 4524 12188 621 35 
H(6B) 7197 11431 612 35 
H(7A) 9978 16105 1036 52 
H(7B) 10158 14246 542 52 
H(7C) 10112 13743 1272 52 
H(8A) 6651 15396 -2 56 
H(8B) 6435 17333 463 56 
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Table 29 - Dihedral angles for gem-dimethyl -lactam 373                                  
Atom1  -  Atom2  -  Atom3  -  Atom4 Dihedral (°) 
C(3) - N(1) - C(1) - O(1) 176.83(17) 
C(3) - N(1) - C(1) - C(2) -2.25(12) 
O(1) - C(1) - C(2) - C(6) -71.4(2) 
N(1) - C(1) - C(2) - C(6) 107.67(14) 
O(1) - C(1) - C(2) - C(3) -176.93(18) 
N(1) - C(1) - C(2) - C(3) 2.13(11) 
C(1) - N(1) - C(3) - C(4) -105.12(15) 
C(1) - N(1) - C(3) - C(2) 2.21(12) 
C(6) - C(2) - C(3) - N(1) -117.80(13) 
C(1) - C(2) - C(3) - N(1) -1.94(10) 
C(6) - C(2) - C(3) - C(4) -1.46(16) 
C(1) - C(2) - C(3) - C(4) 114.40(13) 
N(1) - C(3) - C(4) - C(5) 77.69(16) 
C(2) - C(3) - C(4) - C(5) -17.45(16) 
C(3) - C(4) - C(5) - C(8) 148.77(14) 
C(3) - C(4) - C(5) - C(7) -90.41(16) 
C(3) - C(4) - C(5) - C(6) 29.23(15) 
C(1) - C(2) - C(6) - C(5) -72.09(17) 
C(3) - C(2) - C(6) - C(5) 19.91(16) 
C(8) - C(5) - C(6) - C(2) -149.34(14) 
C(7) - C(5) - C(6) - C(2) 89.83(16) 
C(4) - C(5) - C(6) - C(2) -30.15(16) 
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